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Epidemiological evidence and randomised controlled trials suggests that dietary patterns 
with high intakes of fruit and vegetables are associated with reduced risk of 
cardiovascular disease (CVD) and type 2 diabetes (T2D). Frequent elevated excursions 
in postprandial glucose concentrations are thought to increase risk of T2D, therefore 
dietary strategies to control chronic postprandial hyperglycaemia would strengthen 
efforts to reduce the risk for T2D. Fruit polyphenols are dietary constituents that might 
help to delay glucose absorption following a carbohydrate-containing meal or beverage 
and epidemiological studies have shown a negative relationship between ingestion of 
polyphenols and T2D. Polyphenol dietary intakes and urinary excretions were analysed 
in a free-living population following the UK dietary guidelines and compared with a 
population following the average UK diet. In the intervention group, increased 
consumption of fruit and vegetables (> 5 portions/day) and wholegrain cereals led to an 
increased intake in polyphenols associated with health benefits, such as anthocyanins, 
isoflavones and lignans (P<0.05). Randomised clinical trials were conducted using 
highly purified anthocyanin-rich blackcurrant extract (BE) and polyphenol-rich apple 
extracts (AE) consumed immediately before a high-carbohydrate (starch and sucrose) 
test meal. BE (600 mg of blackcurrant anthocyanins), AE (1200 mg of apple 
polyphenols) and BE+AE (600 mg of blackcurrant anthocyanins + 600 mg of apple 
polyphenol) reduced postprandial glycaemia relative to control by 57, 63 and 73 %, 
respectively (P<0.005), but lower doses of an apple extract had no effect on 
postprandial responses to an oral glucose load. Effective doses of the fruit extracts are 
equivalent to 100 g of fresh blackcurrant and 600 and 300 g of raw apple. In vitro 
studies testing physiological concentrations of the blackcurrant and apple extracts used 
in the randomised clinical trials showed that the polyphenols contained in blackcurrant 
and apple extracts inhibited total and GLUT-mediated glucose uptake in Caco-2/TC7 
cells (a well-known model of the small intestine) and inhibited the sodium-dependent 
glucose transporter SGLT1 expressed in oocytes. Our results suggest blackcurrant and 
apple polyphenols may reduce postprandial glycaemia in vivo at least partly by 
inhibiting glucose uptake in the small intestine. Altogether the findings presented show 
that advice to consume more fruits and vegetables can effectively increase intakes of 
specific polyphenols that have been associated with reduced risk of cardio-metabolic 
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Diet is a major determinant of risk of cardio-metabolic diseases, with dietary 
modification being the keystone to the prevention of chronic diseases. Epidemiological 
evidence and randomised controlled trials suggests that dietary patterns with high 
intakes of fruit and vegetables are associated with reduced risk of cardiovascular disease 
(CVD) and type 2 diabetes (T2D). Data from three prospective longitudinal cohort 
studies (n=66105 women, n=85104 women and n=36173 men) showed reduced risk of 
T2D for individual fruits, with hazard ratios (HR) of 0.74 (95 % CI 0.66, 0.83) for 
blueberries, 0.88 (95 % CI 0.83, 0.93) for grapes and raisins and 0.89 (95 % CI 0.79, 
1.01) for prunes (Muraki et al., 2013). In the Kuopio Ischaemic Heart Disease Risk 
Factor Study (cohort study n= 2332 men), intake of fruit, berries and vegetables showed 
a tendency for T2D reduced risk (HR 0.76 (95% CI: 0.57, 1.02; P-trend = 0.15)) when 
compared higher vs lower quartile (Mursu et al., 2014). In the PREDIMED trial 
(n=7216 elderly men and women at high cardiovascular risk) consumption of nine or 
more servings/d of fruit and vegetables was associated with reduced risk of CVD (HR 
0.60 (95% CI 0.40, 0.96, P=0.005)) compared with consumption of <5 servings/d (Buil-
Cosiales et al., 2016). Increasing fruit and vegetable consumption has been 
recommended for the prevention of chronic diseases, such as cardiovascular disease and 
type 2 diabetes (Bazzano, 2005). Fruits and vegetables are rich in fibre, micronutrients, 
and non-nutrient compounds, such as polyphenols, that may have beneficial health 
effects. This thesis will explore how polyphenols may contribute to some of these 
protective effects by regulating postprandial blood glucose concentrations. 
1.1 Type 2 Diabetes   
Type 2 diabetes (T2D) is a chronic disease characterised by an ineffective utilisation of 
glucose produced by two main defects in the body: diminished insulin sensitivity by 
muscle, liver and adipose tissue (insulin resistance) and inadequate insulin secretion by 
pancreatic β-cells (Oh et al., 2012, WHO, 2016). Insulin is secreted from pancreatic β-
cells in response to increased blood glucose concentrations, thereby stimulating glucose 
uptake and glycogen synthesis (insulin-mediated glucose metabolism). When insulin 
resistance is present, the pancreatic β-cells need to produce more insulin to compensate 
for impaired insulin action, resulting in hyperinsulinaemia. Insulin resistance also 
contributes to the raise of glucagon and catecholamines, which stimulate glycogenolysis 
and gluconeogenesis in liver increasing the release of glucose to blood circulation. 
However, the compensatory activity of pancreatic β-cells diminishes over the time 
making insulin production insufficient to maintain an adequate insulin-dependent 
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glucose uptake in skeletal muscle cells, resulting in a reduced glucose uptake and 
incremented blood glucose levels (hyperglycaemia) (Oh et al., 2012, Papazafiropoulou 
et al., 2012). Years of uncontrolled blood glucose may lead to micro and macrovascular 
complications, such as retinopathy, neuropathy, nephropathy, coronary heart disease, 
peripheral vascular disease or stroke. In addition, blindness, lower extremity 
amputations and end-stage renal disease account for other chronic complications 
(Banerjee and Saxena, 2012, ADA, 2013). Sustained hyperglycaemia is associated with 
oxidative stress, a condition where an imbalance between oxidant and antioxidant 
species leads to damage of cells or organs due to an oxidative burden (Sies et al., 2005). 
Hyperglycaemia presenting in individuals with T2D can be improved or reversed by 
reduction of body weight, increasing physical activity and/or using oral glucose-
lowering drugs, although if glucose level is not controlled by any of the aforementioned 
methods it is necessary to resort to insulin injection (ADA, 2013).  
1.1.1 Risk factors for T2D  
Type 2 diabetes represent 90% to 95% of the cases worldwide and according to the 
World Health Organization, 9 % of the world’s population suffers from T2D and the 
number is predicted to reach exceptional levels (WHO, 2016). T2D is associated with 
age, obesity, history of impaired glucose tolerance, hypertension and dyslipidaemia as 
well as with unhealthy life habits (e.g. smoking, physical inactivity, unhealthy diet) 
(Banerjee and Saxena, 2012). Obesity is the primary cause of T2D, although it has been 
estimated that 10% of T2D patients are not overweight or obese (HSCIC, 2015), and 
most people with obesity do not develop T2D. Risk markers such as visceral fat and 
adipocytokine secretion, which are tightly associated with excess body weight, are 
likely to determine the progression to insulin resistance and eventually β-cell failure 
(Papazafiropoulou et al., 2012). Other risk factors for the development of T2D are the 
two denominated prediabetic stages; impaired fasting glucose (IFG) and impaired 
glucose tolerance (IGT), which can evolve to T2D although not always inevitably 
(WHO, 2016). The glucose-stimulated insulin secretion has two phases, the first one 
(acute or early phase) imply a short and rapid period of insulin release to reduce the 
glucose production in liver, characteristic of fasted states. The second-phase (late phase) 
implies a more sustainable release of insulin to increase insulin-mediated glucose 
uptake and return glucose levels to fasting values. Deficiencies in the acute phase 
response and an exaggerated second-phase response are associated with IFG while 
disruptions in both phases response are present in individuals with IGT 
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(Papazafiropoulou et al., 2012, Eikenberg et al., 2016). Loss of the early phase response 
and deficiency in the second-phase response will elevate postprandial glycaemia.  
Elevated postprandial glycaemia has been implicated in the development of T2D 
(Meyer et al., 2000) and represents a risk factor that can easily be targeted by dietary 
modifications. The concentrations of glucose in the blood following a meal containing a 
known amount of carbohydrate represents the sum total of the rate of digestion and 
absorption of glucose in the gut, as well as the rate of uptake from the circulation into 
the cells for oxidation or storage. An exaggerated postprandial glycaemic response to a 
standard carbohydrate load is indicative of a reduction in insulin secretion or sensitivity. 
Reducing the rate of delivery of glucose to the bloodstream by manipulating the 
carbohydrate type and/or meal composition is one way in which these adverse metabolic 
profiles might be ameliorated. High dietary glycaemic index and glycaemic load 
independently increase risk of T2D (Barclay et al., 2008) (relative risk 1.4 and 1.3 
respectively). Frequent elevated excursions in postprandial glucose concentrations are 
thought to increase risk of T2D and CVD by inducing oxidative stress and glycation of 
proteins, as reviewed by Blaak et al. (Blaak et al., 2012). Studies with acarbose (an 
inhibitor of α-glucosidase) show that reducing the rate of carbohydrate digestion can 
reduce the risk of progression to diabetes in participants with impaired glucose tolerance 
by 25% (Chiasson, 2006), suggesting that dietary strategies to control chronic 
postprandial hyperglycaemia by optimising the functionality of foods would strengthen 
efforts to reduce the risk for T2D. Dietary constituents that help to delay glucose 
absorption, e.g. fibre, polyphenols, following a carbohydrate-containing meal or 
beverage, would therefore also provide a potentially safe and effective approach to 




1.2 Dietary polyphenols and T2D     
Epidemiological studies have shown a negative relationship between ingestion of 
polyphenols and cardiovascular disease (Hooper et al., 2008, McCullough et al., 2012, 
Jennings et al., 2012, van Dam et al., 2013, Cassidy et al., 2013), cancer (Neuhouser, 
2004, Arts and Hollman, 2005, Fink et al., 2007, Yuan, 2011) and type 2 diabetes 
(Wedick et al., 2012, Curtis et al., 2012, van Dam et al., 2013, Jacques et al., 2013, 
Jennings et al., 2014, Tresserra-Rimbau et al., 2016). High intakes of subclasses of 
flavonoids have been associated with a reduced risk of T2D. A lower T2D risk was 
observed when intakes of flavonol and flavan-3-ol were greater in a USA population 
(n=2915 Framingham Offspring cohort) (Jacques et al., 2013). Total flavonoid, flavonol 
and flavanol intakes with associated with reduced risk of T2D in The European 
Prospective Investigation into Cancer and Nutrition-InterAct case-cohort study 
(n=15258 EPIC-InterAct) (Zamora-Ros, 2013). In a more recent study in a case-cohort 
(n=3340 men and women) of the PREDIMED trial, flavonoid and proanthocyanidin 
intakes were inversely associated with diabetes risk (Tresserra-Rimbau et al., 2016).  
Evidence from in vivo and in vitro studies support the epidemiological data. Human 
clinical trials have provided indication of a decreased postprandial glucose after intake 
of polyphenol-rich food followed by a high carbohydrate meal. Decreased postprandial 
hyperglycaemia has been shown following consumption of berries (Törrönen et al., 
2012a, Hoggard et al., 2013) and apple juice (Johnston et al., 2002). Lower postprandial 
glucose levels have also been demonstrated in vivo by individual compounds of 
polyphenol subclasses such as flavan-3-ols (Gutierrez-Salmean et al., 2014), flavonols 
(Hussain et al., 2012), isoflavones (Bhathena and Velasquez, 2002) and phenolic acids 
(van Dijk et al., 2009). In vitro studies support the in vivo data by showing potential 
inhibitory effects on carbohydrate digestion and absorption by polyphenols, 
mechanisms proposed are inhibition of digestive enzymes α-amylase and α-glucosidases 
and glucose transporters in the intestinal tract (Hanhineva et al., 2010, Babu et al., 
2013). In vitro inhibition of digestive enzymes activities has been demonstrated by 
anthocyanins (Akkarachiyasit et al., 2010), proanthocyanidins (McDougall, 2008), 
flavan-3-ols and phenolic acids (Hanhineva et al., 2010) among others. In addition in 
vitro inhibition of glucose transporters has been showed by flavan-3-ols and flavones 
(Kwon et al., 2007), anthocyanins, flavanones and isoflavones (Kottra and Daniel, 




1.3 Classification and main food sources of polyphenols 
Polyphenols are a large group of plant-based, bioactive compounds widely distributed 
in foods of plant origin, and form an important part of the human diet. Fruits, vegetables 
and beverages produced of plants such as tea, coffee, red wine and fruit juices represent 
the main dietary sources of polyphenols although dry legumes, cereals and chocolate 
also contribute to the total consumption (Manach et al., 2004). More than 500 different 
polyphenols have been identified in food (Perez-Jimenez et al., 2010b), modifications in 
the chemical structure modify their biological efficacy, bioavailability and permit its 
classification into classes and subclasses (Williamson and Manach, 2005). Polyphenols 
are commonly classified in four major groups; flavonoids, phenolic acids, lignans and 
stilbenes. The flavonoid group, usually the major component of dietary polyphenols, 
can be further broken down into subclasses including anthocyanins, flavanols, 
flavanones, flavones, flavonols and isoflavones. Phenolic acids represent the second 
component of dietary polyphenols followed by lignans and stilbenes. Average intakes of 
polyphenols vary between countries and populations, and are commonly related to 
socio-demographics and life style factors. In European countries total polyphenol 
intakes vary from 584 mg/d to 1786 mg/d and main food sources are non-alcoholic 
beverages such as coffee, tea and fruit juices, fruits and vegetables, and alcoholic 
beverages as wine (Zamora-Ros et al., 2015). Table 1.1 presents polyphenol 
classifications, with the most common subclasses consumed in a normal diet and their 
richest food sources. Some subclasses’ richest food sources are foods with very low 
intake frequency and/or very low quantity intakes e.g. hydroxycinnamic acids and dried 
peppermint, however the main food sources in daily diets are usually foods with a lower 
content but that are consumed more frequently and in a higher quantity e.g. 




Table 1.1 Classification of most common polyphenols according to Phenol-Explorer 
database 
Polyphenols 
Classes and subclasses 
Main food sources 
Flavonoids  
Anthocyanins Black elderberry, black chokeberry, blackcurrant , blueberry  
Dihydrochalcones Oregano, plum/prune juice, apple 
Flavanols Cocoa powder, dark chocolate, broad bean, black/green tea, apple 
Flavanones Peppermint dried, oregano, grapefruit juice, orange juice 
Flavones Celery seed, peppermint dried, oregano, celery leaves 
Flavonols Cappers, saffron, oregano, red onion, spinach, shallot, chokeberry     
Isoflavones Soy flour, soy paste, soybean, soy tempeh, soy yogurt/milk  
Phenolic acids   
Hydroxybenzoic acids  Chestnut, cloves, pomegranate juice, raspberry, cranberry  
Hydroxycinnamic acids Peppermint dried, common verbena, rosemary dried, spearmint    
Lignans  
Matairesinol  Sesame seed, linseed, sunflower seed, kale, raisin  
Secoisolariciresinol  Linseed, cashew nut, kale, kiwi, peanut 
Stilbenes  
Resveratrol  Red wine, lingonberry, red currant, cranberry, bilberry 
Other polyphenols   
Alkylmethoxyphenols Coffee, rapeseed, beer 
Alkylphenols Breakfast cereals, rye wholegrain flour, common wheat, rye bread 
Hydroxybenzaldehydes Walnut, red wine, fennel, vinegar, oat whole grain flour 
Hydroxycoumarins Chinese cinnamon, white wine, beer, sherry, cocoa powder  
Phenolic terpenes Rosemary, common sage  
Tyrosols Black/green olive, olive oil, sherry, red wine, vinegar 
Adapted from database Phenol-Explorer (Neveu et al., 2010, Rothwell et al., 2012, Rothwell et al., 
2013)  
 
Polyphenols have in common the presence of one or more phenolic ring in their 
backbone structure. Flavonoids share a general structure consisting of two phenolic 
rings bound together by three atoms of carbon that form an oxygenated heterocycle 
(C6C3C6), labelled as rings A, B and C, respectively (Manach et al., 2004). They are 
divided into different subclasses on function of the degree of hydroxylation, 
methoxylation, prenylation or glycosylation (Gonzales et al., 2015). Phenolic acids 
share the basic structure of a phenolic group and a carboxylic acid (C6C1); they are 
classified into different subclasses in function of the degree of hydroxylation, 
conjugation with different groups and glycosylation (Del Rio et al., 2013). The main 
phenolics acids in food are derivatives of hydroxybenzoic and hydroxycinnamic acids, 
the latter are mainly conjugated with tartaric acid and quinic acid forming a group 
denominated chlorogenic acids (Manach et al., 2004, Stalmach et al., 2012). The 
common chemical structure of lignans is formed by two phenyl groups united by two 
propane units (C6C3C3C6), lignans more commonly found in food are 
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secoisolariciresinol and matairesinol (Manach et al., 2004). Stilbenes can occur in a vast 
diversity of forms in the plant kingdom, although their molecular skeleton consist of 
two phenolic rings united by an ethane unit (C6C2C6), variation in structure is due to the 
degree of polymerisation on the backbone structure, the pattern of construction of 
oligomers and the different units present in it. Stilbenes can be classified into two 
groups, monomeric and oligomeric stilbenes, and themselves can be divided into 
subgroups. The largest subgroup of the oligomeric stilbenes is resveratrol (Shen et al., 










Figure 1.1 Chemical structures of the four main classes of polyphenols 
 
1.4 Bioavailability of polyphenols 
The bioavailability of polyphenols is affected by factors such as chemical structure, 
food matrix, food processing, enzymatic activity in mouth, small intestine and liver as 
well as gut microbiota. Structural variations as hydroxylation, glycosylation, 
polymerisation, etc. can affect polyphenol absorption, distribution, metabolism and 
excretion in the body. After consumption polyphenols are absorbed in the intestinal tract 
into enterocytes, although absorption might start in stomach for some flavonoids and 
stilbenes. Flavonoids, lignans, and stilbenes are usually found in food as glycosides, 
with a sugar moiety added to the backbone structure, although some flavanols are 
mainly present as aglycones. Aglycones can be absorbed directly into enterocytes but 









glucoronidation and/or methylation reactions prepare the metabolites before entering 
portal circulation in their way to liver. Once in liver several of those metabolites are 
catabolised, reactions of oxidation, reduction or hydrolysis introduce or eliminate 
hydroxyl and amino groups, making them accessible for the next series of reactions. 
Conjugation with glucuronic acid, glutathione, or glycine and sulfation reactions 
produce metabolites soluble in water that can be excreted in urine. After metabolism in 
liver, flavonoid metabolites might be directed to plasma for their subsequent 
dissemination within the body via bloodstream or redirected to small intestine via bile 
(Manach et al., 2004, Piskula et al., 2012), once redirected to small intestine metabolites 
might be reabsorbed or reach colon to be hydrolysed by the microbiota and reabsorbed 
into the circulatory system (Vitaglione et al., 2012). High molecular weight metabolites, 
such as proanthocyanidins, can be partially digested in small intestine however most of 
them will continue their way to colon and undergo metabolism by microbiota, and a 
proportion of these metabolites are reabsorbed before transport to the liver (Crozier et 
al., 2012). Phenolic acids may cross passively through the intestinal epithelium 
(Stalmach et al., 2012), a minor part of the lignans is absorbed in small intestine, with 
the unabsorbed portion continuing its way to the large intestine where intestinal 
microbiota metabolise lignans into enterodiol and enterolactone (Manach et al., 2004) 
prior to absorption  (Patel et al., 2012). Stilbenes undergo similar process to flavonoids, 
the portion of dietary polyphenols not absorbed in small intestine can reach colon and 
be metabolised by microbiota for their subsequent absorption or excretion in faeces 
(Manach et al., 2004). Considering their different chemical and biological properties, it 
is important to study dietary polyphenols as individual or as similar compounds (classes 
and subclasses) rather than as an entire homogeneous group (Perez-Jimenez et al., 
2010b).  
1.5 Berries and anthocyanins  
Anthocyanins are a subclass of the flavonoid group and are mostly responsible for the 
bright and deep colours associated with certain fruits and vegetables such as grapes, 
berries, cherries, aubergine and red onion (Manach et al., 2005). The six most abundant 
anthocyanin aglycones (anthocyanidins) are malvidin, petunidin, delphinidin, peonidin, 
pelargonidin and cyanidin. These anthocyanidins share a structure of 2-benzene rings (A 
and B rings) united by a heterocyclic ring (C ring) (Fig. 1.2). As suggested by their 
name, aglycones are not bound to a sugar molecule. However, polyphenolic compounds 
mainly exist as O-glycosides in plants, where a sugar moiety resides most often at 
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position 3 of carbon ring C (Fig. 1.2). Commonly linked sugars include glucose, 
galactose, arabinose and rutinose. For example, blackcurrants are high in delphinidin-O-
3-rutinoside and cynanidin-O-3-rutinoside (Rothwell et al., 2013, Neveu et al., 2010, 
Rothwell et al., 2012). Aside from sugars, anthocyanins may also be found acylated to 
aromatic and aliphatic acids. The variety of ways in which anthocyanins might be 
glycosylated or acylated has led to reports of up to 650 varieties of anthocyanins 
identified so far in flowers, fruits, vegetables and other plant material (Andersen and 






Figure1.2 Structure of the most common anthocyanidins and anthocyanins found in 
berries 
 
1.5.1 Main sources and dietary intake   
Dietary intakes of anthocyanins are derived from a relatively narrow range of foods. 
The total anthocyanin content varies widely from 0.28 to 1480 mg/100g in both fruit 
and vegetables. The main sources in the human diet are berries with blue, purple and 
orange/red pigments. Berries with the largest concentrations are elderberries, 
chokeberries, blackcurrants and blueberries with estimated contents in the range of 160 
to 1300 mg per 100 g fresh weight (Koponen et al., 2007, Wu et al., 2006, Rothwell et 
al., 2013, Bhagwat, 2013, Manach et al., 2004, Fernandes et al., 2013) (Table 1.2). 
Mean estimates from food frequency questionnaires (FFQ) and 24-hour recalls (24-HR) 
in adult populations from different countries vary from 0.04 (Lako J, 2006) to 215 mg/d 
(Kuhnau, 1976), but with the majority or reports ranging between 18 and 43 mg/d 
(Zamora-Ros et al., 2011b, Jennings et al., 2012, Cassidy et al., 2011, Wu et al., 2006, 




Table 1.2 Average content of polyphenols in berries (mg/100 g fresh weight) 








American cranberry Vaccinium 
macrocarpon Aiton 
315 32a/50b peonidin-3-galactoside 
Bilberry or 
whortleberry* 
Vaccinium myrtillus 525 299a/38b delphinidin-3-glucose; 
delphinidin-3-
galactoside 
Black chokeberry Aronia melanocarpa 1752 444a/878b cyanidin-3-galactoside 
Black elderberry Sambucus nigra 1950 1317b cyanidin-3-glucoside  
Blackberry Rubus sp. 569 147a/173b cyanidin-3-glucoside 
Blackcurrant Ribes nigrum 821 225a/592b delphinidin-3-
rutinoside 
Gooseberry Ribes uva-crispa 470 14a/9b cyanidin-3-glucoside 
Grapes (black) Vitis vinifera 185 72b malvidin-3-glucoside 







652 45a/60b cyanidin-3-galactoside 
Red raspberry Rubus idaeus 155 44a/73b cyanidin-3-sophoroside 
Redcurrant Ribes rubrum 448 26a/35b cyanidin-3-xylosyl-
rutinoside 




total estimate from pH differential method by spectrophotometry; 
b
sum of 
individual anthocyanin concentrations  estimated by chromatography (may underestimate due to missing 
compounds). Values will vary widely depending on cultivar, environmental factors, method of analysis, 
particularly underestimation due to unidentified/unquantified compounds. All values are ave rages based 
on the Phenol-Explorer database www.phenol-explorer.eu, excepting bilberry*(Chu et al., 2011).  
 
 
FFQs may underestimate true anthocyanidin intakes since questions are not specific to 
individual fruits and averaged values are applied to groups of foods that may vary 
widely in their anthocyanin contents, for example in the EPIC-Norfolk FFQ 
“Strawberries, raspberries, kiwi fruit” are grouped together in one category to indicate 
frequency of consumption, and other anthocyanin-rich foods as blueberries are not 
mentioned in the questionnaire. Food diaries may provide a more accurate 
representation of intake, but estimates represent short-term intakes rather than habitual 
consumption patterns, which could be particularly misleading for seasonally available 
foods like berries. Research groups have created and validated FFQ to estimate dietary 
flavonoid intake in different populations (Somerset and Papier, 2014, Theodoratou et 
al., 2007), which should provide more reliable intake estimations for specific 
populations, although they remain unavoidably susceptible to bias due to self-reporting 
errors, portion size quantification and estimation errors resulting from the lack of data 
on polyphenol content in food (Zamora-Ros et al., 2014). At present, the most common 
databases employed to assess flavonoid intakes are the USDA (Bhagwat, 2013, 
Bhagwat, 2008, Nutrient Data Laboratory, 2004) and Phenol-Explorer (Rothwell et al., 
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2013), which provide information on the content of 35 flavonoids in 506 food items and 
502 polyphenols (of the 4 classes) in 459 food items, respectively. The USDA database 
expressed flavonoid content as aglycone equivalents exclusively while Phenol Explorer 
database expressed polyphenol content as aglycones, glycosides or esterified 
metabolites and also includes retention factors to calculate changes in content due to 
cooking process. Although the Phenol Explorer database offers a wealth of detailed data 
on the polyphenol composition of foods, it might still be considered a work in progress 
when considering the broad diversity of polyphenols in food and the remaining gaps in 
the food analytical literature. New techniques for intake estimation have been examined; 
these include innovative technologies for measuring dietary intakes in epidemiological 
studies (Illner et al., 2012), as well as biomarker approaches. The use of metabolomic 
techniques to analyse phenolic metabolites in urine or plasma has a promising role in 
epidemiological studies (Manach et al., 2009, Edmands et al., 2015). Although current 
estimates of dietary anthocyanins intakes are limited, epidemiological studies suggest 
that higher consumption rates of berries and anthocyanins are associated with beneficial 
effects on risk factors related to vascular function and T2D.  
1.5.2 Epidemiological studies 
Prospective and cross-sectional studies in different populations have investigated 
associations between berry consumption and the risk of T2D, providing some support 
for a potentially protective effect arising from increased berry intakes.   
Prospective cohort and cross-sectional studies 
An inverse association between high consumption of berries and risk of T2D was 
observed in a Finnish cohort study (n=10,054 men and women), with a hazard ratio 
(HR) of 0.74 (95% CI: 0.58, 0.95) when comparing highest and lowest quartiles (Knekt 
et al., 2002). The Kuopio Ischaemic Heart Disease Risk Factor Study in Finnish middle-
aged men (n=2,682) reported that consumption of >59.7 g of berries per day compared 
to <1.3 g lowered risk of T2D (mean follow up 19 y), with a multivariable-adjusted HR 
of 0.65 (95% CI: 0.49, 0.88). Importantly, total fruit or vegetable consumption had no 
statistically significant fully adjusted association with T2D risk, possibly signifying a 
more potent role of berries in modulation of risk (Mursu et al., 2014).  
High intakes of anthocyanins and anthocyanin-containing foods were significantly 
associated with a lower risk for T2D in US men and women (n=199,980, 3 cohorts), 
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with a pooled HR of 0.85 (95% CI: 0.80, 0.91) for the highest quintile of anthocyanidin 
intakes compared with the lowest. Cyanidin exhibited the strongest effect on T2D risk; 
HR: 0.79 (95% CI: 0.72, 0.85), followed by malvidin, delphinidin, peonidin and 
petunidin. Blueberry intakes were most closely negatively associated with T2D risk 
(HR 0.77, 95% CI 0.68, 0.87), as well as apple/pear intakes, followed by strawberry 
intakes (Muraki et al., 2013, Wedick et al., 2012). In contrast, although lower T2D risk 
was observed when intakes of flavonol and flavan-3-ol were greater (n=2915 
Framingham Offspring cohort, USA), no associations with anthocyanin intake were 
detected (Jacques et al., 2013). Furthermore, contrary to the aforementioned studies, 
there was no association between total flavonoid or anthocyanin intake and risk of T2D 
in the Iowa Women's Health Study prospective cohort (n=35,816 postmenopausal 
women, USA) (Nettleton et al., 2006).  
Recently, a high intake of anthocyanins was found to be associated with lower insulin 
resistance (HOMA-IR) in a cross-sectional study using the Twins UK registry (n=1997 
women, UK). Women reporting higher intakes of anthocyanidins by FFQ (Q1: 3.5 
mg/day; Q5: 40 mg/day) had lower HOMA-IR scores and lower fasting serum insulin 
levels following adjustment for BMI, age, smoking, physical activity, diet, menopausal 
status and medication. More specifically, higher intakes of delphinidin, malvidin and 
petunidin were associated with lower HOMA-IR and insulin levels (Jennings et al., 
2014). This supports longitudinal observations of T2D risk and suggests that 
anthocyanins may reduce T2D risk by modulating insulin resistance independently of 
BMI and other major dietary factors. Inconsistent findings from longitudinal studies 
might be due to limitations and errors inherent to dietary intake methodology. Overall, 
there are sufficient epidemiological data to support a likely relationship between greater 
intakes of berries, anthocyanin-rich foods and anthocyanins, and reduced risk of T2D in 
adult populations.  
1.5.3 Bioavailability of anthocyanins 
Bioavailability of anthocyanins was formerly believed to be low (<2 %) (Del Rio et al., 
2013), with levels in plasma varying from 1 to 592 nM following the consumption of an 
anthocyanin-rich meal (Kay, 2006) and up to mM values in the gut lumen (Williamson, 
2013). However, it was demonstrated using a stable isotopically labelled anthocyanin 
that bioavailability may not be lower than other flavonoids; bioavailability of cyanidin-
3-glucoside was estimated to be at least 12 % calculated from 13C recovery in urine and 
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breath (Czank et al., 2013). Anthocyanin metabolites excreted in urine correspond to 15 
% of total intake when consuming 300 g of raspberries in a low polyphenol diet 
(Ludwig et al., 2015). Human studies have shown that the time to reach maximum 
concentrations in plasma varies between 0.5-4 h (Kay, 2006, Del Rio et al., 2013). This 
is consistent with evidence showing that anthocyanins may be partly absorbed in the 
stomach before reaching the small intestine (Talavera et al., 2003, Fernandes et al., 
2012).  
After ingestion, anthocyanins appear to permeate the stomach mucosa; proposed 
mechanisms include a bilitranslocase carrier and a saturable transporter, GLUT1 
(Passamonti et al., 2003, Oliveira et al., 2015, Fernandes et al., 2012). Further down the 
gastrointestinal tract, in the small intestine many flavonoid glycosides undergo 
hydrolysis of the sugar moiety by the membrane-bound enzyme, lactase phlorizin 
hydrolase (LPH) with subsequent passive diffusion of the aglycone into the enterocyte. 
However, some anthocyanin glycosides, such as cyanidin-3-glucoside and cyanidin-3-
galactoside, have shown resistance to LPH (Fang, 2014, Nemeth et al., 2003). In fact, 
anthocyanins that are absorbed in the small intestine are more likely to be taken up into 
enterocytes intact, their metabolites then being formed in the small intestine after 
absorption (de Ferrars et al., 2013, Fang, 2014). Any deglycosylation within the gut 
lumen primarily occurs in the colon due to the action of gut microbiota, as reviewed by 
Fang, 2014 (Fang, 2014).  
Early studies suggested a role for the sodium-dependent glucose transporter 1 (SGLT1) 
for the absorption of glycosides (Day et al., 2003), but SGLT1 expressed in Xenopus 
oocytes does not transport flavonoid glycosides (Kottra and Daniel, 2007). In 
enterocytes, intact glycosides may undergo the action of the cytosolic-β-glucosidase, 
which cleaves the sugar moiety and releases the free aglycone (Day et al., 1998); 
aglycones then undergo phase II metabolism by sulfotransferases, methyltransferases 
and glucoronyltransferases, forming sulphated, methylated and glucuronidated 
metabolites (Del Rio et al., 2013). Efflux of metabolites into the small intestine may 
occur via transporters inserted into the luminal membrane, such as multidrug resistance 
protein 2 and breast cancer resistance protein (van de Wetering et al., 2009, Chen et al., 
2014). Phase II metabolites reach portal circulation via active transporters inserted in 
the basolateral membrane, such as multidrug resistance protein 3 (van de Wetering et 
al., 2009, Chen et al., 2014), studies have also suggested the action of the glucose 
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transporter GLUT2 (Day et al., 1998, Williamson et al., 2000, Manzano and 
Williamson, 2010).  
Once in the portal circulation, metabolites can reach the liver and undergo additional 
phase II metabolism before entering the systemic circulation (Kay, 2006), from where 
they are directed to several organs and tissues (e.g. adipose tissue, heart, eyes, 
cerebrum, kidneys) to exert their biological effects or to be metabolised and eliminated 
in urine (Fernandes et al., Rodriguez-Mateos et al., 2014). Anthocyanin metabolites 
could be directed to the enterohepatic circulation for their subsequent excretion into the 
small intestine via bile for reabsorption or make their way to the large intestine to be 
transformed by microbiota and then reabsorbed or eliminated in faeces (Fernandes et 
al., Talavera et al., 2003). Unabsorbed anthocyanins reaching the large intestine may be 
converted to other metabolites by resident colonic bacteria, followed by absorption or 
excretion in the faeces (Gonzalez-Barrio et al., 2010, Gonzalez-Barrio et al., 2011, Del 
Rio et al., 2013). Microbiota can degrade anthocyanins to phenolic acids and aldehydes 
by splitting the C-ring and modifying the remaining A and B-ring (Rodriguez-Mateos et 
al., 2014). Some of the main metabolites of microbiota degradation are gallic acid, 
vanillic acid, homovanilic acid, protocatechuic acid (PCA), syringic acid and 4-
hydroxybenzoic acid (Vitaglione et al., 2007, Azzini et al., 2010, Fleschhut et al., 2006, 
Forester and Waterhouse, 2008, de Ferrars et al., 2013). Despite knowledge of the high 
rate of anthocyanin degradation by gut microbiota there is still not consensus about the 
proportion absorbed into systemic circulation (Fang, 2014, Czank et al., 2013, de 
Ferrars et al., 2013). See Fig. 1.3 for proposed mechanism of anthocyanin absorption.  
Studies showing higher bioavailability of anthocyanins have been able to detect a 
broader spectrum of metabolites in blood and urine samples. For example, a study 
published in 2007 reported only the recovery of cyanidin-3-glucoside and PCA in 
plasma following ingestion of one litre of blood orange juice (Vitaglione et al., 2007). 
However, de Ferrars et al. (de Ferrars et al., 2013) reported 28 total metabolites, 17 
phenolics and 11 anthocyanin conjugates in urine following consumption of an 
elderberry extract (500 mg mixed anthocyanins) consisted mostly of cyanidin 
glycosides, while plasma analysis discovered 17 phenolics and four anthocyanin 
conjugates. Urine samples demonstrated high amounts of vanillic acid and conjugates 
and were more abundant in anthocyanin conjugates, while plasma was highest in 4-
hydroxybenzaldehyde and protocatechuic acid-sulfate (de Ferrars et al., 2013). Isolated 
and 13C-labelled cyanidin-3-glucoside was traced in healthy males, demonstrating a 
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total of 25 different metabolites, including a range of cyanidin glucuronides and methyl 
compounds as well as aldehydes and phase II PCA conjugates (Czank et al., 2013). The 
metabolism of raspberry anthocyanins produced 18 detectable compounds in urine, 
including cyanidin-3-O-glucoside, peonidin-3-O-glucoside and 16 phenolic metabolites, 
while in plasma nine anthocyanins metabolites were quantified including glucuronides 
and sulphated compounds (Ludwig et al., 2015). Furthermore, not all metabolites were 
recovered, which is in concordance with more recent data that identified a total of 36 
metabolites in serum, urine and faecal samples following ingestion of 500 mg labelled 
cyanidin-3-glucoside (de Ferrars et al., 2014). These studies raise the possibility that the 
health effects associated with berries and their anthocyanins may be in part attributable 
to metabolites of parent anthocyanin compounds. It is now apparent that parent 
anthocyanins maintain a relatively short half-life, whereas their metabolites, which 
includes phase I and II compounds, are active for longer and reach higher maximum 






































Figure 1.3 Metabolism of carbohydrates and effects of anthocyanins on enzymes 
and glucose transporters. Adapted by permission in part from MacMillan Publisher Ltd: 
Nature Reviews Immunology (Mowat and Agace, 2014), copyright 2015. After ingestion, 
anthocyanins appear to permeate the stomach mucosa; possibly via the BLT carrier and GLUT1. 
In the small intestine, anthocyanins can inhibit the action of digestive enzymes and reduce 
glucose transport, the latter mechanism possibly by competition with glucose for GLUT2 and 
SGLT1. Anthocyanins that are absorbed in the small intestine are likely to be taken into 
enterocytes intact, but may also be hydrolysed by LPH to their aglycone before absorption. In 
enterocytes, intact glycosides may undergo the action of cytosolic-β-glucosidase, which cleaves 
the sugar moiety and release the free aglycone. Their glucuronidated, sulphated and methylated 
metabolites can then be formed in the small intestine after absorption. Anthocyanins that reach 
the lower small intestine and colon may be deglycosylated and further metabolised to phenolic 






1.5.4 Human studies 
Research investigating the role of polyphenols in carbohydrate digestion and absorption 
in humans is largely dominated by randomised, placebo-controlled trials, considered the 
gold standard in scientific research. However, the varying types of berries and berry 
combinations, the methods of administering the treatments and the specifics of each 
study design bring a substantial amount of variation. Details of these studies are 
outlined in Table 1.3. 
Edirisinghe et al. (Edirisinghe et al., 2011) tested the effects of a strawberry extract 
milk-based drink on plasma glucose and serum insulin levels. Although no changes in 
glucose were observed, insulin levels were significantly higher in the placebo arm. The 
lack of effect on glucose levels could be explained by the presence of milk proteins, 
which may compete with intestinally-derived proteins (enzymes, transporters expressed 
on the luminal surface) for polyphenol binding (Gonzales et al., 2015, Charlton et al., 
2002). Postprandial glucose and insulin responses were reduced in overweight subjects 
who consumed 0.47 g of encapsulated bilberry extract (equivalent to a 50 g serving of 
bilberries) alongside 75 g Polycal liquid as an oral glucose tolerance test (Hoggard et 
al., 2013). Interestingly, the most significant effects were observed at later time points 
(120, 150 and 180 min), in contrast with other studies (Törrönen et al., 2012a, Törrönen 
et al., 2012c).  
Lingonberry and blackcurrant purées significantly lowered plasma glucose at 15 and 30 
mins, and increased plasma glucose after 60 min relative to control, post-ingestion of 35 
g sucrose, and blackcurrant nectar showed comparable results (Törrönen et al., 2012a). 
Similar studies using a mixed berry purée of blackcurrant, strawberries, cranberries and 
bilberries demonstrated consistent time-dependent glucose and insulin responses to 35 g 
sucrose (reduced 15-45 min, increased at ~90 min), together with a borderline increase 
in plasma concentrations of the gut peptide glucagon-like peptide-1 (GLP-1) in the early 
postprandial phase (Törrönen et al., 2010, Törrönen et al., 2012c). Interestingly, these 
experiments, all by the same group, consistently demonstrate that berries inhibit the 
early phase of postprandial glycaemia, when sucrose is being hydrolysed by α-
glucosidase into glucose and fructose, and glucose is being rapidly absorbed from the 
upper small intestine, whereas there is a compensatory increase in the later postprandial 
phase relative to control, suggesting a more protracted glycaemic response to sucrose 
ingestion when consumed with berries.  
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More recently, the same group reported that a blackcurrant, strawberry, bilberry and 
cranberry purée reduced postprandial glycaemia 0-30 min in response to white wheat 
bread consumption (50 g starch) by 32 % (Törrönen et al., 2013). On the other hand, a 
study investigating the effect of blueberries and raspberries found no differences in 
postprandial glycaemia compared to control, although the authors suggested that there 
may have been inadequate mastication of the whole berries and therefore limited release 
of free polyphenols from cell walls (Clegg et al., 2011). Additional studies investigating 
the effects of anthocyanins on glycaemic responses to solid and liquid mixed meals 
containing starches and/or sucrose will further elucidate the potential effects of berry 
polyphenols on metabolic response. 
The above mentioned studies investigate the acute response to the administration of 
anthocyanins; however, there may also be a longer-term effect as a consequence of daily 
consumption. Obese men and women administered a blueberry smoothie (668 mg 
anthocyanins; 1462 mg total phenolics) twice daily for 6 weeks demonstrated a positive 
effect on insulin resistance compared to a nutritionally matched blueberry-free smoothie 
(Stull et al., 2010). Subjects followed an ad libitum diet, suggesting the addition of this 
amount of blueberries, around two cups fresh blueberries per day, even without dietary 
changes may influence the current state of insulin resistance, although it is possible that 
other dietary changes were made in a motivated study population.  
Overall, the evidence base to date indicates an inhibitory effect of berry extracts or 
purées in the initial postprandial glycaemic response, suggesting that berry components 
such as anthocyanins and proanthocyanidins might be acting in the gut as a “brake” on 
the rate of glucose absorption, but not the total amount. However, the majority of the 
study designs involve administering whole berries or berry purées, making it difficult to 
pinpoint the relative effects of the polyphenols versus other components such as fibre, 
which might delay the rate of glucose absorption by slowing down gastric emptying. It 
is impossible to distinguish the relative contributions of the berry anthocyanins, 
proanthocyanidins, ellagitannins, flavonols, and phenolic acids from the human studies 
published to date. In vitro experiments using Caco-2 cells and controlled expression of 
glucose transporters in Xenopus oocytes may help to shed light on these questions in 
order to optimise the efficacy of mixed berry extracts intended for nutraceutical or 
functional food applications. Further randomised controlled trials using alternative 
study designs may also address the relative contributions of anthocyanins compared to 
other berry polyphenols, for example comparing high anthocyanin blackcurrants with 
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low anthocyanin greencurrants, or using powdered berry extracts concentrated in 








Table 1.3 Summary of randomised controlled acute and chronic dietary intervention trials using berry meals 
References  n (sex), status, country 
Subjects 







(Stull et al., 2010) 32 (M+F), insulin 
resistant, USA 
51 3 DB P; chronic 
(6 wk) 
freeze-dried BB powder 668 mg 
ACN 
- stimulation of  IS + 
         
(Törrönen et al., 
2010) 
12 (M+F), healthy,  
Finland 
54 15 SB CO; acute puree of  BC, BIB, CB and 
SB 
150 g - ↓plasma glucose in early stages 
of post prandial glucose curve 
Æ 
 
         
(Edirisinghe et al., 
2011) 
24 (M+F), overweight, 
USA 
51 15 SB CO; acute freeze-dried SB powder 82 mg 
ACN 
- insulin ↓ at 60 and 180 min 
post meal 





         
(Clegg et al., 2011) 12 (M+F), healthy, 
Finland 




- no effect on postprandial 
glucose response 
+ 
         
(Törrönen et al., 
2012c) 
12 (M+F), healthy, 
Finland 




- glucose curve normalised + 
         
(Törrönen et al., 
2012a) 
20 (F), healthy or 
overweight, Finland 
57 10 SB CO; acute BB puree and nectar, LB 
puree and nectar 
150 g 
 
- normalised postprandial 
glucose curve by puree and less-
so by nectar 
+ 
         
(Hoggard et al., 
2013) 
8 (M), T2D, UK 62 5 DB CO; acute BIB extract 169 mg 
ACN 







Table 1.3 continued 
References  n (sex), status, country 
Subjects 







(Törrönen et al., 
2013) 
            
-Study 1 15 (F), healthy, Finland 48 14 SB CO; acute puree of SB, BIB or LB  150 g - SB puree may improve 
glycaemic response  
+ 
-Study 2 13 (F), healthy, Finland 50 12 SB CO; acute puree of RB, CLB or CHB  150 g - no significant effects on blood 
glucose 
+ 
-Study 3 20 (F), healthy, Finland 57 12 SB CO; acute 
 
puree of SB, BIB, CB + 
BC  
150 g - ↓early postprandial 








16 (NS), healthy, UK 26 4 SB CO; acute freeze-dried AP, BKB, 
BC, SB powder + GT 
powder 
40.5/81 g - 27 % and 49 % ↓plasma 
glucose iAUC 
- 47 % ↓ insulin iAUC 
+ 
Quality assessment was based on the method recommended by the American Dietetic Association (ADA, 2009). Studies were assessed and given one of the following three 
scores: Minus (-), indicating that the study scored poorly on at least 6 out  of 10 points; Neutral (Æ), indicating that the study was not exceptionally strong (scores were poor on 
points relating to validity/reliability of outcomes, whether the intervention was described in enough detail, whether selection of study participants was free from bias, and whether 
study groups were comparable and methods of randomisation was described and unbiased); and Plus (+), indicating that the stud y was of very high quality, i.e. scores were high 
on the previous 4 points and also high on at least one other point. ACN, anthocyanins; M, males; F, females; USA, United States of America; SB CO, single-blind cross-over; SB, 
strawberry; T2D, type 2 diabetes mellitus; UK, United Kingdom; DB CO, double-blind cross-over; BIB, bilberry; iAUC, incremental area under the curve; OGTT, oral glucose 
tolerance test; BB, blueberry; LB, lingonberry; BC, blackcurrant; CB, cranberry; RB, raspberry, CLB, cloudberry; CHB, chokebe rry; CO, cross-over. DB P, double-blind parallel, 
; IS, insulin sensitivity; NS, non-specified; AP, apple peel; BKB, blackberrry; GT, green tea.    
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1.5.5 Berries and anthocyanins; modulation of glucose metabolism (In vitro 
studies) 
Consumption of anthocyanin-rich foods have been associated with beneficial effects on 
metabolic biomarkers in humans, including postprandial concentrations of glucose, insulin, 
free fatty acids and gastrointestinal hormones such as glucose-dependent insulinotropic 
polypeptide (GIP) and GLP-1 (Törrönen et al., 2012a, Törrönen et al., 2010, Törrönen et al., 
2012c, Johnston et al., 2005, Johnston et al., 2002). There is increasing evidence for a 
potential role for dietary anthocyanins in glucose homeostasis, but there is a lack of 
understanding of the mechanisms by which these effects are played out. In order to elucidate 
the mechanisms different extracts and individual compounds have been tested using in vitro 
experiments. Enzymatic studies suggest that anthocyanins may inhibit digestive enzymes 
such as salivary and pancreatic α-amylases and α-glucosidases; sucrase and maltase (Figure 
1.3). Studies using Caco-2 cells, as a model of the small intestine, and Xenopus laevis 
oocytes, expressing glucose transporters, show sugar uptake inhibition by anthocyanin 
extracts and individual compounds (Figure 1.3).    
Carbohydrates digestion and absorption  
Carbohydrate digestion begins in the mouth by α-amylases that hydrolyse α(1,4)-glycosidic 
bonds of polysaccharides (e.g. starch), which are broken down into smaller peptides, amylose 
and amylopectin (Englyst et al., 2007). In the small intestine, additional pancreatic α-
amylases are secreted. Alpha-glucosidases act on sucrose and maltose, generating monomers 
of glucose and fructose that are absorbable by brush border cells of the small intestine. 
Glucose may be transported by SGLT1and GLUT2 at the apical membrane, the latter of 
which is primarily functional during high luminal glucose concentrations (Wright et al., 
2007, Kellett et al., 2008). Higher free glucose in the gut lumen may influence the net uptake 
of glucose, contributing to a higher release of glucose into the bloodstream. Therefore, the 
ability to slow the rate of carbohydrate digestion and the release of free glucose may be 
important in managing postprandial hyperglycaemia. 
1.5.5.1 Digestive enzymes: in vitro studies 
Anthocyanins are highly bioactive molecules, but defining their bioactivities in vivo can 
present many challenges. As previously mentioned, anthocyanins are thought to reach 
millimolar concentrations within the gut lumen and intestinal tissues, although only 
nanomolar concentrations are present in the blood stream (Fang, 2014). The relatively higher 
concentrations in the gut tissues may provide sufficient potency for the effects observed 
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within in vitro studies, which are discussed further below. Many cellular models testing 
inhibition of digestive enzymes and intestinal transporter proteins by anthocyanins have 
found IC50 values within the range of micromolar concentrations, which are well within a 
physiologically feasible range. Strawberry extracts from various species of Brazilian 
strawberry significantly inhibited α-glucosidase activity up to 70 % in a dose-dependent 
manner (Da Silva et al., 2008). Although these effects were marked, it is difficult to pinpoint 
whether enzyme activity inhibition was attributable to specific anthocyanins or other 
polyphenols in the strawberry extract. Therefore, many in vitro studies focus on testing 
individual anthocyanins, as described below. The results of these studies are also displayed in 
Table 1.4.  
One of the first studies investigating the effects of cyanidin-3-galactoside, high in blueberries, 
lingonberries and cranberries, showed inhibition of both sucrase and maltase enzyme activity. 
Furthermore, kinetic analysis suggested both competitive and non-competitive inhibition, 
meaning cyanidin-3-galactoside may interact directly at the active site of the enzyme, 
inhibiting substrate binding, or at another site (Adisakwattana et al., 2009). Comparable 
results were observed by the same authors for cyanidin-3-rutinoside, which is found in 
particularly concentrated amounts in blackcurrants (Adisakwattana et al., 2011a). Similarly, 
sucrase was inhibited to a larger extent than maltase, and cyanidin-3-rutinoside was 
significantly more potent compared to cyanidin-3-galactoside, which might be related to the 
disaccharide structure of rutinose (Adisakwattana et al., 2011a). Aglycone cyanidin also 
shows inhibition of sucrase activity, although to a much lesser extent than its glucosides, 
while cyanidin-3,5-diglucoside showed relatively no inhibition (Akkarachiyasit et al., 2010) 
and cyanidin-3-rutinoside show inhibition of α-amylase as well in a non-competitive manner 
(Akkarachiyasit et al., 2011). These data highlight the potent effects of cyanidin glycosides 
on carbohydrate-digesting enzymes within the gut, and suggest that cyanidin glycoside-
containing berry species, such as blackcurrant, blackberry and lingonberry (Rothwell et al., 
2013), might have particularly potent postprandial glycaemia-lowering effects.  
Separate extracts of strawberry, raspberry, blueberry and blackcurrant showed dose-
dependent inhibition of α-amylase, with strawberry and raspberry (also rich in hydrolysable 
tannins, ellagitannins) demonstrating the most significant effects (McDougall et al., 2005). 
Anthocyanins present in high amounts in raspberries and strawberries include cyanidin and 
pelargonidin glycosides, however they may also contain significant amounts of phenolic 
acids and other flavonoids (Rothwell et al., 2013). Alternatively, blackcurrant and blueberry 
extracts were more potent α-glucosidase inhibitors in comparison to the other two extracts. 
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By separating the anthocyanin-containing portion of the extract from the whole raspberry 
extract, McDougall et al (McDougall et al., 2005) demonstrated that the inhibitory effects on 
α-amylase are largely mediated by non-anthocyanins, while α-glucosidase activity is 
modulated by the anthocyanin-containing portion. In fact, in a separate study it was found 
that the inhibitory effects of rowanberries on α-amylase are primarily carried out by 
proanthocyanidins, a flavonoid subclass constituted of dimers, oligomers or polymers of 
catechins or epicatechins linked together, also known as condensed tannins (Manach et al., 
2004), by their protein-binding activity (Grussu et al., 2011). This was further exemplified by 
the low inhibition of α-glucosidase by a proanthocyanidin-rich rowanberry extract, signifying 
the specific importance of this group of compounds for α-amylase inhibition (Boath et al., 
2012). Both red and yellow raspberries significantly influenced α-amylase activity, 
suggesting that synergism between proanthocyanidins, which are more concentrated in 
yellow raspberries compared to red, anthocyanins, which are much higher in red raspberries, 
and other compounds such as ellagitannins, flavonols and hydroxycinnamic acids may occur 
to effect α-amylase inhibition (Grussu et al., 2011). More recently, the same authors provided 
significant evidence of anthocyanin-rich blackcurrant extract inhibition of α-glucosidase in 
vitro (Boath et al., 2012). However, no synergistic effects were apparent after combining the 
extracts (Boath et al., 2012). As this particular rowanberry extract was low in anthocyanins, it 
suggests they are not the sole compounds contributing to these effects, as observed for 
proanthocyanidins and α-amylase inhibition.  
Acarbose is a competitive inhibitor of maltase and sucrase in the digestive tract and is a drug 
used in the management of T2D. European regulations suggest doses between 25-200 mg 
three times daily, depending on severity of disease (Fischer et al., 1998). Gastrointestinal side 
effects associated with acarbose have limited the success of the drug (Aoki et al., 2010). 
Administration of certain polyphenols may pose synergistic effects on sucrase and maltase 
activity (Adisakwattana et al., 2009, Adisakwattana et al., 2011a, Akkarachiyasit et al., 2010, 
Akkarachiyasit et al., 2011) depending on doses of polyphenol and acarbose (Adisakwattana 
et al., 2009). Together these studies suggest that acarbose acts via different mechanisms than 
some polyphenols, providing the synergistic inhibition observed, and may give insight into 




Table 1.4 In vitro evidence for berries and anthocyanins inhibition at digestion enzymes 
Reference Enzyme source Extract/ACN DDose IC50 Enzyme Effect 
(Adisakwattana et 
al., 2009) 




- inhibition of α-glucosidase and 
synergism with acarbose 
- mixed type inhibition  
       
(Adisakwattana et 
al., 2011b) 
RIAP C3R 0.1, 0.5 and 
1.0 mM 
sucrase: 250.2 μM 
maltase: 2.3 mM 
sucrase 
maltase 
- bigger inhibition on sucrase than 
maltase 







 NS sucrase: 
1.42 mM (cyanidin); 0.97 mM 
(C3G); 0.50 mM (C3Gl) 
α-amylase: 
0.38 mM (cyanidin);  




- α-amylase and sucrase inhibited by 
cyanidin glucosides   
- C3,5-dG shows no inhibition 
- synergistic effects of acarbose with 
C3G, C-3,5-dG and C3Gal  
       
(Akkarachiyasit et 
al., 2011) 
PP α-amylase C3R 0.1-1.0 mM α-amylase: 24.4 μM α-amylase - dose-dependent inhibition of α-
amylase 
-  synergism with acarbose 
       
(Boath et al., 2012) RIAP PA-rich BC and 
RWB extract 
10-40 μg/mL BC: 20 μg/mL GAE 
RWB: 30 μg/mL GAE 
α-glucosidase - dose-dependent inhibition 
       
(Da Silva et al., 
2008) 
PP α-amylase  
RI α-glucosidase 




- dose-dependent inhibition of α-
glucosidase, up to 70 % 
-  lower inhibition of α-amylase  





Table 1.4 continued 
Reference    Enzyme source    Extract/ACN D    Dose IC50    Enzyme Effect 
(Grussu et al., 2011) PP α -amylase fractionated RWB 
extract  
 
- yellow RB extract 
- red RB extract 
NS whole extract: epicatechin-
containing PA: 5 μg/mL (8.4 
μM) 
- 16.5 μg/mL GAE 
- 13.5 μg/mL GAE 
α-amylase - whole extract and epicatechin-
containing PA inhibited α-amylase 
       




extracts of  SB, RB, 
BB and BC 
50-500 μg of 
phenols 
NS α-amylase;   
α-glucosidase 
 
- α-amylase inhibited by non-ACN 
fraction; SB + RB most efficient 
- α-glucosidase inhibited by ACN; 
BC + BB dose-dependent inhibition 







Sugar-free extracts of 
BKB, BC and SB  
0-4 mg of 
powder/ml 
BKB: 1.2 and 1.6 mg/ml 
BC: 1.5 and 1.7 mg/ml 
SB: 2.5 and 3.9 mg/ml 
α-amylase   
 
- α-amylase inhibited by powder 
extracts of BKB, BC and SB at 
physiological concentrations  
ACN, anthocyanin; RIAP, rat intestinal acetone powder; C3Gal, NS, non-specified; C3Gal, cyanidin-3-galactoside; C3R, cyanidin-3- rutinoside; PP, porcine pancreatic; C3G, cyanidin-3-
glucoside; C-3,5-dG, cyanidin-3,5-diglucoside; PA, proanthocyanidin; BC, blackcurrant; RWB, rowanberry; SB, strawberry; RI, rat intestinal; RB, raspberry; GAE, gallic acid equivalent; BB, 
blueberry; BKB, blackberry.  
* using amylose and amylopectin as substrates
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1.5.5.2 Sugar uptake: in vitro studies 
Following the release of glucose from sucrose and starch by digestive enzymes, glucose 
absorption may be further disrupted by interactions between berry anthocyanins and 
intestinal sugar transporters. The human cell line Caco-2, has been widely used as an in 
vitro model of the small intestine, the cell line obtained from a human colon 
adenocarcinoma, under culture conditions develop as a cell monolayer with 
characteristics of a mature enterocyte. Caco-2 cell system expresses the enzymes 
sucrase, maltase and lactase, along with the transporters GLUT1, GLUT2, GLUT3, 
GLUT5 and SGLT1 on its apical border (Sambuy et al., 2005).   
Johnston et al. tested the effect of polyphenols on glucose transport in the Caco-2 cell 
line. Although no berry-specific anthocyanins were tested, it was one of the first studies 
suggesting competitive inhibition of SGLT1 and inhibition of GLUTs in a cellular 
model of the human intestinal lining (Johnston et al., 2005). Manzano and Williamson 
(Manzano and Williamson, 2010) monitored the rate luminal glucose uptake and of 
basolateral GLUT-mediated glucose transport, showing that strawberry extract is able to 
hinder translocation to a much larger extent within sodium-free conditions (GLUT-
mediated), although transport was also inhibited during sodium-dependent conditions 
(SGLT1 and GLUTs), suggesting that the inhibition of GLUTs was greater than the 
inhibition of SGLT1. Strawberry extract (50-400 mg/ml) showed inhibition of total 
(SGLT1 and GLUTs) apical glucose uptake and basal transport on the Caco-2 cells in 
vitro model, with an IC50= 324 mg/ml, a high concentration compared to physiological 
levels. Although the specific strawberry compounds responsible for these effects were 
not clear, HPLC analysis showed the extract was relatively high in pelargonidin-3-
glucoside, which showed inhibition of glucose transport into and across the Caco-2 cell 
(IC50= 802 μM) (Manzano and Williamson, 2010). These results suggest that strawberry 
compounds may influence glucose transport across intestinal cells, thereby modulating 
the rate of glucose flux into the bloodstream.  More recently, Alzaid et al. (Alzaid et al., 
2013) demonstrated that acute exposure of Caco-2 cells to cyanidin, cyanidin-3-
glucoside and cyanidin-3-rutinoside (100 μM each), significantly reduced total and 
facilitated (GLUT-mediated) glucose transport. Whole mixed berry extract (4 mM) also 
significantly inhibited uptake of glucose in this model (Alzaid et al., 2013).  
Although the exact mechanisms for anthocyanin absorption are not clearly identified, 
glucose transporters GLUT2 and SGLT1 may play an important role. An in vitro study 
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using Caco-2 cells treated with cyanidin-3-glucoside showed decreased absorption of 
the anthocyanin when specific inhibitors of GLUT2 and SGLT1 were added compared 
to without inhibitors; the same effect was observed in cells with decreased expression of 
GLU2 and SGLT1, suggesting the involvement of both transporters in the absorption of 
cyanidin-3-glucoside (Zou et al., 2014). Furthermore, expression of GLUT2 in the 
apical side of Caco-2 cells was decreased at the same time as glucose uptake was 
decreased following cyanidin-3-glucoside treatment (Faria et al., 2009). Competition 
between glucose and anthocyanins for glucose transporters may represent a potential 
mechanism for inhibition of postprandial glycaemia.  
Interestingly, longer-term exposure (16 h) of berry extracts (4 mM) to Caco-2 cells 
showed an inhibitory effect on both GLUT2 and SGLT1 expression, which was further 
exemplified at the protein level for GLUT2. However, the 16 h exposure showed 
minimal effects on total glucose uptake, with only facilitated (GLUT-mediated 
transport) uptake demonstrating a statistically significant reduction (Alzaid et al., 2013). 
Caco-2 cell model pre-treated for 96 h with anthocyanin extract (200 μg/ml) increased 
the expression of GLUT2 but not SGLT1 and GLUT5. Acute glucose transport, 
mediated by GLUT2 was decreased in cells pre-treated with anthocyanin extract and 
malvidin-3-glucoside (200 μg/ml), pre-treatment with malvidin (200 μg/ml) showed no 
inhibitory effect (Faria et al., 2009). In summary, the evidence for opposing results on 
glycoside and aglycone treatments suggest that the sugar moiety may interfere on 
GLUT2-mediated glucose transport and upregulation of GLUT2 gene expression may 
be relevant for longer term glycaemic control.   
In vitro studies using Xenopus oocytes to express either SGLT1 or GLUT2 under 
controlled conditions have shown an inhibitory effect of polyphenols and anthocyanins 
on glucose uptake.  Xenopus laevis oocytes are resilient cells that are easy to handle in 
laboratory studies. The expression system in oocytes has gained popularity due to their 
high transcriptional capacity and their ability to express multi-subunit proteins correctly 
assembled, post-translationally modified and correctly orientated following the injection 
of exogenous RNA or DNA (Gurdon et al., 1971, Sigel and Minier, 2005, Bianchi and 
Driscoll, 2006). Pelargonidin and pelargonidin-3-glucoside inhibit glucose absorption (1 
mM), with IC50= 1.34 and 2.47 mM respectively, in oocytes expressing SGLT1 (Kottra 
and Daniel, 2007). In a separate in vitro study using Xenopus oocytes expressing 
GLUT2, Kwon et al. (Kwon et al., 2007) were not able to detect an inhibitory effect on 
glucose uptake (10 mM) when testing delphinidin and cyanidin (0-300 μM), although 
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their glycosidic forms were not tested and other flavonoids present in berries, such as 
quercetin, were observed to inhibit GLUT2 mediated glucose transport.  
Overall, experiments using oocytes expressing individual sugar transporters and 
cultured intestinal cells have shown that berry extracts and individual anthocyanins may 
interfere with glucose transport from the gut lumen into the enterocyte, and also across 
the basolateral membrane into the blood. This may occur via inhibition of GLUT2 
under postprandial glycaemic conditions, since this transporter is believed to be 
functionally important under conditions of high luminal glucose concentrations (Zheng 
et al., 2012). However, inhibition of SGLT1 activity may also play a significant role in 
berry polyphenol-mediated control of glucose homeostasis since SGLT1 is instrumental 
in the regulation of GIP and GLP-1 secretion and upregulation of GLUT2 (Gorboulev et 
al., 2012). Extracts of berries used in the different studies may contain a range of 
different classes of polyphenols, and further in vitro studies testing individual 
anthocyanins are needed in order to pinpoint exact mechanisms for these intestinal 




1.6 Apple polyphenols  
Polyphenol content in fruit and vegetables is influenced by several factors as cultivar, 
ripeness and environmental factors as well as storage and processing conditions. Simple 
processing and cooking methods (freezing, cutting, slicing, heating, etc.) can alter the 
polyphenol content, e.g. a peeled apple differs in polyphenol content from an unpeeled 
one (Manach et al., 2004). Despite the likely variability in polyphenol content within 
food categories, databases on food average polyphenol content have been developed 
(Bhagwat, 2013, Neveu et al., 2010) and are commonly used to estimate polyphenols 
content in food and dietary intake. The main polyphenol subclasses in apple (Malus 
domestica) are represent by flavonoids followed by phenolic acids (Table 1.5). Apple is 
particularly rich in flavanols monomers (flavan-3-ols) and polymers 
(proanthocyanidins), although flavonols and phenolic acids are also present in 
considerable quantities. Characteristic phenolic compounds of apple are the 
dihydrochalcones, phloretin and its glycoside phlorizin; both compounds are found in 
peel (exocarp), flesh (mesocarp), seeds and stems (pedicel) of apple although higher 
concentrations are contained in peel than in flesh (Tsao et al., 2003). Phloretin and 
phlorizin have showed a wide variety of beneficial effects on in vitro and in vivo 
studies, including control of blood glucose and antioxidant capacity (de Oliveira, 2016). 
The diversity of polyphenols contained in apple and it worldwide availability had made 





Table 1.5 Major polyphenols contained in unpeeled raw dessert apple 







   Cyanidin-3-O-galactoside 0.8 ± 0.9 
Dihydrochalcones 5.4 
   Phloretin 2'-O-xylosyl-glucoside 2.6 ± 2.1 
   Phlorizin (phloretin-2’-O-glucoside) 2.7 ± 1.9 
Flavanols 24.2 
   (+)-Catechin 1.2 ± 0.8 
   (-)-Epicatechin 8.4 ± 3.7 




   01mers 7.2 ± 3.5  
   02-03 mers 19.8  
   04-06 mers 26.5 ± 5.2 
   07-10 mers 22.5 ± 4.2 
   Polymers (> 10 mers) 32.7 ± 7.0 
Flavonols  6.9 
   Quercetin  0.1 ± 0.1 
   Quercetin-3-O-arabinoside 1.4 ± 1.1 
   Quercetin-3-O-galactoside 2.4 ± 1.2 
   Quercetin-3-O-glucoside 0.6 ± 0.8 
   Quercetin-3-O-rhamnoside 1.3 ± 1.6 
   Quercetin-3-O-rutinoside 0.2 ± 0.1 




Hydroxybenzoic acids 1.1  
Hydroxycinnamic acids 17.9  
   4-p-coumaroylquinic acid 2.3 ± 1.9  
   5-caffeoylquinic acid (Chlorogenic acid) 13.4 ± 11.3 
   5-p-coumaroylquinic acid 1.1 ± 0.1   
Total polyphenols
4
  200.9 ± 104.8 
All values are mean ± SD 
1
FW fresh weight, all values are averages based on the 
Phenol-Explorer database www.phenol-explorer.eu  
2
 Analysed by chromatography  
3
 Analysed by normal phase HPLC 
4 





1.6.1 Dietary intake  
Dietary intake of flavonoids and phenolics acids estimated from FFQ and 24-HR in 
adult populations from different European countries vary from 200 to 1000 mg/d for 
flavonoids and from 250 to 900 mg/d for phenolic acids. The study showed the main 
food sources of flavonoids and phenolic acids for Mediterranean and non-Mediterranean 
countries and for a UK health-conscious group, “apples and pears” accounted for 22, 13 
and 5% of the flavonoid, and 4, 2 and 2% of phenolic acid intake, respectively. The 
main consumed individual flavonoids were proanthocyanidins polymers (>10 mers) and 
proanthocyanidins oligomers (4-6 mers) while the most consumed phenolic acids were 
5-caffeoylquinic acid (chlorogenic acid), 4-caffeoylquinic acid and 3-caffeoylquinic 
acid (Zamora-Ros et al., 2015).  
The same study also provided estimates of intakes of the main polyphenol subclasses 
contained in apple in a UK general population. Intake of flavan-3-ols monomers and 
proanthocyanidins in men and women were 213.5 ± 5.4 mg/d and 178.6 ± 4.5 and 217.1 
± 12.8 mg/d and 172.9 ± 10.5, respectively. Main food sources of flavan-3-ols 
monomers were tea (51%), followed by “apples and pears” (12%), whereas “apples and 
pears” were the main food source of proanthocyanidins (22% of intake) followed by tea 
(15%) (Knaze et al., 2012). In the same population flavonols intake were 51.0 ± 2.2 
mg/d and 42.4 ± 1.8 mg/d in men and women respectively. In the same study but in a 
UK health-conscious population, flavonol intakes were 54.9 ± 4.1 mg/d and 50.1 ± 3.1 
mg/d in men and women, respectively (Zamora-Ros et al., 2011a) and “apples and 
pears” were the main food source of procyanidin B2, proanthocyanidin oligomers (4-10 
mers) and proanthocyanidin polymers (>10 mers) and the third of chlorogenic acid 
(Zamora-Ros et al., 2015). All together these data revealed that apples represent one of 
the main food sources of flavonoids and phenolic acids.   
1.6.2 Epidemiological studies  
Epidemiological studies have shown an association between polyphenols intakes and 
reduced risk of T2D. Especial focus on flavonoid food sources and flavonoid subclasses 
has shown a reduced risk of T2D at higher apple, and its major flavonoid (flavanol and 
flavonol), intakes. A case-cohort study in a Finish population (n=10054 men and 
women) reported that consumption of >47 g of apple per day compared to no 
consumption (0 g) was inversely associated with occurrence of T2D. Although not 
significant association was found, a tendency in reduced risk of T2D was related with 
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higher quercetin intake with a relative risk (RR) of 0.81(95% CI: 0.64, 1.02) when 
comparing highest and lowest quartiles (Knekt et al., 2002). In the Women’s Health 
Study, a randomised controlled trial in a US population (n= 38,018) consumption of  >1 
apple per day compared with no apple intake showed a significant reduced risk of T2D 
with a multivariate-adjusted RR of 0.72 (95% CI: 0.56, 0.92) (Song et al., 2005). 
Recently in an elderly people at high cardiovascular risk-cohort (n=3340 men and 
women) of the PREDIMED trial, flavonoid and proanthocyanidin intakes were 
inversely associated with diabetes risk with a HR of 0.67 (95% CI: 0.48, 0.93) and 0.75 
(0.54, 1.04), respectively, when compared highest to lowest tertile (Tresserra-Rimbau et 
al., 2016). In the Framingham Heart Study Offspring Cohort (n=2915) flavonol intake 
was associated with a lower incidence of T2D with a multivariable-adjusted HR of 0.74 
(95% CI: 0.61, 0.90) when compared highest to lowest percentile (Jacques et al., 2013). 
In addition an inverse association between risk of T2D and high consumption of the 
flavan-3-ols monomers; catechin and epicatechin and proanthocyanidins; dimers and 
trimers was observed in a European case-cohort study population (n=26,088 men and 
women). Catechin and epicatechin showed a HR of 0.86 (95% CI: 0.75, 0.99) and 0.84 
(0.69, 1.04) respectively, when compared highest and lowest quintiles. 
Proanthocyanidins dimers and trimers showed a HR of 0.81 (95% CI: 0.71, 0.92) and 
0.91 (0.80, 1.04), respectively (Zamora-Ros et al., 2013). Epidemiological data suggests 
that apple and apple flavonoids may reduce T2D risk, although associations must be 
considered cautiously due to limitations on dietary assessment methodology, such as 
questionnaires not validated for polyphenol intakes and errors in self-reported intakes. 
Moreover higher intakes of fruit and/or flavonoids are related to indicators of a healthier 
lifestyle, therefore some confounders might be present in the models even after 
adjustment.         
1.6.3 Bioavailability of apple polyphenols 
The main requisite for polyphenols in order to exert any effect in vivo is their absorption 
from the gastrointestinal tract into bloodstream in order to reach target organ and 
tissues. Bioavailability of flavonoids and phenolic acids in apple and apple-derived food 
depends of several factors as food matrix, food processing, enzymatic activity in mouth, 
small intestine and liver and gut microbiota. See section 1.5.3 for further details on 




In a study on subjects with colectomy with terminal ileostomy, consuming one litre of 
cloudy apple juice (250 mg of polyphenols) only 33% of the polyphenols ingested were 
collected in the ileostomy bags after 6-8 h, which in normal conditions would reach the 
colon. Results suggested that the remaining 67% of the polyphenols were absorbed into 
enterocytes. Maximum excretion in ileostomy extract was reached at 2 h post 
consumption (Kahle et al., 2006). Of the total polyphenols collected (8 h) only 14% of 
the parental compounds determined in the apple juice were recovered. Different 
compound such as caffeic acid, procyanidins B, (+)-catechin, phlorizin, quercetin-3-O-
glucoside, quercetin-3-O-galactoside, and quercetin-3-O-xyloside were not detected in 
the collected fluid, suggesting that these compounds were absorbed or metabolised in 
small intestine. The aglycone phloretin, although not present in the apple juice, was 
quantified in the ileostomy extract with a maximum excretion between 2-4 h and the 
phloretin glucuronide was detected after 1 h with a maximum concentration at 2 h, 
indicating that phlorizin was hydrolysed before absorption (Kahle et al., 2005). A 
subsequent study by the same group identified in 24 h urine samples 90-95 % of the 
polyphenols consumed. Approximately 20% of the polyphenols consumed were found 
in the forms of hydroxylated phenolic and hippuric acids (Kahle et al., 2011). Results 
suggest a high bioavailability of apple polyphenols when consumed in juice. In vivo 
studies have tested the effect of the food matrix on individual apple polyphenols’ 
bioavailability. A randomised controlled trial testing the bioavailability of epicatechin 
(241 μmol), when contained in drinks supplemented with apple extract and in an apple 
purée, showed that epicatechin metabolism was faster when provided in the 
supplemented drink, Tmax 0.9 vs 1.7 h, respectively. Plasma concentration area under 
the curve (AUC 0–24 h), absorption and urinary excretion of epicatechin were also 
higher after consumption of epicatechin contained in drink compared with apple purée 
(Hollands et al., 2013). Results suggest that the apple purée matrix affected the 
bioavailability of epicatechin in small intestine. Other phenolic compounds present in 
apple have showed different metabolism absorption rate when consumed as pure 
compound vs contained in apple juice. Supplementation with one gram of chlorogenic 
acid showed absorption rate of 33% (Olthof et al., 2003), while consumption of 113 mg 
of chlorogenic acid contained in apple juice showed an absorption rate of 90% (Kahle et 
al., 2005). A latter study by Kahle’s group analysing serum and 24 h urine samples 
showed maximum absorption of chlorogenic acid at 0.7 h and recovery of 95-99% of 
apple-derived phenolic acids, indicating a high metabolism of phenolic acids contained 
in apple juice (Kahle et al., 2011).    
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1.6.4 Human studies on postprandial glycaemia 
Reports of clinical trials have shown that consumption of apple juice and apple extracts 
reduce significantly plasma glucose concentrations in early postprandial response. 
Individual polyphenols contained in high quantities in apple or apple derived food have 
also shown a lowering effect on plasma glucose response following the consumption of 
a high carbohydrate meal.    
In previous reports a cloudy apple juice containing 26 mg of phlorizin, 25 g glucose and 
30.7 g fructose significantly lowered plasma glucose in human volunteers compared to a 
control drink, as demonstrated by a lower glucose incremental area under the curve 
(iAUC) 0-30 and 30-90 min (Johnston et al., 2002). Furthermore, a dose of 2.8 g of an 
apple extract that appeared to be derived from apple pomace, containing a very large 
dose (448 mg) of phlorizin, reduced plasma glucose iAUC between baseline and 15, 30 
and 45 min in healthy human subjects following a 75 g glucose load (Schulze et al., 
2014), and 25 g of unripe apple extract, derived from apple pomace, containing 315 mg 
of phlorizin reduced postprandial glucose response in healthy volunteers following by a 
50 g glucose load (Makarova et al., 2015). The use of individual apple polyphenols in 
high and acute doses has also proved a hyperglycaemic effect. In a randomised clinical 
study 400 mg of quercetin reduced the plasma glucose AUC 0-180 min after a maltose 
load (2 g/Kg) but not after a glucose load (100 g) in T2D patients (Hussain et al., 2012). 
In a separate clinical study one gram of chlorogenic acid reduced plasma glucose and 
insulin concentrations after 15 min of an oral glucose tolerance test (OGTT) (van Dijk 
et al., 2009). Epicatechin, dosed at one mg per kg of body weight, consumed prior to an 
oral metabolic tolerance test (39 g of carbohydrates, 9 g of proteins and 6 g of lipid) 
decreased postprandial glycaemia at 2 h in normal and overweight subjects (Gutierrez-
Salmean et al., 2014). All together these findings suggest that apple polyphenols might 
have a protective effect on glucose response by decreasing plasma glucose levels after a 
high carbohydrate load. 
1.6.5 Effect of apple and apple polyphenols on carbohydrate metabolism 
Potential mechanisms for hypoglycaemic effect of apple polyphenols include inhibition 
of digestive enzymes activity, decrease of intestinal glucose absorption, and stimulation 
of insulin secretion and protection of pancreatic β-cells.     
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1.6.5.1 Digestive enzymes: in vitro studies  
During digestion of carbohydrates digestive enzymes, α-amylase and α-glucosidase play 
a central role degrading polysaccharides and oligosaccharides into shorter-chain 
oligosaccharides, disaccharides and ultimately, monosaccharides. 
In vitro studies have shown inhibitory effects on the activity of digestive enzymes -
amylase and -glucosidase (maltase and sucrase) by extracts from pulp and peel of 
different apple varieties. Concentrations from 10 to 500 μl of the extracts showed high 
α-amylase and α-glucosidase inhibitory activities in a dose-response manner. Peel 
extracts showed a higher α-glucosidase and a low α-amylase inhibitory activity when 
compared with pulp extracts while pulp extracts proved a higher α-amylase and low α-
glucosidase inhibitory activity. A positive correlation between α-glucosidase inhibitory 
activity and total phenolics in extracts was observed, peel extracts demonstrated higher 
total phenolic content than pulp extracts. However no correlation between α-amylase 
inhibitory activity and total phenolic content was observed (Barbosa et al., 2010).  
Apple polyphenols compounds of the flavonoid and phenolic acid subclasses have 
showed inhibitory effect on α-amylase and α-glucosidases activity. Flavan-3-ols 
catechin and epicatechin inhibited maltase activity with IC50 of 1.4 and 1.8 mM, 
respectively and sucrase activity with IC50 of 2.5 and 2.0 mM, respectively (Ishikawa et 
al., 2007), showing a marker effect on maltase activity. The flavonol quercetin showed 
inhibition of α-glucosidase; maltase and sucrase activity with IC50 of 0.7 and 1.5 mM, 
respectively (Ishikawa et al., 2007). In a separate study quercetin also proved to be an 
inhibitor of rat small intestine maltase and porcine pancreatic α-amylase with an 
inhibition of 28 and 50 % by quercetin 0.5 mM, respectively (Tadera et al., 2006). Later 
studies showed quercetin as an effective α-amylase activity inhibitor with and IC50 of 21 
μM, modelling studies suggested flavonols act by binding to the active site of the 
enzyme (Lo Piparo et al., 2008), and α-glucosidases activity inhibitor; maltase and 
sucrase (Pereira et al., 2011). Chlorogenic acid (5-caffeoyl quinic acid) showed 
inhibitory activity on α-glucosidases; sucrase and maltase action with IC50 of 1.4 and 
24.9 mM, respectively (Iwai et al., 2006). In a separate in vitro study chlorogenic acid 
inhibited maltase and sucrase activity with IC50 of 2.9 and 2.2 mM, respectively in a 
non-competitive manner (Ishikawa et al., 2007). Chlorogenic acid has also showed α-
amylase inhibition activity, with IC50 values of 0.07-0.08 mM (Narita and Inouye, 
2009). Proanthocyanidins from a persimmon peel extract showed α-amylase and α-
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glucosidase inhibition activity. Proanthocyanidins polymers proved higher inhibition on 
α-amylase activity, 100 μg/ml polymers or oligomers inhibited activity by 54% vs 5%, 
respectively. Oligomers showed a stronger inhibition on α-glucosidase activity, 25 μg of 
oligomers or polymers per millilitre inhibited activity by 90% vs 30%, respectively. 
Data suggest that the degree of polymerisation might play important role on the 
inhibition activity on α-amylase (Lee et al., 2007), previous studies have suggested 
proanthocyanidins act by binding to the protein rather than the active site (Grussu et al., 
2011). In a separate study proanthocyanidins from a maritime pine bark extract showed 
α-glucosidase inhibition activity (IC50= 5 μg/ml), the inhibitory effect of the extract was 
stronger in fractions containing proanthocyanidins with higher degree of 
polymerisation, when oligomers and dimer and trimers where compared. In the same 
study the flavan-3-ol catechin showed inhibition of α-glucosidase activity in a weaker 
manner (IC50= 52 μg/ml) (Schafer and Hogger, 2007).  
1.6.5.2 Glucose uptake by the intestine: in vitro studies  
In addition to potential polyphenol-induced delayed digestive breakdown of 
carbohydrates, inhibition of glucose transporters (SGLT1 and GLUT2) by apple extracts 
and phlorizin (Manzano and Williamson, 2010, Schulze et al., 2014) as well as 
quercetin glycosides (Ader et al., 2001) have been showed in in vitro systems.  
A flavonoid- and phenolic acid-rich apple extract showed 50% inhibition of total 
glucose uptake (1 mM) when 300 mg of apple solid extract were tested in Caco-2 cells. 
The apple extract also inhibited the GLUT-mediated glucose uptake by 50% at 146 mg 
of apple extract; results suggest a greater effect on the GLUT-mediated glucose uptake 
component in this in vitro system (Manzano and Williamson, 2010). However the 
effective doses represent supra-physiological concentrations, which are unlikely to be 
present in gut lumen under normal dietary conditions unless pureed and concentrated. 
Individual flavonoids and phenolics acid have also been tested in in vitro systems. The 
flavan-3-ols catechin and epicatechin (100 μM) when tested in the Caco-2 cells system 
caused a significant decrease in GLUT-mediated glucose uptake (1 mM) (Johnston et 
al., 2005), although they did not inhibit total glucose uptake (SGLT1- and GLUT-
mediated) either at 100 μM, nor at 50 μM as tested in a separate study (Shimizu, 2000). 
Results suggest that the flavan-3-ols monomers exerted inhibition of GLUT transporters 
in the Caco-2 model. The flavonol quercetin 100 μM inhibited GLUT-mediated glucose 
uptake (1 mM) by 75% but no total glucose uptake in Caco-2 cells (Johnston et al., 
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2005) and quercetin-3-O-rhamnoside inhibited total glucose uptake (1 mM) and apical 
to basolateral glucose transport with IC50 values of 380 and 31 μM, respectively 
(Manzano and Williamson, 2010).    
The dihydrochalcones phlorizin and phloretin have been proven to inhibit total and 
GLUT-mediated glucose uptake, respectively in Caco-2 cells in vitro model. Phlorizin 
100 μM inhibited total glucose uptake by 50% (Johnston et al., 2005) while the same 
degree of inhibition was showed on total glucose uptake by phloretin 468 μM (Manzano 
and Williamson, 2010), and in a separate study phloretin 100 μM inhibited by 47% 
GLUT-mediated glucose uptake (1 mM) but not total glucose uptake (Johnston et al., 
2005). Results suggest a higher inhibitory effect on total glucose uptake by phlorizin 
and higher inhibitory effect on GLUT-mediated glucose uptake by phloretin, which has 
been well documented (Wright et al., 2011). In the same in vitro model, 50% inhibition 
of total glucose uptake was exerted by chlorogenic acid 1.3 mM (Manzano and 
Williamson, 2010), and similar results were shown in a separate study using everted rat 
gut sacs, with 48 % inhibition of total glucose uptake by chlorogenic acid 1 mM 
(Ishikawa et al., 2007). On rat small intestine bush border membrane vesicles 
chlorogenic acid 1 mM inhibited total glucose uptake by 80 % (Welsch et al., 1989).   
In an in vitro model of oocytes injected to express SGLT1, 0.24 μg/ml of a phlorizin-
rich apple extract showed 50% inhibition of glucose uptake (Schulze et al., 2014). 
Phlorizin is a well-known competitive inhibitor of SGLT1 with a Ki ∼200 nM (Wright 
et al., 2011) and its aglycone phloretin has also showed a SGLT1 inhibitory effect in a 
non-competitive manner (Hirayama et al., 2001, Schulze, 2014). Other flavonoids 
contained in apple and apple derived food, as flavonols quercetin (IC50= 0.62 mM), 
quercetin-3-O-galatoside (IC50= 1.32 mM) and quercetin-4’-O-glucoside (IC50= 0.17 
mM) have showed inhibition of SGLT1 (Kottra and Daniel, 2007, Schulze et al., 2015). 
In the same in vitro system but with oocytes injected to express GLUT2, quercetin 




1.7 Proanthocyanidins  
Proanthocyanidins (also known as condensed tannins) is a complex group of the 
flavanol subclass, consisted of monomers, dimers, oligomers and polymers of catechin 
and/or epicatechin units (Figure 1.4) that may also contain gallate esters. 
Proanthocyanidins consisting exclusively of catechin/epicatechin units are named 
procyanidins and are the most common type in plants. Fruit and vegetables are among 
the main food sources of proanthocyanidins, but nut skin contains the highest quantities 












Figure1.4 General structure of proanthocyanidin oligomer 
 
As mention in the previous section, proanthocyanidin intakes have been associated with 
reduced risk of T2D and in vitro studies have showed inhibition of digestive enzymes 
activity. Bioavailability studies on proanthocyanidin have showed a decreased 
permeability into intestinal cells and high interaction with the plasma membrane. 
Probable factors affecting the permeability are molecular weight, polymerisation 
degree, hydrophilic characteristic and affinity for luminal proteins (Deprez et al., 2001). 
The permeability of proanthocyanidins tends to decrease when polymerisation increase, 
proanthocyanidins dimers and oligomers (2-5 mers) have demonstrated being 
absorbable but proanthocyanidins with a higher polymerisation degree (>5 mers) has 
showed nil permeability into intestinal cells in studies with animals and humans 
(Neilson et al., 2016). High molecular phenolic molecules as proanthocyanidins, with a 
size up to 10 kDa (Yanagida et al., 2003), present a significant number of hydroxyl 
groups in their structure what give them hydrophilic characteristics. It is known that 
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hydrophilic flavonoids may interact by hydrogen bonding with the polar head groups of 
the phospholipids in the outer leaflet of the plasma membrane (Oteiza et al., 2005), the 
degree of interaction appears to be mediated by the presence of hydroxyl groups in the 
flavonoid compound. A research group has suggested that big molecules of polyphenols 
may interact with phospholipids coating the surface and covering proteins inserted in 
the plasma membrane (Tarahovsky, 2008). Their capacity to bind to membrane 
phospholipids and a possible interaction with proteins by covalent and non-covalent 
bonds (Kroll et al., 2005) might explain some of their effects. Although consumption of 
proanthocyanidin-rich food (such as tea and wine) has showed to inhibits the absorption 
of non-heme dietary iron through the gut, due to their affinity for iron (III) and the non-
specific binding of proanthocyanidin to phospholipids and proteins possibly interfere 
with other nutrients transporters, its nutritional implication is probably of limited 






1.8 Overall aims  
Polyphenol-rich fruit intake is associated with reduced risk of T2D. Epidemiological 
studies suggest that berry and apple intakes in particular correlate with beneficial health 
effects. UK dietary guidelines recommend that the average intake of fruit and 
vegetables is increased from the current estimates of 4.1 portions per day (adults aged 
19-64 y (Bates et al., 2014)) to “5-a-day”, but there is no special recommendation for 
polyphenol-rich fruit and/or vegetables. Therefore, the first aim of this project was to 
investigate whether adherence to UK dietary guidelines and increasing the consumption 
of fruit and vegetables to at least 5 portions/day led to an actual increased intake in 
polyphenols associated with beneficial effects on health (Chapter 2).       
Fruit polyphenols may help to delay glucose absorption and thereby control glucose 
levels following a carbohydrate-containing meal or beverage. Many of the clinical trials 
testing effects of polyphenol-rich fruits on postprandial glucose have used the entire 
fruit, fruit purées, fruit juices or similar foodstuff that include in the food matrix other 
components as fibre that might interfere with glucose response, besides some trials 
using carbohydrate loads that might not simulate normal dietary habits. The second aim 
of this project was to determine whether plasma glucose concentrations were reduced by 
consumption of highly purified blackcurrant and apple extracts immediately before a 
high-carbohydrate (starch and sucrose) test meal (Chapter 3).   
Blackcurrant and apple–based test meals have been shown to lower postprandial 
glycaemia in vivo, and some reports suggest that polyphenols derived from these fruits 
can inhibit glucose uptake in in vitro models of the small intestine. However 
concentrations tested in vitro frequently exceed achievable concentrations in normal 
diets therefore the third and final aim of this thesis was to identify the mechanisms of 
glucose uptake inhibition by physiological concentrations of blackcurrant and apple 
extracts, consumed in our clinical trials, using the intestinal sugar transport model Caco-
2/TC-7 cells and the Xenopus laevis oocytes system (Chapter 4).   
The specific aims and hypotheses are detailed within the individual chapters, but the 
overarching thesis is that regular dietary intakes of blackcurrant and apple polyphenols 
may help reduce risk of type 2 diabetes and cardiovascular disease by reducing the rate 
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2.1 Introduction  
The World Health Organization recommends consumption of 5 portions of fruit and 
vegetables per day (WHO, 1990), UK dietary guidance follows this recommendation 
(NHS, 2005) but the National Diet and Nutrition Survey (NDNS) (Bates et al., 2014) 
reveals that consumption of fruit and vegetables are below the recommendation in 70 % 
of UK adult population. UK government guidelines also recommend an increase from 
23 g to 30 g for the average adult population intake of dietary fibre (SACN, 2015) and 
although there is not a specific guideline on whole grains, data from the NDNS revealed 
that UK adult population intake is below other countries recommendations (Mann et al., 
2015). High intake of fruit and vegetables, and dietary fibre/whole grains are associated 
with a reduced risk of chronic diseases (Boeing et al., 2012, Muraki et al., 2013, Mursu 
et al., 2014, Buil-Cosiales et al., 2016, Aune et al., 2016); the increased consumption of 
different components present in these food groups, like fibre (Ötles and Ozgoz, 2014), 
micronutrients (Woodside et al., 2005) and polyphenols (Rodriguez-Mateos et al., 
2014), have been identified as responsible for some of the beneficial effects.   
Dietary intakes of polyphenols are derived from a wide range of foods: fruits, 
vegetables, cereals and plant-based beverages such as tea, coffee, red wine, fruit juices 
and cocoa represent the main dietary sources (Manach et al., 2004). Epidemiological 
studies have shown a negative relationship between ingestion of polyphenols and 
cardiovascular disease (Hooper et al., 2008, Jennings et al., 2012, McCullough et al., 
2012, Cassidy et al., 2013, van Dam et al., 2013), cancer (Neuhouser, 2004, Arts and 
Hollman, 2005, Fink et al., 2007, Yuan, 2011) and type 2 diabetes (Wedick et al., 2012, 
Curtis et al., 2012, van Dam et al., 2013, Jennings et al., 2014, Jacques et al., 2013). 
Although epidemiological studies rely on the estimation of polyphenol intakes this is a 
difficult enterprise, since the most common dietary assessment methods employed for 
estimation, such as FFQ, 24-HR and food diaries, depend on the ability of the subject to 
accurately describe their own food intake and the availability of adequate databases for 
the content of polyphenols on food (Zamora-Ros et al., 2014). At present, the most 
common databases employed to assess polyphenol intakes are the USDA (Nutrient Data 
Laboratory, 2004, Bhagwat, 2008, Bhagwat, 2013) and Phenol-Explorer (Neveu et al., 
2010, Rothwell et al., 2012, Rothwell et al., 2013) which provide information on the 
content of 35 flavonoids in 506 food items and 502 polyphenols (of the 4 classes) in 459 
food items, respectively.  
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New techniques for intake estimation have been examined; these include innovative 
technologies for measuring dietary intakes in epidemiological studies, like personal 
digital assistant and camera and tape recorder (Illner et al., 2012), as well as biomarker 
approaches, like urine and plasma metabolites. Urinary excretion of polyphenols has 
proved to be a valid and reliable biomarker for the intake of polyphenols (Mennen et al., 
2008, Perez-Jimenez et al., 2010a), fruit and vegetables (Nielsen et al., 2002, Krogholm 
et al., 2004), polyphenol-rich beverages (Ito et al., 2005, Mullen et al., 2010) and 
polyphenol-rich food (Mennen et al., 2006, Edmands et al., 2015). The presence of 
polyphenol metabolites in urine is closely related to the quantity consumed and the 
overall metabolism in the body, however different polyphenols may produce common 
metabolites therefore the biomarker selected must reflects the specific intake of the 
parent polyphenol in question (Spencer et al., 2008).   
No dietary recommendations exist for polyphenols, although the advantages and 
disadvantages of this approach have been debated (Williamson and Holst, 2008, Lupton 
et al., 2014). It is assumed that a dietary pattern consistent with current dietary 
guidelines will be richer in polyphenols than the average UK dietary pattern due to 
increased intakes of fruit and vegetables and whole grains. However, not all fruits and 
vegetables are polyphenol rich (Perez-Jimenez et al., 2010b), and in fact the majority of 
UK average polyphenol intakes are determined by tea, coffee, and chocolate intakes 






Intakes of total polyphenols and subclasses of polyphenols will be greater in a free-
living population following UK dietary guidelines when compared to average 
traditional UK diet.  
2.3 Methodology 
The Cardiovascular risk REduction Study: Supported by an Integrated Dietary 
Approach (CRESSIDA) was a parallel-designed, randomised, controlled trial funded by 
the Food Standards Agency/Department of Health (UK) (N02047), sponsored by King’s 
College London and approved by the St. Thomas' Hospital Research Ethics Committee 
(10/H0802/24) (Reidlinger et al., 2015). Recruitment commenced in 2010 and the last 
participant completed the trial in July 2012. This trial was registered at Current 
Controlled Trial (http://www.controlled-trials.com/ISRCTN) as ISRCTN92382106. The 
primary aim of the study was to compare a traditional UK diet with what is currently 
believed to be a cardioprotective diet (following UK government dietary guidelines), a 
dietary guidelines (DG) diet, to assess effects on well-established and emerging CVD 
risk factors. Changes in blood pressure and plasma total cholesterol/HDL cholesterol 
ratio were primary outcomes as these are powerful and well-established predictors of 
future CVD risk. Secondary outcomes included endothelial function, arterial stiffness, 
C-reactive protein and measures of insulin sensitivity. 
Participants between the age of 40-70 y were chosen because risk increases markedly 
with age and an upper age limit of 70 y was selected because absolute annual risk of 
CVD exceeds 2 % beyond that age in the majority of people and a higher proportion are 
receiving medication on daily basis. In selecting the control diet, it was decided to 
compare the DG diet adhering to current UK dietary guidelines with a nutritionally 
balanced traditional UK control diet that would be acceptable to study participants and 
formulated with familiar foods (full cream milk, cheese, butter, meat and meat products, 
non-wholegrain cereals) which reflected typical UK intakes of fruit and vegetables (3 
portions/d), had a high saturated fatty acids content (14 % energy), unrestricted intakes 
of salt and sugar and low intakes of oily fish.  
The lead researcher was Prof Thomas Sanders, co-investigators were Dr Wendy Hall, 
Dr Sarah Berry, Prof Phil Chowienczyk and Dr Paul Seed, and study investigators 
included Dr Dianne Reidlinger, Dr Julia Darzi, Ms Virginia Govoni, Dr Louise Goff, 
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Mr Robert Gray and Ms Laura O'Sullivan. The author’s participation consisted in the 
adaptation of the dietary database provided by Dr Dianne Reidlinger for its post hoc use 
in the analysis of flavonoids and total polyphenols consumption.                 
2.3.1 Participants    
A total of 165 healthy men and women aged 40–70 years were recruited, and 162 
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Participants received dietary advice in person at baseline and at week 4, and by phone at 
week 6 and 8. Dietary assessment included two food frequency questionnaires (FFQ), 
two four-day food diaries (4-DFD) and two 24-HR recalls (Figure 2.2).   
 
Figure 2.2 CRESSIDA study timeline 
 
2.3.2 Dietary advice 
Participants randomised to the DG diet group were given advice to consume 2 portions 
of fish per week (1 of which should be oily); to consume reduced fat dairy products 
instead of full-fat products; to replace fats rich in saturated fatty acids with spreads/oils 
low in saturated fatty acids and high in monounsaturated fatty acids; to increase intake 
of fruit and vegetables to 5 portions/day; to restrict salt intake to <6 g/d (<100 mmol/d); 
to reduce intake of free1 sugars; and to increase whole grains intake to >50% of cereal 
intake. On the other hand, the participants randomised to the control diet (reflecting the 
average traditional British diet) were advised to restrict intake of oily fish to less than 1 
per month; to consume oils, spreads and dairy products that were higher in saturated 
fatty acids; to restrict intake of fruit and vegetables to 3 portions/day; there was no 
restriction on salt or free sugars intake; and to consume refined cereals. The study 
included provision of spread, oil, whole grain pasta, rice and cereal bars, high fibre 
breakfast cereal (oats, muesli, etc.), almonds and macadamia nuts and tinned oily fish to 
the intervention group and spread, oil and refined cereals as pantry items to the control 
group (Reidlinger, 2015).  
                                                                 
1
 CRESSIDA study was done before SACN 2015 where definition of ‘free sugars’ was stablished instead of 
the previous ‘non-milk extrinsic sugars’ term and guidelines on sugar and fibre were changed.    
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2.3.3 Food frequency questionnaires (FFQ) 
Dietary intake of flavonoids was quantified from 322 FFQs (n=161) (EPIC-Norfolk 
FFQ v.6) (Bingham et al., 1994) at baseline and endpoint of the 12-wk intervention; 
data from one participant had to be omitted because both FFQ were not completed. 
Flavonoid intake was estimated from 6 subclasses and most representative compounds 
for each: flavanones (hesperetin, naringenin, eriodictyol), anthocyanins (cyanidin, 
delphinidin, malvidin, pelargonidin, peonidin, petunidin), flavones (apigenin, luteolin), 
flavonols (quercetin, kaempferol, myricetin, isorhamnetin), flavan-3-ols (catechin, 
gallocatechin, epicatechin, epigallocatechin, epicatechin-3-gallate, epigallocatechin-3-
gallate) and polymers (theaflavins, thearubigins and proanthocyanidins). In total 32 
types of flavonoids were analysed using a database created and provided by Prof Aedin 
Cassidy at University of East Anglia (Jennings et al., 2012) and modified for the 
requirements of the FFQ´s analysis, so that the flavonoid content of 130 food items 
were analysed.  
FFQ registers the frequency of consumption of specific foods, of standard portion size, 
in a month. There were nine answer options which varied from “never or less than once 
in a month” to “six or more per day”. To calculate the total intake of subclasses of 
flavonoids, frequencies were converted to a daily portion (Table 2.1) and then 
multiplied for the flavonoid content in each specific food item; the results were summed 
for each subclass and for each participant.  
Table 2.1 Example of conversion of FFQ answers to a daily portion on the item 
strawberries, raspberries and kiwi fruit 
Subject 
Food item 
Strawberries, raspberries, kiwi fruit 






(100 g in database-




003 1 Never or less than once a month 0 0 
015 3 Once a week 0.14 14 
040 2 1-3 per month 0.06 6 
140 4 2-4 per week 0.43 43 
028 6 Once a day 1 100 
225 5 5-6 per week 0.785 78.5 
1
Values for different foodstuffs in the same food variable were averaged out to create a 
single food item. 
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For calculation of total intake of flavonoids per subject, Microsoft Excel 2007 for 
Windows was used, different equations were used to import data from database, 
multiply flavonoid content in each specific food per daily portion and finally to sum up 
values on each subclass and individual flavonoid for each participant (Table 2.2).    
Additional food not included in the FFQ standard items but mentioned by participants 
as food they eat more than once a week were also included in the calculation of 
flavonoid intakes.   
For assessment of the main food sources of the subclasses and individual flavonoids 
pivot tables were created using Microsoft Excel 2007 for Windows. Final calculations 
on flavonoid intakes were included in three separate tables; one for baseline estimations 
in control and intervention group, one for endpoint estimations on control group and 



















Figure 2.3 Example of pivot table for assessment of main food sources of flavonoids in CRESSIDA population based on FFQ analysis 















003 Strawberries, raspberries, kiwi fruit 0 0 0 0 0 0 0 0 
015 Strawberries, raspberries, kiwi fruit 14 11.53 0.012 3.34 0.53 0.13 0.052 7.47 
040 Strawberries, raspberries, kiwi fruit 6 4.95 0.005 1.43 0.23 0.06 0.022 3.20 
140 Strawberries, raspberries, kiwi fruit 43 35.46 0.037 10.26 1.63 0.41 0.159 22.96 
028 Strawberries, raspberries, kiwi fruit 100 82.46 0.086 23.86 3.80 0.96 0.370 53.38 
225 Strawberries, raspberries, kiwi fruit 78.5 64.73 0.067 18.73 2.98 0.75 0.290 41.91 
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2.3.4 Four-day food diary (4-DFD) 
Dietary intake of polyphenols was quantified from 322 x 4-DFD (n=161), at baseline 
and endpoint of the 12-wk intervention. A polyphenol food composition database was 
created using Phenol-Explorer (Neveu et al., 2010, Rothwell et al., 2013, Rothwell et 
al., 2012) and USDA databases (Bhagwat, 2013, Bhagwat, 2008, Nutrient Data 
Laboratory, 2004), and extended using polyphenol retention factors and recipes 
provided by participants. If a recipe was not provided by participant, a standard recipe 
was obtained from either the UK food tables (Finglas, 2015), a UK food industry recipe 
book (Campbell, 2012), the BBC Good Food website (Worldwide, 2009) or additional 
websites specialised in UK recipes and other countries typical cuisine.  
Polyphenol intake was estimated for four classes of polyphenols: flavonoids, lignans, 
phenolic acids and stilbenes. An additional group of polyphenols were included under 
the name “other polyphenols”; since Phenol-Explorer (PE) grouped here a series of 
compounds as alkylmethoxyphenols, alkylphenols, curcuminoids, furanocoumarins, 
tyrosols among others. 
The flavonoid intake was analysed in eight subclasses: anthocyanins, dihydrochalcones, 
flavanols (flavanol-3-ols monomers and theaflavins), proanthocyanidins, flavanones, 
flavones, flavonols and isoflavones, for each subclass a range of two to eleven of the 
most representative individual compounds were selected. For lignans subclass four 
individual compounds were analysed: pinoresinol, lariciresinol, secoisolariciresinol and 
matairesinol. For phenolic acids subclass two groups were analysed: hydroxybenzoic 
acids and hydroxycinnamic acids, for each group a range of four to six of the most 
representative individual compounds were selected. For stilbenes subclass one 
individual compound was selected and analysed: resveratrol. A total of 52 individual 
polyphenols were analysed and 1141 food items were included in the final database 
(Table 2.3). The selection of the database (USDA/PE) was based on availability and 
polyphenol profile description of the food item, if both databases described the food the 
one with the more detailed profile was used.      
The food diary registers the grams or millilitres of food ingested by participant per day, 
to calculate the total intake of polyphenols subclasses and individual compounds, grams 
or millilitres of food were multiplied for the polyphenols content in each specific food 




The creation of the database for analysis of total polyphenol intake was a meticulous 
process, involving the description of polyphenol contents on raw food as fruit and 
vegetables than can be consumed without exposure to any cooking (boil, fry, bake, 
roast, etc.) or physical process (peeling, freezing, storing, etc.). Retention factors, when 
available, were used to modify the polyphenol content on particular food after 
experiencing cook or physical modifications, retention factors indicate how much of the 
content of raw food is keep after the alteration (for examples see Table 2.4). The 
process of creation started on November 2012 and the database was finished on April 
2015.   
In addition to the values of individual food items, 403 recipes were broken down in 
order to estimate the total polyphenol content on them (Table 2.5). As previously 
mentioned recipes were obtained from different sources; in total 118 recipes were 
obtained from participants, 93 from UK food tables, 20 from a UK food industry recipe 
book, 78 from the BBC Good Food website and 94 from other websites.  
For calculation of total intake of polyphenols per subject, Microsoft Excel 2007 for 
Windows was used, different functions were used to import data from databases (food 
polyphenol content and food dietary intake); multiply polyphenol content in each 
specific food per grams or millilitres ingested and finally to sum up values on each 
subclass and individual polyphenols for each participant (Table 2.3). Although nutrient 
intakes on the CRESSIDA population were calculated using Weighed Intake analysis 
Software Package (Tinuviel Software, WISP version 3.0), the software allowed only the 
storage of information for 30 polyphenols to be quantified limiting the analysis planned 
and leading to the preference for Excel, allowing unlimited number of polyphenols to 
include in the final polyphenol intake analysis.      
For assessment of the main food sources of the subclasses and individual polyphenols 
pivot tables were created using Microsoft Excel 2007 for Windows. Final calculations 
on polyphenols intakes were included in three separate tables; one for baseline 
estimations in control and DG group, one for endpoint estimations on control group and 






Table 2.3 Small section of the database created to calculate the total polyphenol intake estimated by 4-DFD 
 
Food code Food name 
Database 
Food weight 











13148 Alfalfa, sprouts, raw USDA 100 1.70 0.00 0.00 0.00 1.70 
8293 Almond cake, homemade, recipe RFP 495
1
 194.78 0.00 11.99 0.00 206.77 
10214 American muffins, chocolate M&W 532
1
 3744.37 0.00 51.92 0.17 3796.46 
11279 Apple pie, pastry top and bottom  BBC 1926.5
1
 1294.20 0.00 262.69 0.00 1556.89 
30376 Apple sponge OW 584
1
 129.42 0.00 39.17 0.00 168.59 
14012 Apples, eating, average, raw PE 100 146.11 0.00 19.89 0.00 166.00 
14014 Apples, eating, average, raw, peeled PE 100 129.42 0.00 19.91 0.00 149.33 
11 Apricot, jam PE 100 0.89 0.00 0.00 0.00 0.89 
14025 Apricot, raw PE 100 26.18 0.00 5.33 0.00 31.51 
USDA, United States Department of Agriculture databases; RFP, recipes from participants; M&W, recipes from UK food tables; BBC, BBC Good food website, 
OW; other websites, PE; Phenol-Explorer database.  
1 
Grams per recipe 
 





Table 2.4 Example of retention factor used to modify polyphenol contents 
 
Food 
















13342 Shallots, raw  PE 100 
 
112.00 112.00 112.00 1.00 1.00 113.00 
43 Shallots, fried PE 100 0.79 88.48 88.48 88.48 1.00 1.00 89.48 
13446 Carrots, old, raw  PE 100  0.72 0.45 0.00 19.51 18.83 20.23 
47 Carrots, old, fried PE 100 1.22 0.72 0.45 0.00 23.66 22.97 24.38 
13009 Old potatoes, average, raw  PE 100  0.06 0.06 0.005 28.35 28.35 28.41 
13014 Old potatoes, average, boiled PE 100 0.82 0.06 0.06 0.005 23.25 23.25 23.31 











Table 2.5 Example of breakdown of recipes and quantification of polyphenol content 
Food 













8174 Shepherd's Pie (RFP) 
 
        
18040 Beef, mince, extra lean, raw 500 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0 
13461 Tomatoes, canned, whole contents  400 1.74 0.00 1.26 0.00 0.48 0.00 13.18 14.92 
13822 Curry powder 9 6.67 6.67 0.00 0.00 0.00 25.67 0.00 32.34 
43 Shallots, fried 60 53.09 0.00 0.00 0.00 53.09 0.00 0.60 53.69 
13451 Celery, fries 80 3.61 0.00 0.00 3.12 0.49 0.00 0.00 3.61 
13466 Leeks, fried 100 2.98 0.00 0.00 0.00 2.98 0.00 0.00 2.98 
47 Carrots, old, fried 85 0.61 0.00 0.00 0.23 0.38 0.00 20.11 20.72 
13014 Old potatoes, average, boiled 800 0.48 0.00 0.00 0.00 0.48 0.00 186.00 186.48 
17516 Tomato puree 15 0.63 0.00 0.00 0.00 0.63 0.00 0.00 0.63 
12002 Skimmed milk, pasteurised 150 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0 
5017 Study spread 80% fat 20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0 
 
Total     2219    69.81         6.67           1.26           3.35    58.53  25.67  219.89  315.37 





Figure 2.4 Example of pivot table for assessment of main food sources of polyphenols in CRESSIDA population based on 4-DFD analysis
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2.3.5 Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) 
A previously published protocol for polyphenol analysis in urine (Ito et al., 2005) was 
adapted and developed by the author for the quantification of ten aglycone metabolites 
of polyphenols in 24 h urine samples from the CRESSIDA study participants. 
A subsample of the CRESSIDA study was selected for the analysis; the selection was 
based in the intake of fruit and vegetables (F&V) reported in the endpoint FFQ, 45 
samples from participants in the control group reporting the lowest intakes of F&V, and 
46 samples from participants in the intervention group reporting the highest intakes of 
F&V were analysed. Quantification of endpoint samples allowed the comparison 
between groups at the end of the dietary intervention; the aim was to detect greater 
amounts of polyphenols excreted in urine by participants randomised to the intervention 
group, in order to determine whether this mirrored the dietary intake pattern observed in 
FFQ and 4-DFD analysis.    
 
One or two of the most representative aglycones of different subclasses of polyphenol 
were selected for their quantification, the ten phenolic compounds analysed were as 
follows; phloretin (dihydrochalcones), epicatechin (flavan-3-ols), hesperetin and 
eriodictyol (flavanones), luteolin (flavones), quercetin (flavonols), daidzein 
(isoflavones), gallic and vanillic acid (phenolic acids) and enterolactone as a product of 
microbial metabolism of lignans in colon. The phenolic compounds selected for 
quantification had proved to be convenient biomarkers of polyphenol intake (Perez-
Jimenez et al., 2010b) with a high recovery and good correlation with fruit and 
vegetable intakes when estimated by FFQ, 24-h recalls or food diaries (Edmands et al., 
2015). The major food sources of the ten phenolics compounds are fruit, vegetables and 
wholegrain products, or represent the main metabolites of parent glucosides present in 












Table 2.6 Main food sources of the ten phenolic compounds selected for LC-MS/MS 
analysis 
Polyphenol Main food sources
*
 




Phloretin  Apple Apple 
Epicatechin Cocoa, dark and milk chocolate, 
apple, green tea, black tea, 
blackberry  
Black tea, apples and pears, milk 
beverages, cakes and sweet pies, 
chocolate candy/bars (Knaze et al., 
2012)  
Hesperetin Orange, blood and blond, 
lemon, tangerine, peppermint  
Fruit juices, citrus fruit, 
carbonated/soft drinks (Zamora-Ros et 
al., 2015) 
Eriodictyol Peppermint, oregano, lemon, 
sour orange, almond 
Main sources of flavanones: citrus 
fruits, juices, wine (Zamora-Ros et al., 
2011a) 
Luteolin Oregano, thyme, sage, 
artichoke, cabbage, brussels, 
black olive, olive oil, pistachio  
Main sources of flavones: herbal tea, 
juices, condiments, citrus fruits, wine, 
olives (Zamora-Ros et al., 2011a) 
Quercetin Chokeberry, black tea, red 
raspberry, greencurrant, dark 
chocolate, red lettuce, red 
onion, broccoli  
Main sources of flavonols: black tea, 
apples and pears, onion, garlic, soups 
(Zamora-Ros et al., 2011a)  
Daidzein Soy tempeh, soy tofu, soybean, 
soy milk, black bean, soy flour   
Main source of isoflavones: bread
2 
and 





, soy milk (Mulligan 
et al., 2013)  
Gallic acid Cloves, green and red chicory, 
black tea, blackberry, red wine  
Black tea, wine, mixed fruits 
(Zamora-Ros et al., 2015) 
Vanillic acid Dried sweet basil, dried dates, 
dried thyme, cranberry, green 
olive  
Main sources of phenolic acids: 
coffee, black tea, breakfast cereals, 
herbal tea, wine, apples and pears, 







Table 2.6 continued 





Main source of lignans: 
linseeds, sesame seed, 
sunflower seed, dried date, 
cashew nut, peanut 
Main source of lignans: Seeds, 
vegetable oils, condiments, bread 
(Zamora-Ros et al., 2015) 
*Data obtained from Phenol-Explorer and USDA databases  
§ 
Data obtained from the European Prospective Investigation into Cancer and Nutrition (EPIC) study  
1
 Enterolactone is a metabolite of lignans  
2 








Purified standards and reagents used in the processing of 24 h urine samples are listed in 
Table 2.7. Stock solutions were prepared for all the purified phenolic compounds, two 
milligrams of each of the following compounds; phloretin, epicatechin, eriodictyol, 
hesperetin, luteolin, quercetin, gallic acid, vanillic acid and enterolactone were diluted 
in one millilitre of methanol, two milligrams of daidzein in one millilitre of dimethyl 
sulfoxide and one milligram of Catechin-2, 3, 4-13C3 (internal standard) in one millilitre 
of methanol. Stock solutions were kept at -40 o C or -80 o C (internal standard). Enzyme 
β-glucoronidase/sulfatase (0.05 g) type H-5 from Helix Pomatia was diluted in one 
millilitre of 0.2% sodium chloride solution to have a working solution of ~50,000 units 
per millilitre; the enzyme solution was stored at -40 o C.   
Table 2.7 List of material used to process 24 h urine samples 
Material Supplier details 
Phloretin Santa Cruz Biotechnology, cat. no. sc-3548 
Epicatechin Santa Cruz Biotechnology, cat. no. sc-205672 
Eriodictyol Sigma-Aldrich, cat. no. 74565-5MG-F 
Hesperetin Santa Cruz Biotechnology, cat. no. sc-252878 
Luteolin Santa Cruz Biotechnology, cat. no. sc-203119A 
Quercetin Sigma-Aldrich, cat. no. Q4951-10G 
Daidzein  Santa Cruz Biotechnology, cat. no. sc-24001 
Gallic acid Santa Cruz Biotechnology, cat. no. sc-205704 
Vanillic acid Santa Cruz Biotechnology, cat. no. sc-251422 
Enterolactone Sigma-Aldrich, cat. no. 45199-5MG-F 
(+/-) Catechin-2, 3, 4-
13
C3 Sigma-Aldrich, cat. no. 719579-1MG 
β-glucoronidase type H-5  
from Helix Pomatia 
Sigma-Aldrich, cat. no. G1512-100KU 
Methanol Fisher Scientific CAS-No 67-56-1 
Dimethyl sulfoxide (DMSO) Fisher Scientific CAS-No 67-68-5 
HPLC-grade water Fisher Scientific CAS-No 7732-18-5 
Ethyl acetate Fisher Scientific CAS-No 141-78-6 
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2.3.5.2 Working solutions  
Working solutions were freshly prepared the same day that samples were processed; 
mixed polyphenols working solution was prepared by taking 10 μl of each stock 
solution (ten purified compounds), in total 120 μl and made up to 10 ml with HPLC-
grade water for a final concentration of 2 ng/μl. The internal standard working solution 
were prepared by taking 12 μl of stock solution and made up to 4 ml with HPL-grade 
water for a final concentration of 3 ng/μl. Working solutions were used to prepare 
calibration curves.    
2.3.5.3 Urine collection  
Urine samples were collected at five time-points (Figure 2.2), but LC-MS/MS analysis 
was only performed on endpoint samples, collected at week 12 of the intervention to 
coincide with dietary assessment by 4-DFD. A urine collection protocol was developed 
based on standardised methods used in previous studies (Sadler et al., 2012). 
Participants were asked to collect all urine from the second pass of the day until the first 
pass of the following day in 2.5 L bottles containing boric acid as preservative, as used 
in the EPIC study for preservation of urine stored at -20 ο C for at least 15 years prior to 
polyphenol analysis (Achaintre et al., 2016). Participants were asked to mark the 
meniscus of the urine on each bottle and then carefully transfer 10 ml aliquot from each 
bottle using a 10 ml Urine Monovette (Sarstedt, cat no 10.252), labelled with the 
relevant bottle number. The remaining urine was disposed of and the Urine 
Monovette(s) containing the urine aliquot(s) and empty urine bottle(s) marked with the 
urine meniscus were conserved. The total urine volume was recorded and 7 x 1.5 ml 
aliquots of pooled 24 h urine samples were stored at -80oC until analysis. Completeness 
of urine collection was measured using recovery of para-aminobenzoic acid according 
to a standard protocol (Bingham and Cummings, 1983), participants were asked to take 
3 x 80 g para-aminobenzoic acid at three regularly spaced intervals throughout the day 
of urine collection.  
2.3.5.4 Enzymatic hydrolysis  
Hydrolysis of metabolites in urine started with the acidification of 250 μl of urine 
sample with 20 μl of acetic acid (0.58 M), following by addition of 1300 units of β-
glucoronidase/sulfatase contained in 26 μl of 0.2% sodium chloride solution, for 
hydrolysis of glucuronide and sulphated metabolites. Catechin-13C3 (3 ng/μL) was used 
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as internal standard, 100 μl were added to each sample. The mixture was incubated in a 
shaking water bath at 37 o C, 120 rpm for 1.5 h, after incubation the mixture was 
acidified by addition of 10 μl of hydrochloric acid (HCl, 1 M) followed by a liquid-
liquid extraction. Extraction was performed twice by adding 400 μl and 300 μl of ethyl 
acetate, mixed by vortex for 20 min and centrifuged at 3000 rpm, 25 o C for 10 min. The 
two organic layers were pooled and evaporated until dryness under N2 followed by 
reconstitution in 100 μl of 40 % methanol immediately before injection. Batches of 
urine samples were hydrolysed, dried under N2, and kept at -80 
o C for 1-4 days until 
their reconstitution with 40% methanol previous to injection.           
2.3.5.5 LC-MS/MS quantification  
Analysis of urine samples was performed on a HPLC system Hewlett-Packard series 
1100 binary pump, coupled to a triple quadrupole mass spectrometer, Micromass 
Quattro LC (Micromass, Limited), operating in negative electrospray ionisation (ES-) 
mode, N2 gas flow of 550 L/h, cone voltage 35 V and desolvation temperature 350 
o C. 
The analysis was performed in multiple reaction monitoring (MRM) mode. Ionisation 
and fragmentation was optimised for each polyphenol by direct infusion of a standard 
solution, 200 ng/ml of pure polyphenol in 5 mM of ammonium acetate in 45% aqueous 
methanol solution. Specific values for collision energy parameters were identified for 
each polyphenol. Parent (precursor) and daughter (product) ions and retention time are 
shown in Figure 2.5. Peak for each polyphenol identity was established by both the 
characteristic parent and daughter ion pair and retention time. The chromatographic 
column for separation was a Zorbax SB-C18 (2.1 x 50mm, 3.5mm, Agilent) maintained 
at 25 o C. Solvent A consisted of water with 0.1% v/v of formic acid and solvent B 
acetonitrile with 0.1 % v/v of formic acid were run in a 95/5% proportion at a flow rate 
of 0.2 ml/min, injection volume of 10 μl and a run time of 15 min. The chromatographic 
conditions of elution were as follows: 0–1 min, 5 % solvent B; 1–4 min, increase 
solvent B from 5% to 10%; 4–5 min, increase solvent B from 10% to 90%; 5-5.2 min, 
decrease solvent B from 90% to 5%, 5.2-15 isocratic for 9.8 min. Peak areas of the 10 
polyphenols were plotted against the internal standard response. A good linearity (r2 
0.970–0.990) was observed for almost all the polyphenols quantified except for luteolin, 
r2= 0.922. All samples were run in the same batch and all chromatograms were 
processed automatically by MassLynx Mass Spectometry Software (MASSLYNXTM 
version 3.5) using the same processing integrate parameters, peak-to-peak amplitude 
and peak detection. Manual integration was performed only when peaks were difficult 
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to differentiate after the automatic integration. Values for intra-assay coefficients of 
variability varied from, 5–21% for the different compounds; phloretin 7.5%, epicatechin 
6%, hesperetin 21.9%, eriodictyol 9.6%, luteolin 9.8%, quercetin 10.8%, daidzein 3.1%, 
gallic acid 21.4%, vanillic acid 14.4% and enterolactone 5.1%.  Final concentrations of 
phenolics compounds were estimated after adjustment by urinary volume and corrected 
by milligram of creatinine.    
2.3.5.6 Calibration curves  
Calibration curves were prepared by spiking HPLC-grade water with 2.5, 5, 12.5, 25, 
50, 100, 150, 200 and 250 μl of mixed polyphenols working solution and 100 μl of 
internal standard working solution, the calibration curve range was 5-500 ng/ml. Spiked 
HPLC-grade water samples were treated with enzyme and extracted with ethyl acetate 
as were the urine samples, spiked samples were injected in duplicate at each 
concentration level. Limits of quantification were established using the spiked samples 
for calibrations curves; minimum detected value were 5 ng/ml for phloretin, 
epicatechin, eriodictyol, hesperetin, luteolin, daidzein, gallic acid and vanillic acid and 
























2.3.6 Statistical analysis  
Statistical analysis was performed using Statistical Package for the Social Sciences 
(SPSS) v.21.  Normality of data distribution was evaluated visually by inspection of 
histograms and normal Q-Q plots and verified using the Kolmogorov-Smirnov test. In 
normally distributed data independent sample t-tests were conducted to compare groups 
at both baseline and endpoint. If there was a statistically significant difference at 
baseline, one-way analysis of variance with baseline value as covariate (ANCOVA) was 
conducted to find differences between groups at endpoint. Comparison between groups 
at endpoint was done to determine the differences in polyphenol intakes in populations 
adhering to the different dietary interventions rather than investigating changes in 
polyphenol intakes over time. For non-normally distributed data, Mann-Whitney U test 
was conducted to find differences between groups at both baseline and endpoint. If there 
was a statistically significant difference at baseline, Mann-Whitney U tests were 





2.4.1 Dietary flavonoid intakes estimated by food frequency questionnaire  
Descriptive data of the CRESSIDA study population at baseline is shown in Table 2.8, 
the largest contributor to the total flavonoid intake in this population is represented by 
polymeric flavonoids (theaflavins and proanthocyanidins) accounting for 70% of the 
total intake following by the flavan-3-ols class with a 14% the rest 16% was accounted 
for the subclasses flavanones, anthocyanidins, flavones and flavonols.  
                               
Table 2.8 Characteristics of the CRESSIDA study population (n=161) 
Characteristic Baseline 
Gender (F/M) 97/64 
Age1 (years) 53 ± 8 
BMI1 (kg/m2) 26.1 ± 3.9 
Total flavonoids1 (mg/d) 664 ± 343 
Flavanones2 (mg/d) 23 (34) 
Anthocyanidins2 (mg/d) 19 (26) 
Flavones2 (mg/d) 2 (2) 
Flavonols2 (mg/d) 35 (24) 
Flavan-3-ols2 (mg/d) 90 (103) 
Polymeric flavonoids2  (mg/d) 231 ± 171 
1  
Values are mean ± SD 
2








There were no differences between groups for any of the flavonoid dietary intakes (total and subclasses) at baseline. Dietary intake of total flavonoids 
and the subclasses anthocyanidins, flavones, flavan-3-ols and polymeric flavonoids were statistically significantly higher in the group following the 
DG diet at endpoint (Table 2.9); flavanones and flavonols did not differ between intervention groups at endpoint. 









Baseline Endpoint Change Baseline Endpoint Change 
Total flavonoids1 
 
618 (337) 621 (347) 3 (-61, 67) 711 (344) 7524 (299) 41 (-20, 102) 
Flavanones2 
 
23 (7, 43) 25 (10, 43) 0 (-11, 11) 22 (11, 39) 27 (8, 49) 2 (-7, 20) 
Anthocyanidins3 
 
16 (3) 15 (2) 1 (1, 1) 20 (3) 314 (2) 2 (1, 2) 
Flavones2 
 
2 (2, 4) 3 (2, 4) 0 (-1, 1) 3 (2, 3) 35 (2, 4) 1 (0, 2) 
Flavonols2 
 
35 (22, 47) 39 (21, 54) 4 (-3, 9) 36 (24, 47) 39 (31, 50) 4 (-3, 11) 
Flavan-3-ols2 
 
84 (38, 142) 85 (35, 146) 1 (-7, 12) 93 (54, 143) 975 (80, 143) 0 (-12, 30) 
Polymeric1 
 
437 (249) 441 (261) 4 (-46, 53) 510 (265) 5234 (220) 13 (-33, 61) 
1
 Values are mean (SD); Change mean (95% CI)          
2
 Values are median (interquartile range)            
3
 Values are geometric mean (geometric standard deviation); Change, mean (95% CI)       
4
 Independent sample t-tests were carried out to find differences between groups at baseline and endpoint, there were no differences 
between groups at baseline. There were statistically significant differences between groups at endpoint, P<0.05    
5
 Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were no differences 




There were no differences between groups for any of the individual compounds of the flavanones subclass at baseline and endpoint (Table 2.10).  
 









Baseline Endpoint Change Baseline Endpoint Change 
Flavanones1  
 












0.04 (0.01, 0.07) 0.04 (0.01, 0.07) 0 (-0.01, 0.03)  0.04 (0.01, 0.09) 0.01 (0.01, 0.06) -0.01 (-0.05, 0.00) 
1
 Values are median (interquartile range) 






In the anthocyanidins subclass there was a difference between groups in the intake of 
petunidin at baseline, with higher intake in the group randomised to the DG diet, there 
were no differences between groups for any other of the individual compounds at 
baseline. There were statistically significant differences between groups in all the 
individual compounds of anthocyanidins at endpoint, higher intakes were observed in 
the group following the DG diet (Table 2.11). For petunidin intake data on changes 
(endpoint-baseline) for both groups were analysed by Mann-Whitney U test due to the 
initial difference in the intervention group and the fact that a non-normal distribution 
prevented analysis by ANCOVA with baseline as covariate. The main food sources of 
anthocyanidins in the DG group at endpoint, within the limitations of the FFQ 
categories available, were as follows: strawberries, raspberries, kiwi fruit (32%), grapes 
(26%) and wine (9%). As for the individual compounds the main food sources follow 
the same tendency; pelargonidin and cyanidin with strawberries, raspberries, kiwi fruit 
counted for 92% and 37% respectively, and delphinidin, malvidin, peonidin and 
petunidin with grapes as main food source and counted for 42%, 70%, 60% and 33% 














Baseline Endpoint Change Baseline Endpoint Change 
Anthocyanidins1 
 




















0.4 (0.2, 0.9) 0.4 (0.2, 0.9) -0.1 (-0.2, 0.2) 0.6 (0.3, 1) 0.74 (0.4, 1) 0.1 (-0.1, 0.4) 
  Petunidin
2   0.7 (0.4, 1) 0.6 (0.4, 1) 0.1 (-0.3, 0.3) 0.9
4 (0.5, 1) 1 (1, 2) 0.1 (-0.1, 0.5)5 
1
 Values are geometric mean (geometric standard deviation); Change mean (95% CI).  
2
 Values are median (interquartile range)   
3
 Independent sample t-tests were carried out to find differences between groups at baseline and endpoint, there were no differences between groups at 
baseline. There were statistically significant differences between groups at endpoint, P<0.05 
4
 Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were differences between groups at baseline 
on petunidin intakes. There were statistically significant differences between groups at endpoint, P<0.05 
5
 Mann-Whitney U test was carried out on change values to compare groups at endpoint given the statistical significant difference between groups at 






There were no differences between groups for any of the individual compounds of the flavones subclass at baseline. There was a statistically 
significant difference between groups in luteolin intake at endpoint, an increased intake was observed in the group following the DG diet (Table 2.12). 
The main food sources of flavones in the DG group at endpoint were ranked as follows: oranges, satsumas, mandarins (28%), sweet peppers (19%), 
green salad, lettuce, cucumber, celery (13%), wine (10%) and grapes (7%). Luteolin main food sources in the DG group at endpoint ranked the same 
way as for flavones subclass except for grapes and wine were grapes contribute with a higher percentage than wine.  









Baseline Endpoint Change Baseline Endpoint Change 
Flavones1  
 




0.5 (0.3, 0.8) 0.6 (0.3, 0.9) 0.0 (-0.1, 0.2) 0.6 (0.3, 1.0) 0.6 (0.4, 0.9) 0.0 (-0.2, 0.2) 
  Luteolin
1   1.6 (0.9, 2.8)  2.0 (1.0, 2.8) 0.2 (-0.6, 0.6) 1.8 (1.0, 2.7) 2.32 (1.4, 3.4) 0.5 (-0.3, 1.5) 
1
 Values are median (interquartile range)       
2
 Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were no differences between 






There were no differences between groups for any of the individual compound of the flavonols subclass at baseline. There was a statistically significant 
difference between groups in myricetin intake at endpoint; an increase was observed in the group following the DG diet (Table 2.13). The major 
dietary sources of flavonols in the DG group at endpoint were as follows: onions (35%), tea (26%) and apples (8%). Myricetin main food sources were; 
tea (64%), wine (13%), tomatoes (5%).   
 





 Dietary Guidelines (n=80) 
 Subclass Individuals 
 
Baseline Endpoint Change Baseline Endpoint Change 
Flavonols1 
 
















0.1 (0.04, 0.20) 0.10 (0.04, 0.21) 0.01 (-0.02, 0.07) 0.10 (0.05, 0.22) 0.1 (0.04. 0.25) 0 (-0.03, 0.06) 
1
 Values are median (interquartile range)      
2
 Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were no differences between groups at baseline. There 




In the flavan-3-ols subclass there were no differences between groups for any of the individual compounds at baseline. There were statistically 
significant differences between groups in the (+)-catechin, (-)-epicathechin-3-gallate and (-)-epigallocatechin-3-gallate intakes at endpoint, an 
increased was observed in the group following the DG diet (Table 2.14). The major dietary sources of flavan-3-ols in the DG group at endpoint were 
as follows: tea (77%), apples (6%) and bananas (4%). The main food sources for (+)-catechin in the DG group at endpoint were bananas (29%), tea 
(27%) and wine (13%), for (-)-epicathechin-3-gallate were; tea (99%), grapes (0.4%) and peaches, plums, apricots (0.4%) and for (-)-epigallocatechin-
3-gallate; tea (98%), apples (1%) and strawberries, raspberries, kiwi fruit (0.4%). 
Table 2.14 Daily intake of flavan-3-ols, as estimated by FFQ (n=161) 
Flavonoids (mg/d)   Control (n=81)  
 Dietary Guidelines (n=80)   
Subclass Individuals 
 
Baseline Endpoint Change Baseline Endpoint Change 
Flavan-3-ols1  
 




















15 (3, 27) 15 (3, 27) 0 (0, 0) 15 (6, 27) 152 (15, 27) 0 (0, 2) 
  (-)-Epigallocatechin-3-O-gallate
1   23 (5, 42) 23 (4, 42) 0 (0, 1) 23 (9, 42) 24
2 (23, 42) 0 (0, 4) 
1
 Values are median (interquartile range)       
2
 Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were no differences between groups at baseline. 
There were statistically significant differences between groups at endpoint, P<0.05 
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There were no differences between groups for any of the individual compounds of 
polymeric flavonoids at baseline. There were statistically significant differences 
between groups in the proanthocyanidins (PA) and proanthocyanidins polymers intake 
at endpoint, an increased was observed in the group following the DG diet (Table 2.15). 
The major dietary sources of polymeric flavonoids in the DG group at endpoint were as 
follows: tea (52%), apples (15%) and peanuts or other nuts (7%). The main food 
sources for PA were apples (27%), peanuts or other nuts (13%), tea (13%) and grapes 
(8%); for PA polymers were apples (29%), grapes (21%), peanuts or other nuts (14%) 





Table 2.15 Daily intake of polymeric flavonoids, as estimated by FFQ (n=161) 
Flavonoids (mg/d) Control (n=81) 
 
 Dietary Guidelines (n=80)   
Subclass Individuals Baseline Endpoint Change Baseline Endpoint Change 
Polymeric
1
  436.7 (249.0) 440.6 (260.9) 3.9 (-45.6, 53.3) 509.8 (264.9) 523.1
4
 (220.0) 13.3 (-34.0, 60.6) 
Theaflavin
2
 3.9 (0.7, 7.1) 3.9 (0.7, 7.1) 0.0 (0.0, 0.1) 3.9 (1.6, 7.1) 3.9 (3.9, 7.1) 0.0 (0.0, 0.6) 
Theaflavin 3-O-gallate
2
 3.1 (0.5, 5.6) 3.1 (0.5, 5.6) 0.0 (0.0, 0.1) 3.1 (0.5, 5.6) 3.1 (3.1, 5.6) 0.0 (0.0, 0.5) 
Theaflavin 3'-O-gallate
2
 3.8 (0.7, 6.8) 3.8 (0.7, 6.8) 0.0 (0.0, 0.1) 3.8 (1.5, 6.8) 3.8 (3.8, 6.8) 0.0 (0.0, 0.6) 
Theaflavin 3,3'-O-digallate
2
 4.4 (0.8, 7.9) 4.4 (0.8, 7.9) 0.0 (0.0, 0.1) 4.4 (1.8, 7.9) 4.4 (4.4, 7.9) 0.0 (0.0 ,0.6) 
Thearubigins
2
 203.3 (34.9, 365.9) 203.3 (34.9, 365.9) 0.0 (0.0, 3.3) 203.3 (81.3, 365.9) 203.3 (203.3, 365.9) 0.0 (0.0, 30.1) 
Proanthocyanidins (PA)
3 
 238.5 (1.9) 250.8 (1.7) 1.1 (0.9, 1.2) 282.3 (1.8) 296.0
4
 (1.6) 1.0 (0.9, 1.2) 
PA monomers
2
 50.2 (30.4, 69.4) 48.8 (31.4, 71.6) 2.9 ( -10.6, 10.4) 57.7 (36.9, 71.8) 49.7 (34.7, 65.2) -4.5 (-17.1, 8.1) 
PA dimers
3
 38.0 (1.8) 39.4 (1.7) 2.2 (1.9, 2.5) 44.3 (1.8) 41.8 (1.5) 2.0 (1.7, 2.2) 
PA trimers
3
 18.1 (2.0) 19.7 (1.7) 0.4 (0.3, 0.4) 21.2 (1.9) 19.8 (1.7) 0.3 (0.3, 0.4) 
PA 4-6 mers
3
 50.3 (2.0) 53.6 (1.8) 1.9 (1.6, 2.1) 57.9 (2.0) 58.3 (1.7) 1.7 (1.5, 2.0) 
PA 7-10 mers
3
 28.6 (2.0) 30.3 (1.8) 0.6 (0.5, 0.7) 33.7 (2.0) 35.5 (1.8) 0.6 (0.5, 0.7) 
PA polymers (>10 mers)
3
 52.2 (2.1) 55.0 (1.8) 1.3 (1.1, 1.5) 62.8 (2.2) 85.2
4
 (1.9) 1.6 (1.4, 1.9) 
1
Values are mean (SD)       
2
Values are median (interquartile range); Change mean (95% CI)        
3
Values are geometric mean (geometric standard deviation)        
4
Independent sample t-tests were carried out to find differences between groups at baseline and endpoint, there were no differences between groups at baseline. There were 
statistically significant differences between groups at endpoint, P<0.05 
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2.4.2 Dietary polyphenol intakes estimated by 4-day food diary (4-DFD) 
Descriptive data of the CRESSIDA study population at baseline is shown in Table 2.16, 
the largest contributor to the total polyphenol intake in this population is represented by 
the flavonoids subclass counting for a 67% of the total intake followed by the phenolic 
acids with a 21% the rest 12% was accounted for by lignans and stilbenes and other 
polyphenols. The major dietary sources of polyphenols for the CRESSIDA study 
participants estimated at baseline were: black tea (35%), coffee (16%), fruit and 
vegetables (15%) and plain chocolate (4%).    
 
Table 2.16 Characteristics of the CRESSIDA study population (n=161) 
Characteristic Baseline 
Gender (F/M) 97/64 
Age1 (years) 53 ± 8 
BMI1 (kg/m2) 26.1 ± 3.9 
Total polyphenols2 (mg/d) 1183 (868) 
Flavanoids2 (mg/d) 790 (648) 
Lignans2 (mg/d) 0.4 (3.9) 
Phenolic acids2 (mg/d) 243 (29) 
Stilbenes2 (mg/d) 0.08 (0.63) 
Other polyphenols2 (mg/d) 19 (29) 
1
 Values are mean ± SD 
2











There were no differences between groups for the subclasses: lignans, phenolics acids, stilbenes and other polyphenols at baseline. There were 
statistically significant differences between groups in the total polyphenols and flavonoids intakes at baseline, with higher values in the group 
randomised to the DG diet. There were statistically significant differences between groups in lignans, phenolic acids and other polyphenols intakes at 
endpoint, with higher intakes in the group following the DG diet (Table 2.17). The main food sources of lignans in the DG group at endpoint were as 
follows: linseeds (46%), hummus (16%) and sesame oil (14%); for phenolic acids: coffee (47%), black tea (22%), herbal tea (3%) and apples (2%); 
and for other polyphenols: muesli, luxury fruit and nuts (41%), wholemeal spaghetti (23%) and coffee (6%).     
 
Table 2.17 Daily intake of polyphenols, as estimated by 4-DFD (n=161) 
Polyphenols (mg/d)) Control (n=82) 
 
 Dietary Guidelines (n=79)   
 
Subclasses Baseline Endpoint Change Baseline Endpoint Change 
 
Total polyphenols 1009 (634, 1468) 977 (621, 1597) 17 (-216, 223) 1273
1
 (868, 1644) 1290 (775, 1894) 83 (-390, 252) 
 
 
Flavonoids 645 (337, 988) 675 (409, 1035) 27 (-128, 182) 919
1
 (590, 1143) 788 (536, 1314) 0.9 (-262, 218) 
 
 
Lignans 0.34 (0.18, 2.45) 0.26 (0.13, 0.44) -0.05 (-0.42, 0.07) 0.52 (0.21, 4.43) 0.421 (0.20, 5) 0.03 (-0.37. 2) 
 
 
Phenolic acids 228 (121, 502) 217 (114, 467) 3 (-83. 53) 248 (164, 576) 3001 (155, 554) 3 (-52, 71) 
 
  Stilbenes 0.05 (0.01, 0.54) 0.09 (0.02, 0.85) 0 (-0.07, 0.16) 0.11 (0.02, 0.73) 0.19 (0.05, 1) 0.03 (-0.10, 0.34) 
 
 Other polyphenols 21 (10, 49) 14 (6, 24) -6 (-23, 2) 16 (8, 29) 341 (16, 50) 11 (-6, 33)  
All values are median (interquartile range) 
1
Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were no differences between groups at 
baseline. There were statistically significant differences between groups at endpoint, P<0.05 
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There was a statistically significant difference between groups in proanthocyanidins 
intake at baseline, with greater intake in the group randomised to the DG diet. There 
were no differences between groups for any other flavonoids subclass at baseline. There 
was a statistically significant difference between groups in isoflavones intake at 
endpoint with higher intakes in the group following the DG diet (Table 2.18). The main 
food sources of isoflavones in the group following the DG diet at endpoint were as 
follows: soy drinks/fat free/fruit (65%), soy yogurt/fruit (16%) and plain soy milk 




















 Dietary Guidelines (n=79)   
Subclass Individuals 
 
Baseline Endpoint Change Baseline Endpoint Change 
Flavonoids 
 
645 (337, 988) 675 (409, 1035) 27 (-128, 182) 919
1
















160 (77, 266) 187 (99, 271) 12 (-42, 98) 247
1












62 (40, 103) 68 (42, 100) 5 (-16, 21) 78 (45, 105) 75 (52, 117) 4 (-15, 24) 
  Isoflavones   0.26 (0.10, 6) 0.13 (0.06, 0.39) -0.11 (-5, 0.06) 0.25 (0.13, 16.04) 0.52
1 (0.06, 51) 0.05 (-0.21, 41) 
All values are median (interquartile range) 
1
Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were differences between groups at baseline for 









There were no differences between groups for any of the individual compounds in the anthocyanidins subclass at baseline. There were statistically 
significant differences between groups in cyanidin, malvidin and peonidin intakes at endpoint, with higher intakes in the group following the DG diet 
(Table 2.19). In the DG group at endpoint, the major food sources of cyanidin are as follows: raspberries (46%), blackcurrant juice/concentrated (10%) 
and plums (8%); for malvidin: red wine (73%), grapes (20%) and blueberries (6%) and for peonidin: red wine (52%), grapes (21%), plums (11%) and 
blueberries (8%). These results confirm the findings from FFQ analysis where berries (strawberries, raspberries and grapes) are ranked as the major 
food sources of the anthocyanidins individual compounds.  






 Dietary Guidelines (n=79)   
Subclass Individuals 
 
Baseline Endpoint Change Baseline Endpoint Change 
Anthocyanidins 
 




















4 (1, 13) 3 (1, 11) 0 (-4, 6) 6 (1, 13) 4 (1, 12) 0 (-6, 6) 
  Petunidin   1 (0, 4) 0 (0, 4) 0 (-2, 0) 1 (0, 6) 1 (0, 6) 0 (-2, 1) 
All values are median (interquartile range)       
Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were no differences 
between groups at baseline.  
1
There were statistically significant differences between groups at endpoint, P<0.05 
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There was a statistically significant difference between groups in phloretin intakes at baseline, with higher intake in the group randomised to the 
DG diet. There were no differences between groups for phlorizin and dihydrochalcones at baseline. There were no differences between groups 
for any of the individual compounds of the dihydrochalcones subclass at endpoint (Table 2.20).      
 
           Table 2.20 Daily intake of dihydrochalcones, as estimated by 4-DFD (n=161) 
Polyphenols (mg/d)   Control (n=82)  




Baseline Endpoint Change Baseline Endpoint Change 
Dihydrochalcones 
 




0.2 (0.0, 1.4) 0.7 (0.0, 2.0) 0.0 (-0.1, 0.9) 0.71 (0.0, 1.8) 0.8 (0.1, 2.4) 0.0 (-1.0, 0.8) 
  Phlorizin 
 
0.7 (0.0, 1.4) 0.8 (0.0, 2.1) 0.1 (-0.4, 0.8) 0.8 (0.1, 1.7) 0.9 (0.4, 2.3) 0.0 (-0.6, 0.8) 
All values are median (interquartile range)       
1






There were statistically significant differences between groups in flavan-3-ols and (-)-
epicatechin intakes at baseline, with higher intakes in the group randomised to the DG 
diet. However, there were no differences between groups for any of the individual 






















Table 2.21 Daily intake of flavanols, as estimated by 4-DFD (n=161) 
All values are median (interquartile range)       
1
Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were differences between groups at baseline on 
catechins and epicatechin intakes. The difference was no longer significant between groups at endpoint, P<0.05 
 
Polyphenols (mg/d)   Control (n=82)  




Baseline Endpoint Change Baseline Endpoint Change 
Flavanols  
 




205 (72, 355) 198 (81, 340) 2 (-10, 64) 275
1








31 (16, 41) 32 (17, 44) 2 (-4, 10) 38
1




































10 (0, 21) 11 (0, 22) 0 (-2, 4) 14 (0, 25) 14 (0, 26) 0 (-4, 4) 
  Other    22 (4, 49) 24 (6, 46) 0 (-6, 8) 31 (5, 54) 30 (4, 55) -1 (-11, 8) 
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In the proanthocyanidins (PA) subclass there were statistically significant differences between groups in PA 1-3 mers, PA 4-6 mers, PA 7-10 mers 
and PA polymers intakes at baseline, with higher values in the group randomised to the DG diet. However, there were no differences between groups 
in PA 1-3 mers and PA 4-6 mers intakes at endpoint; and following Mann-Whitney U test for changes (endpoint – baseline) in both groups the 
difference was no longer significant in PA 7-10 mers and PA polymers intakes at endpoint (Table 2.22). 
 
Table 2.22 Daily intake of proanthocyanidins, as estimated by 4DFD (n=161) 
Polyphenols (mg/d)   Control (n=82)  




Baseline Endpoint Change Baseline Endpoint Change 
Proanthocyanidins (PA) 
 
160 (77, 266) 187 (99, 271) 12 (-42, 98) 2471 (138, 337) 214 (127, 305) 10 (-108, 113) 
Procyanidins  46 (19, 76) 43 (23, 71) 0 (-1, 14) 60 (33, 86) 54 (28, 91) -5 (-22, 16) 
Prodelphinidins  5 (1, 11) 5 (1, 10) 0 (-1, 1) 7 (1, 12) 7 (1, 12) 0 (-2, 3) 
PA 1-3 mers 
 
25 (10, 52) 31 (14, 63) 4 (-11, 25) 421 (17, 72) 30 (15, 51) -7 (-36, 15) 
PA 4-6 mers 
 
25 (9, 59) 27 (12, 57) 1 (-15, 25) 401 (17, 86) 32 (18, 55) -6 (-39, 18) 
PA 7-10 mers 
 
14 (5, 22) 17 (6, 27) 0 (-6, 11) 181 (8, 34) 23 (15, 37) 3 (-6, 15) 
PA polymers (>10 mers) 
 
30 (13, 53) 39 (15, 66) 1 (-16, 25) 511 (18, 90) 63 (42, 97) 14 (-21, 46) 
All values are median (interquartile range)      
1
Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were differences between groups at 
baseline. There were no statistically significant differences between groups at endpoint, P<0.05 
    
101 
 
There were no differences between groups for any of the individual compounds in the flavanones subclass at baseline, nevertheless there was a 
statistically significant difference between groups in eriodictyol intakes at endpoint, with higher values in the group following the DG diet (Table 
2.23). In the DG diet at endpoint, lemons (52%), bitter orange marmalade (30%) and almonds (8%) were the main food sources for eriodictyol.       
 
Table 2.23 Daily intake of flavanones, as estimated by 4-DFD (n=161) 
Polyphenols (mg/d)   Control (n=82)  




Baseline Endpoint Change Baseline Endpoint Change 
Flavanones 
  












15 (1, 32) 12 (1, 25) 0 (-13, 9) 11 (0, 32) 15 (3, 41) 3 (-8, 15) 
 
Other   4 (0, 15) 1 (0, 10) 0 (-5, 3) 2 (0, 9) 1 (0, 10) 0 (-5, 1) 
All values are median (interquartile range)       
1
Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were no differences between groups at 
baseline. There was a statistically significant difference between groups at endpoint, on eriodictyol intake, P<0.05. 







There were no differences between groups for any of the individual compounds in the flavones subclass at baseline and endpoint (Table 2.24).  
 
Table 2.24 Daily intake of flavones, as estimated by 4-DFD (n=161) 
Polyphenols (mg/d)   Control (n=82)  




Baseline Endpoint Change Baseline Endpoint Change 
Flavones 
  




2 (1, 5) 2 (0, 6) 0 (-2, 3) 3 (1, 6) 2 (0, 5) 0 (-2, 2) 
  Luteolin   1 (0, 3) 1 (0, 2) 0 (-1, 0) 1 (0, 2) 1 (1, 3) 0 (-1, 0) 
All values are median (interquartile range) 










There were no differences between groups for any of the individual compounds in the flavonols subclass at baseline and endpoint (Table 2.25).  
 
Table 2.25 Daily intake of flavonols, as estimated by 4-DFD (n=161) 
Polyphenols (mg/d)   Control (n=82)  




Baseline Endpoint Change Baseline Endpoint Change 
Flavonols 
  












2 (1, 3) 1 (1, 4) 0 (-1, 1) 2 (1, 4) 2 (1, 4) 0 (-2, 2) 
  Isorhamnetin    2 (1, 3) 1 (1, 3) 0 (-1, 1) 1
1 (1, 2) 1 (1, 3) 0 (-1, 1) 
All values are median (interquartile range)  
1
Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were differences 







There were no differences between groups for any of the individual compounds in the isoflavones subclass at baseline. There were statistically 
significant differences between groups in daidzein and genistein intakes at endpoint, with greater intakes in the group following the DG diet (Table 
2.26).  In the DG group at endpoint the main food sources for daidzein were: soy drinks/fat free/fruit (62%), plain soy milk (17%), soy yogurt/fruit 
(16%) and soy and linseed bread (2%); for genistein main food sources were: soy drinks/fat free/fruit (66%), soy yogurt/fruit (16%), plain soy milk 
(12%) and soy and linseed bread (2%).  
 
Table 2.26 Daily intake of isoflavones, as estimated by 4-DFD (n=161) 
Polyphenols (mg/d)   Control (n=82)  





Baseline Endpoint Change Baseline Endpoint Change 
Isoflavones  
 
0.26 (0.10, 6) 0.13 (0.06, 0.39) -0.11 (-5, 0.06) 0.25 (0.13, 16.04) 0.521 (0.06, 51) 0.05 (-0.21, 41) 
Daidzein  
 
0.09 (0.03, 2) 0.04 (0.02, 0.12) -0.06 (-1, 0.02) 0.09 (0.04, 6.57) 0.111 (0.01, 16) 0.03 (-0.06, 13) 
Genistein    0.14 (0.05, 3) 0.08 (0.04, 0.28)  -0.06 (-3, 0.05) 0.16 (0.09, 8.23) 0.47
1 (0.03, 31) 0.02 (-0.13, 24) 
All values are median (interquartile range)       
1
Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were no differences between groups at baseline. 
There were statistically significant differences between groups at endpoint, P<0.05. 







There were no differences between groups for any of the individual compounds in the lignans subclass at baseline. There were statistically significant 
differences between groups for secoisolariciresinol and matairesinol intakes at endpoint. Higher intakes were observed in the group following the DG 
diet (Table 2.27). Linseeds (94%), black tea (3.5%), brown bread (0.9%) and crispbread rye (0.7%) were the main food sources for 
secoisolariciresinol and linseeds (56%), black tea (23%), muesli, luxury fruit and nut (7%), and sunflower seeds (3.5%) were the major food sources 
for matairesinol.      










Baseline Endpoint Change Baseline Endpoint Change 
Lignans 
 
0.34 (0.18, 2.45) 0.26 (0.13, 0.44) -0.05 (-0.42, 0.07) 0.52 (0.21, 4.43) 0.42
1
 (0.20, 5) 0.03 (-0.37. 2) 
Pinoresinol 
 
0.05 (0.02, 0.11) 0.02 (0.01, 0.04) -0.02 (-0.07, 0.01) 0.07 (0.02, 0.15) 0.01 (0, 0.03) - 0.04 (-0.11, 0.01) 
Lariciresinol 
 
0.02 (0.01, 0.05) 0.02 (0.01, 0.04) 0 (-0.02, 0.02) 0.03 (0.01, 0.05) 0.03 (0.01, 0.06) 0 (-0.02, 0.02) 
Secoisolariciresinol 
 
0.16 (0.05, 0.30) 0.14 (0.06, 0.26) 0 (-0.04, 0.04) 0.19 (0.10, 0.30) 0.18
1
 (0.10, 0.38) 0.01 (-0.08, 0.09) 
Matairesinol   0.01 (0.01, 0.02) 0.01 (0.01, 0.02) 0 (-0.01, 0.01) 0.02 (0.01, 0.03) 0.02
1
 (0.01, 0.03) 0 (0, 0.01) 
All values are median (interquartile range)       
1
Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were no differences between groups at baseline. 
There were statistically significant differences between groups at endpoint, P<0.05. 





There were statistically significant differences between groups for 4-hydroxybenzoic 
acid and p-coumaric acid intakes at baseline, with higher intakes in the group 
randomised to the DG diet. However, following Mann-Whitney U test for changes 
(endpoint – baseline) in both groups the difference was no longer significant at 
endpoint. There were no differences between groups for any other individual compound 
in the phenolic acids subclass at baseline. There were statistically significant differences 
between groups for protocatechuic acid, vanillic acid and syringic acid intakes at 
endpoint. Greater values were observed in the group following the DG diet (Table 
2.28). The main food sources, in DG group at endpoint, for protocatechuic acid were: 
apples (16%), strawberries (15%) and white wine (12%); for vanillic acid were: dates 
(17%), beer (lager) (10%) and muesli, luxury fruit and nuts (9%); and for syringic acid 
were: apples (26%), Swiss chard (17%) and hummus (16%).          
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 Dietary Guidelines (n=79)   
Subclass Individuals 
 
Baseline Endpoint Change Baseline Endpoint Change 
Phenolic acids 
 
228 (121, 502) 217 (114, 467) 3 (-83. 53) 248 (164, 576) 300
1








0.8 (0.5, 1) 0.8 (0.6, 1) 0.1 (-0.5, 0.4) 1 (0.6, 2) 1
1








0.2 (0.1, 0.4) 0.2 (0.1, 0.3) 0 (-0.1, 0.1) 0.3 (0.1, 0.5) 0.3
1




2 (1, 3) 2 (1, 3) 0 (-2, 1) 2
1




0.5 (0.2, 1) 0.4 (0.2, 1) 0.2 (-0.4, 0.5) 0.6 (0.3, 1) 0.9
1












8 (4, 13) 9 (5, 14) 1 (-2, 2) 11
1








23 (9, 56) 13 (6, 53) -4 (-19, 5) 24 (6, 59) 23 (8, 57) 1 (-14, 15) 
  Other   13 (5, 31) 7 (3, 24) -1 (-9, 6) 9 (3, 36) 11 (4, 25) 0 (-9, 6) 
All values are median (interquartile range)       
1
Mann-Whitney U tests were carried out to find differences between groups at baseline and endpoint, there were differences between groups at baseline on 4-
Hydroxybenzoic acid intakes. There were statistically significant differences between groups at endpoint, P<0.05.   
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There were no differences between groups for any of the individual compounds in the stilbenes subclass at baseline and endpoint (Table 2.29) 
Table 2.29 Daily intake of stilbenes, as estimated by 4-DFD (n=161) 
Polyphenols (mg/d) Control (n=82) 
 
 Dietary Guidelines (n=79) 
 
Subclass Individuals Baseline Endpoint Change Baseline Endpoint Change 
Stilbenes 0.05 (0.01, 0.54) 0.09 (0.02, 0.85) 0 (-0.07, 0.16) 0.11 (0.02, 0.73) 0.19 (0.05, 1.00) 0.03 (-0.10, 0.34) 
  Resveratrol 0.05 (0.01, 0.34) 0.09 (0.02, 0.54) 0 (-0.06, 0.14) 0.11 (0.02, 0.45) 0.19 (0.04, 0.65) 0.02 (-0.07, 0.24) 
All values are median (interquartile range) 








When comparing results obtained from the EPIC-Norfolk FFQ and 4-DFD it was found 
that FFQ report more changes at endpoint in dietary flavonoid intakes than 4-DFD did, 
more subclasses and individual compounds showed significant higher intakes in the 
intervention group when estimated by FFQ (Table 2.30). However FFQ and 4-DFD 
agree in results derived from anthocyanidins; cyanidin, malvidin and peonidin intakes. 
It can be also noted that 4-DFD is more sensitive in estimating the different compounds 
analysed, since it was able to detect higher values of intakes in most of the flavonoids 
analysed. Worth to mention is the fact that the database used for the FFQs analysis 
estimates only flavonoid intakes while the database for 4-DFD analysis contemplated a 



















Table 2.30 Flavonoid intakes in the Dietary Guidelines intervention group at endpoint 
and comparison with control group    
Flavonoids (mg/d) Intakes at endpoint  
Subclasses Individuals FFQ 4-DFD 
Total flavonoids 714  > 788   
Anthocyanidins 32   > 69   
Cyanidin 15  > 7 > 
Malvidin 8  > 11 > 
Peonidin 0.7  > 2 > 
Pelargonidin 5  > 3   
Delphinidin 2  > 4   
Flavones 3  > 4    
Luteolin 2  > 1    
Flavan-3-ols  97  > 257    
(+)-Catechin 15  > 41   
(-)-Epicatechin 3-O-gallate 15  > 35   
(-)-Epigallocatechin 3-O-gallate 24  > 44   
Flavonols 39   75   
Myricetin 2  > 2   
Flavanones 27   26   
Eriodictyol 0.01   0.02 > 
Isoflavones NE 0.52  > 
Daidzein  NE 0.11 > 
Genistein NE 0.47 > 
Polymeric flavonoids 4961  > 2682    
Proanthocyanidins (PA) 290 > 214    
PA polymers (>10 mers) 85  > 63   
All values are median 
> Greater at endpoint relative to control;  not greater at endpoint relative to control 
group, NE not estimated; PA, proanthocyanidins. 
1
Theaflavins, thearubigins and PA 
2
Theaflavins and PA 
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2.4.2.1 Relationships between dietary polyphenol intakes estimated by 4-DFD 
and markers of glucose homeostasis   
In a correlation analysis, higher intake of the lignan, pinoresinol, was associated with 
lower fasting blood glucose levels. Major food sources of lignans in the entire 
population of CRESSIDA study were linseeds (40%), olive oil (9%) and granary bread 
(6%). Flavonoids subclasses, proanthocyanidins, flavanones and flavones, and the 
phenolic acid, ferulic acid, were associated with lower insulin levels. Main food sources 
for proanthocyanidins were black tea (20%), apples (19%), plain chocolate (10%) and 
strawberries (5%); for flavanones, orange juice (31%), oranges (23%) and fruit drinks 
(22%); for flavones, herbal tea (33%), orange juice (23%) and granary bread (7%); and 
for ferulic acid, coffee (59%), cous cous (9%) and soft wholemeal bread (4%). 
Following the tendency, flavanones, flavones and ferulic acid were significantly 
associated with lower values of HOMA-IR, an index used to estimate insulin resistance. 
Delphinidin was significantly associated with lower insulin values and higher values on 
RQUICKI, an index used to estimate insulin sensitivity. Major food sources of 
delphinidin were concentrated fruit drinks (41%), concentrated blackcurrant juice (27%) 
and red wine (9%). No other significant correlations were noted for other polyphenol 
classes, subclasses or individual polyphenols. See Table 2.31 for correlation 













 Table 2.31 Spearman’s correlation coefficients between biomarkers of glucose homeostasis and dietary intake of polyphenols at endpoint (n=161) 
Polyphenols (mg/d)  Pinoresinol Proanthocyanidins Flavanones Flavones Ferulic acid Delphinidin 
Biomarker  r P value r P value r P value r P value r P value r P value 
Glucose (mg/dl) -0.184 0.020 0.000 0.999 0.017 0.827 -0.003 0.970 0.007 0.931 -0.005 0.950 
Insulin (mU/L)      -0.037 0.641 -0.162 0.040 -0.232 0.003 -0.188 0.017 -0.190 0.016 -0.104 0.019 
HOMA-IR -0.065 0.410 -0.153 0.052 -0.221 0.005 -0.190 0.016 -0.183 0.020 -0.101 0.203 
RQUICKI 0.103 0.194 0.045 0.567 0.211 0.007 0.175 0.026 0.096 0.226 0.181 0.021 
r; Spearman’s correlations coefficient, P is significant at 0.05 level (2-tailed)   
HOMA-IR; homeostatic model assessment of insulin resistance, RQUICKI; revised quantitative insulin sensitivity check index 
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2.4.3 Urinary polyphenol excretion by Liquid Chromatography – Tandem 
Mass Spectrometry (LC-MS/MS) 
In order to provide a more objective estimate of polyphenol intake, urinary analysis of 
ten selected aglycones was carried out on a subsample, as described in section 2.3.5. 
Descriptive data of the CRESSIDA study subsample at baseline is shown in Table 2.32, 
demonstrating that the sub sample was similar in age, BMI and gender distribution to 
the whole cohort daily polyphenol intake was estimated from the 4-DFD. Similarly to 
the total population the major contributors of polyphenol intake in this subsample, are 
represented by the subclasses; flavonoids and phenolic acids followed by stilbenes and 
lignans.  
 
Table 2.32 Characteristics of the CRESSIDA study subsample (n=91) selected for 







Gender (F/M) 54/37 97/64 
Age1 (years) 54 ± 8 54 ± 8 
BMI1 (kg/m2) 25.4 ± 3.9 26.0 ± 3.9 
Total polyphenols2 (mg/d) 1178 (928) 1124 (924) 
Flavanoids2 (mg/d) 742 (797) 727 (623) 
Lignans2 (mg/d) 0.3 (0.5) 0.3 (0.5) 
Phenolic acids2 (mg/d) 253 (428) 239 (408) 
Stilbenes2 (mg/d) 0.26 (0.96) 0.15 (0.91) 
1
 Values are mean ± SD   
2





Data on the excretion of the ten phenolic compounds quantified are displayed in Table 
2.33; the highest quantities detected in the 24 h urine samples were for enterolactone 
followed by quercetin whereas lowest quantities were for phloretin and daidzein.    
 
Table 2.33 Excretion of polyphenols in 24 h urine in a subsample of the CRESSIDA 




Phloretin 0.04 (0.12) 
Epicatechin 0.10 (0.11) 
Eriodictyol 0.08 (0.16) 
Hesperetin 0.13 (0.68) 
Luteolin 0.53 (0.55) 
Quercetin 1.26 (2.13) 
Daidzein 0.01 (0.09) 
Gallic acid 0.13 (0.35) 
Vanillic acid 0.26 (0.42) 
Enterolactone 1.73 (3.09) 
 
1













The aglycones quantified are either metabolites of parent glucuronide or sulphated 
compounds formed in human tissues, or metabolites formed by the gut microbiota, e.g. 
enterolactone from lignans present in fibre-rich food. There were statistically significant 
differences between groups for phloretin, eriodictyol, hesperetin, luteolin, quercetin, 
gallic acid, vanillic acid and enterolactone with higher excretion in the group following 
the DG diet (Table 2.34). There were no differences between groups for epicatechin 
and daidzein at endpoint. Although data suggests a tendency in daidzein excretion, there 
was no statistical significant difference between groups. Daidzein was not detected in 
37 participants of the 91 subsample; this could contribute to the lack of significance in 
the results given that values observed are considerably higher in the intervention group. 
The data on urinary excretion is presented along with data in dietary intake of the same 





































Table 2.34 Excretion of polyphenols in 24 h urine in a subsample of the CRESSIDA study population and dietary intake of the direct 
dietary precursor estimated by 4-DFD (n=91) 
All values are median (interquartile range) 
1 
Values adjusted for 24 h urine volume and g of creatinine 
2
 Mann-Whitney U tests were carried out to find differences between groups at endpoint, there were statistically significant differences between groups 
in dietary intakes and urinary excretion of polyphenols, with higher values in group following the intervention diet, P<0.05.  
3 
Intake of lignans was used as direct dietary precursor of enterolactone




Urinary excretion1  
(mg/g creatinine) 





Phloretin 0.5 (0.0 – 1.4) 0.02 (0.00, 0.04) 1.32 (0.3 – 2.7) 0.092 (0.05, 0.18)  0.000 
Epicatechin 28 (14 – 46) 0.10  (0.05, 0.15) 38 (19 – 52) 0.09 (0.05, 0.18)  0.557 
Eriodictyol 0.00 (0.00 – 0.02) 0.05 (0.02, 0.09) 0.022 (0.01 – 0.05) 0.122 (0.05, 0.23)  0.005 
Hesperetin 6 (1 – 22) 0.04 (0.00, 0. 34) 152 (4 – 32) 0.442 (0.02, 0.98)  0.005 
Luteolin 0.4 (0.3 – 0.8) 0.34 (0.20, 0.64) 1.12 (0.7 – 3.0) 0.702 (0.35, 0.92)  0.004 
Quercetin 38 (24 – 69) 0.94 (0.41, 1.97) 56 (34 – 74) 1.802 (0.61, 3.35)  0.038 
Daidzein 0.03 (0.02 – 1) 0.00 (0.00, 0.07) 3.62 (0.0 – 19) 0.04 (0.00, 0.20)  0.065 
Gallic acid 54 (19 – 108) 0.09 (0.02, 0.25) 70 (19 – 117) 0.212 (0.07, 0.61)  0.026 
Vanillic acid 0.1 (0.1 – 0.2) 0.23 (0.03, 0.44) 0.32 (0.2 – 0.5) 0.502 (0.15, 0.99)  0.010 
Lignan/Enterolactone3 0.2 (0.1 – 0.4)  1.71 (0.64, 3.16) 0.42 (0.2 – 5.4)  3.032 (1.15, 6.74)  0.001 
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Urinary excretion of polyphenols in 24 h samples was correlated with dietary intakes 
estimated by 4-DFD in the whole subsample (n=91). Most of the individual polyphenols 
quantified have a significant and positive correlation with intake of their direct 
precursor. There was a strong and positive correlation between urinary excretion and 
estimated dietary intake of gallic acid (r = 0.730, P < 0.001) and phloretin (r =0.472, P 
< 0.001). There was a weaker correlation between urinary excretion and estimated 
dietary intake of epicatechin, hesperetin, daidzein and enterolactone (rs between 0.235 
and 0.375, P < 0.05). There was no significant correlation between urinary excretion 
and estimated dietary intake of eriodictyol, luteolin, quercetin and vanillic acid (Table 
2.35).     
118 
 
Table 2.35 Spearman's correlations coefficients between urinary excretion of polyphenols in 24 h urine samples and dietary intake of direct dietary 
precursors estimated by 4-DFD (n=91)  
 
Polyphenols      Urinary  Phloretin  Epicatechin Eriodictyol Hesperetin Luteolin 
Dietary  r P value r P value r P value r P value r P value 
Subclass Individual           
Dihydrochalcones 0.506 0.000 0.385 0.000 0.159 0.135 0.110 0.301 0.123 0.248 
     Phloretin 0.472 0.000 0.407 0.000 0.158 0.138 0.109 0.306 0.109 0.306 
     Phlorizin 0.512 0.000 0.385 0.000 0.165 0.119 0.112 0.291 0.140 0.183 
Flavan-3-ols 0.092 0.390 0.207 0.050 0.207 0.050 -0.145 0.173 0.279 0.008 
     Epicatechin 0.151 0.155 0.360 0.000 0.360 0.000 -0.177 0.095 0.271 0.010 
Flavanones 0.237 0.025 0.014 0.897 0.193 0.068 0.217 0.040 0.050 0.637 
     Naringenin 0.318 0.002 0.212 0.044 0.277 0.008 0.213 0.043 0.178 0.093 
     Eriodictyol 0.124 0.244 0.053 0.620 0.002 0.982 -0.114 0.284 0.123 0.250 
     Hesperetin 0.245 0.020 -0.006 0.956 0.228 0.031 0.258 0.014 0.065 0.540 
Flavones 0.161 0.129 0.083 0.438 0.095 0.373 0.059 0.579 0.003 0.778 

































r; Spearman’s correlation coefficient, P is significant at the 0.05 level (2-tailed) 
Polyphenols          Urinary  Quercetin  Daidzein Gallic acid Vanillic acid Enterolactone 
Dietary  r P value r P  value r P  value r P  value r P  value 
Subclass Individual           
Flavonols  0.199 0.060 -0.121 0.254 0.498 0.000 0.209 0.049 0.184 0.083 
Kaempferol 0.263 0.012 -0.068 0.523 0.688 0.000 0.309 0.003 0.217 0.040 
     Quercetin 0.194 0.067 -0.100 0.351 0.493 0.000 0.164 0.123 0.114 0.283 
     Myricetin 0.260 0.013 0.122 0.253 0.139 0.193 0.077 0.471 0.302 0.004 
Isoflavones -0.007 0.949 0.354 0.000 -0.109 0.307 0.161 0.129 0.056 0.603 
Daidzein -0.029 0.787 0.375 0.000 -0.127 0.234 0.138 0.196 0.070 0.514 
Genistein  0.006 0.953 0.367 0.000 -0.105 0.324 0.152 0.325 0.051 0.634 
Phenolic acids 0.208 0.049 -0.033 0.757 0.253 0.016 0.226 0.032 0.241 0.022 
Gallic acid 0.247 0.019 -0.036 0.737 0.730 0.000 0.284 0.007 0.162 0.126 
Vanillic acid 0.159 0.135 -0.040 0.706 0.010 0.925 0.034 0.753 0.092 0.386 
Lignans 0.317 0.002 0.124 0.245 0.352 0.001 0.306 0.003 0.311 0.003 
Secoisolariciresinol 0.270 0.010 -0.147 0.167 0.609 0.000 0.239 0.023 0.235 0.026 
Matairesinol  0.323 0.002 -0.019 0.856 0.553 0.000 0.216 0.041 0.347 0.001 
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2.4.3.1 Relationships between urinary excretion of polyphenols estimated by 
LC-MS/MS and markers of glucose homeostasis   
In a correlation analysis, higher excretion of the phenolic compounds; enterolactone, 
eriodictyol, hesperetin, phloretin and quercetin were associated with biomarkers of 
glucose homeostasis and cardiovascular disease risk (vascular function and blood 
pressure). Higher excretion of enterolactone was associated with lower values of insulin 
and HOMA-IR. Higher excretion of eriodictyol, hesperetin and phloretin were 
associated with lower values for pulse wave reflection index (higher reflection index 
indicates increased systemic vascular resistance). Hesperetin showed an inverse 
association with 24 h systolic and diastolic blood pressure as well as quercetin with 24 h 




































Table 2.36 Spearman’s correlation coefficients between urinary excretion of polyphenols in 24 h urine samples and biomarkers of glucose homeostasis 
and vascular function (n=91) 
 
 
r; Spearman’s correlations coefficient, P is significant at 0.05 level (2-tailed) 
HOMA-IR; homeostatic model assessment of insulin resistance 
 Polyphenol  Enterolactone Eriodictyol Hesperetin Phloretin Quercetin 
Biomarker  r P value r P value r P value r P value r P value 
Insulin (mU/L) -0.214 0.042 -0.118 0.267 -0.067 0.541 -0.001 0.990 -0.057 0.593 
HOMA-IR -0.215 0.041 -0.090 0.399 -0.041 0.699 0.031 0.772 -0.056 0.595 
Reflection index (%) -0.053 0.633 -0.237 0.030 -0.241 0.027 -0.236 0.031 -0.085 0.443 
24 h systolic blood pressure  (mmHg) -0.057 0.591 -0.145 0.184 -0.227 0.031 -0.081 0.445 -0.076 0.473 
24 h diastolic blood pressure  (mmHg) -0.013 0.210 -0.086 0.419 -0.271 0.009 -0.129 0.223 -0.234 0.026 
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2.5 Discussion  
In the present study we estimated dietary intake of total polyphenols, polyphenol 
subclasses and individual polyphenols on the CRESSIDA population using two dietary 
methods; FFQ and 4-DFD and one biomarker approach; urinary excretion estimated by 
LC-MS/MS. Total intake of 52 polyphenol aglycones were estimated from dietary 
records and excretion of ten polyphenol aglycones from 24 h urine samples, major food 
sources were also identified. To our knowledge this is the first study using 
simultaneously three different approaches for dietary assessment in a randomised 
controlled trial. Compliance to dietary advice was evaluated and reported in the main 
CRESSIDA report (Reidlinger et al., 2015). Self-reported average intakes of fruit and 
vegetables were of 6 portions/d according to the FFQ and slightly less than 5 portions/d 
in the 4-DFD. Urinary potassium excretion was 9 mmol/d greater in the intervention 
group indicating higher consumption of fruit and vegetables by the participants. Dietary 
fiber intakes at baseline were higher than those reported in the National Diet and 
Nutritional Survey (24 g/d compared with 20 g/d). Whole-grain intake increased to 81 
g/d in the intervention group compared with 32 g/d in control group, main food sources 
were wheat, oats, and rice, therefore dietary fiber intake was 7 g/d higher in the 
invertion group, reflecting increased cereal fiber from whole grains and confirmed by 
higher plasma alkylresorcinol concentrations, which reflect intakes of whole grains 
mainly from wheat, barley, and rye but not rice or oats.  
Our polyphenol intake estimates are in agreement with other reports in UK populations 
using 24-HR (Zamora-Ros et al., 2011a, Zamora-Ros et al., 2011b, Vogiatzoglou et al., 
2013, Zamora-Ros et al., 2015) or FFQs (Cassidy et al., 2011, Jennings et al., 2012). 
Most remarkable findings were increased intakes of individual polyphenols which main 
food sources were fruits (berries, citrus, apples and bananas), vegetables (sweet peppers 
and lettuce), nuts (peanuts, mixed nuts), seeds (linseeds, sesame seeds) and soy products 
(soy drinks and soy milk).  
Results demonstrate that following advice to conform to current UK dietary guidelines, 
compared to the average UK dietary pattern, does result in a higher intake of specific 
polyphenols that may confer cardiometabolic protective effects. This study reinforces 
the finding from previous report (Reidlinger et al., 2015) that providing advice to follow 
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UK dietary guidelines effectively increases the consumption of wholegrains, fruits and 
vegetables. CRESSIDA (ISRCTN92382106).  
2.5.1 FFQ 
Dietary intake of six flavonoid subclasses and 32 aglycone polyphenols were estimated 
by FFQ and main food sources were also identified. Consumption of flavonoids; 
anthocyanidins, flavones, flavan-3-ols and polymeric flavonoids increased in 
participants of the CRESSIDA study following a DG diet. FFQ methodology indicated  
increased intakes of 12 individual aglycone polyphenols in the CRESSIDA population 
following the DG diet. Differences in polyphenol intakes where major food sources 
were fruit and vegetables accounted for most of the changes detected on the flavonoid 
subclasses, anthocyanidins represented by consumption of berries (strawberries, 
raspberries and kiwi fruit), flavones for citrus fruit (oranges, satsumas and mandarins) 
and proanthocyanidins for apples. Increased estimated intakes of individual compounds 
such as myricetin, flavan-3-ols; epicathechin-3-gallate and epigallocatechin-3-O-gallate 
and polymeric flavonoids were found in the group following the DG diet. Although 
intakes of those particular flavan-3-ols mainly represent consumption of black tea in 
this population analysis of reported tea-drinking discards more tea-drinking at endpoint. 
Secondary food sources analysis indicates that the increases correspond to a greater 
intake of grapes and stone fruits (peaches, plums and apricots) for epicathechin-3-
gallate and berries, stone fruits and pears for epigallocatechin-3-O-gallate.      
Although the FFQ is a valid and reliable dietary assessment tool, it has limitations in the 
way that it can collect information, since is based on estimated portion sizes and is 
semi-quantitative on its answers. The EPIC-Norfolk FFQ although validated for whole 
food intake, validation for flavonoid intake has not been reported (McKeown et al., 
2001). The method has some limitations in regard to flavonoid estimation since some 
foods have been grouped incongruously with their flavonoid composition such as 
strawberries, raspberries and kiwi, or peaches, plums and apricots and red and white 
wine. Some important flavonoid sources are missing such as blueberries, soy beverages, 
and lemon, among others. The inadequacy of the method could lead to under or 
overestimation of flavonoid intakes. More specialised questionnaires for intake 
estimation of individual compounds like quercetin and naringenin (Ranka et al., 2008), 
flavonoid subclasses such as flavonols and flavones in Chinese population (Zhang et al., 
2010), complete flavonoid class in Australian population (Somerset and Papier, 2014) 
and Flemish population (Mullie et al., 2007) have been developed and used in diverse 
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studies. The database created for FFQs analysis might also add some limitations in the 
flavonoid intake estimation, since it was developed in 2012 before the release of the 
latest update of the flavonoid USDA composition food table and some values might be 
inaccurate, due to methodological aspects in the quantification. In addition the USDA 
composition food tables do not include retention factors that allow the adjustment of 
polyphenol food content after cooking process. Standardisation of a food frequency 
questionnaire for flavonoid and/or polyphenol intake and agreement in the polyphenol 
database used for estimation might improve intake estimation and facilitate comparison 
between populations.     
2.5.2 4-DFD 
Dietary intake of flavonoids, lignans, phenolic acids, stilbenes and other polyphenol 
subclasses was estimated by 4-DFD. Total intake of 52 polyphenol aglycones were 
estimated and main food sources were identified. Consumption of lignans, phenolic 
acids and other polyphenols increased in participants of the CRESSIDA study following 
the DG diet. 4-DFD indicated increased intakes of 11 out of 52 individual aglycone 
polyphenols in the CRESSIDA population following the DG diet. Differences in 
polyphenol intakes occurred for subclasses mainly where major food sources were fruit 
and vegetables. For example, anthocyanidins represented by consumption of berries and 
berry beverages (raspberries, red wine, grapes and blackcurrant juice), eriodictyol for 
citrus fruit and citrus jams (lemon and orange marmalade), isoflavones for soy 
beverages (soy drinks and soy milk), lignans by seeds (linseeds), phenolic acids by 
apples and dates and proanthocyanidins by apples. Where there were no differences in 
polyphenols they were provided mainly by food sources representative of the UK 
population diet, like black tea. This discrimination of the 4-DFD is in agreement with 
the aim of the intervention of increasing intakes of fruit and vegetables instead of 
modifying representative dietary patterns. 
The 4-DFD is a more accurate tool for the quantification of food portions consumed but 
is more of a burden on the study participants to complete it accurately, and only 
represents eating habits during those four days (which include one weekend day), 
thereby missing or overstimating foods that might be consumed seasonally or 
infrequently. The main advantage of this method is the description and quantification of 
all foods consumed in the four-day period. The detailed and specific analysis of all 
foods must account for a big part on the differences between results from FFQ and 4-
DFD. In addition the use of different food composition tables used, USDA for the FFQ 
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analysis and Phenol-Explorer/USDA for the 4-DFD analysis might explain as well some 
of the discrepancies in results (Peterson et al., 2015). In a separate study comparison 
between FFQ and 7-DFD have showed that food diaries provided a better estimation of 
nutrient intakes than FFQ (Day et al., 2001), although could be an overwhelming 
method for participants and expensive for its use on a big population study.                
Some studies have used food diaries for estimation of flavanol intake in European 
population (Vogiatzoglou et al., 2013) and isoflavone and lignan intakes (Mulligan et 
al., 2013) and 20 subclasses of polyphenols (Yahya et al., 2015) in UK population, each 
one creating their own database for polyphenol analysis. The database developed for the 
4-DFD polyphenol analysis in the present study included the estimation of 52 individual 
compounds of the different four polyphenol classes, and contained 1141 foods 
representative of an average UK diet and some of the most commonly eaten food from 
different cuisine as Turkish, Indian, Italian, Chinese, Japanese, among other. This 
database could be used for future studies analysing diet patterns in the UK population, 
comparing polyphenols intake and/or linking intake with health benefits.            
2.5.3 LC-MS/MS 
Urinary excretion of ten representative aglycone polyphenols were quantified in 24 h 
urine samples by LC-MS/MS. Urinary excretion of phloretin, eriodictyol, hesperetin, 
luteolin, vanillic acid and enterolactone increased in the CRESSIDA study subsample 
following the DG diet. Increases in urinary excretion mirror some of the findings in 
dietary intake analyis, however LC-MS/MS detected some changes not reported by FFQ 
and 4-DFD. Differing findings may be result of the high specificity and sensitivity of 
the LC-MS/MS method (Nielsen et al., 2000) or due to the nature of dietary methods 
where inaccuracies can be introduced by self-reported intakes, portion size estimation, 
food classification and food composition tables used (Bingham et al., 1994, Zamora-
Ros et al., 2012).  
The analysis by dietary methods may not be sensitive enough to detect changes in 
phloretin intakes, as LC-MS/MS analysis did, but was able to detect increases in apple 
intakes in the DG group at endpoint. Apple is the main food source of phloretin and 
both dietary methods reported higher intakes in polyphenols for which main food 
sources were apples, in FFQ there was an increase in proanthocyanidins intakes and in 
4-DFD there were increases in protocatechuic acid and syringic acid intakes. However, 
high phloretin urine concentrations could also be result of endogenous metabolism of 
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naringenin to phloretin (Ito et al., 2005). Besides apples, strawberries and white wine 
were the main food sources of protocatechuic acid and Swiss chard and hummus of 
syringic acid. Vanillic acid can be find in high concentrations in foods consumed in 
small quantities as herbs, basil, thyme and oregano; also in moderate concentration in 
fruits as dates and cranberries and in lower quantities in foods more frequently 
consumed as oat and rice (Rothwell et al., 2013). It is also a common metabolite of 
anthocyanins (Nurmi et al., 2009, de Ferrars et al., 2013), therefore increased urinary 
excretion could reflect increased intakes of vanillic acid per se as well as parent 
metabolites such as anthocyanins. Vanillic acid has also showed to be present in urine 
after consumption of characteristic UK diet foods as black tea (Olthof et al., 2003) and 
dark chocolate (Rios et al., 2003) which did not increase at endpoint in the CRESSIDA 
population, therefore are unlikely to account for the increased urinary excretion. 
However correlation analysis did not show a statistically significant association between 
dietary intakes of vanillic acid and urinary excretion therefore is likely that the 
increased value at endpoint reflect intake of parent compounds of vanillic acid.  
Enterolactone is the main colonic metabolite of lignans, phenolic compounds present in 
high concentrations in seeds, nuts and berries (Patel et al., 2012). FFQ and 4-DFD 
reported increases at endpoint in polyphenols which main food sources were seeds 
(lignans), nuts (other polyphenols) and berries (anthocyanidins) and LC-MS/MS 
detected increases in enterolactone excretion. Enterolactone has also showed an increase 
excretion in urine after supplementation with soy protein (Xu et al., 2000), consumption 
of soy-containing food (Rowland et al., 2000) and whole grain cereals (Johnsen et al., 
2004), so increases are likely to be related to the content of lignans in the food. 4-DFD 
reported increases in isoflavones intakes at endpoint in the intervention group; therefore 
increase in enterolactone excretion, as a microbiota metabolite, might reflect dietary 
intakes of diverse polyphenols subclasses. Our results are in agreement with previous 
studies associating polyphenol dietary intakes and urinary excretion in epidemiologial 
studies (Valls-Pedret et al., 2012), supplementation studies where known doses of 
polyphenols were administrated (Shi and Williamson, 2015, Perez-Jimenez et al., 
2010a), in RCTs aiming to increase flavonid-rich fruit and vegetables intake (Chong et 
al., 2012) and with population under free-living conditions (Mennen et al., 2008). 
Polyphenol urinary excretion has proved to be an efficient biomarker of fruit and 
vegetables intakes, capable of detecting even small changes in studies under controlled 
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diets (Nielsen et al., 2002, Brevik et al., 2004) but no similar analysis has been done in 
a RCTs with a free-living population following advice to adhere  to dietary guidelines.           
Limitation of the urinary excretion analysis is that according to dietary assessment 
methods there were differences at baseline intakes but we did not measure baseline 
values in urine excretion to verify this. The LC-MS/MS quantification of urine 
polyphenols eliminate the inaccuracies of the dietary methods but, since urinary 
excretion of polyphenols depends on intake and bioavailability, results may reflect 
interindividual variability in absorption and metabolism (Chen et al., 2014, Rodriguez-
Mateos et al., 2014) and not only dietary intakes, moreover the method required the 
preselection of polyphenols to be analysed which means that many other polyphenols 
present in 24 h urine that are not detected and quantified could function as biomarkers 
of intake. Relevant polyphenols that were not analysed include anthocyanins, which 
have showed low recovery percentages and weak correlation with dose ingested (Perez-
Jimenez et al., 2010). The use of a high sensitive method like LC-MS/MS represents a 
high cost for the researcher and is not always practical when a large population is 
involved.  
Although LC-MS/MS is the most common method used to quantify polyphenols other 
methodologies, such as ultra-performance liquid chromatography coupled to quadrupole 
time of flight (UPLC-QTOF)/MS and quantitative nuclear magnetic resonance (qNMR) 
spectroscopy offer advantages allowing the quantification of a wide range of 
metabolites without the need of sample hydrolysis by glucoronidase/sulphatase enzymes 
prior to analysis, which could compromise the stability of polyphenols that are to be 
quantified (Ding, et al., 2013; Cheynier et al., 2015).   
2.5.4 Conclusion  
The use of FFQ and 4-DFD appear to be effective approaches as proxy estimates of 
compliance to advice to follow polyphenol-rich diet over prolonged periods (FFQ) or 
during shorter pre-specified periods, although differences in the level of detail of the 
data collected meant that there was not complete agreement between the two methods. 
Future research in this area could include the development of a specific FFQ for 
estimation of polyphenols intake including all classes and main subclasses as was done 
for 4-DFD in this study. The development, validation and use of a standardised FFQ 
and updated polyphenol databases in different studies would permit better intake 
estimation and would make comparisons between populations an achievable goal. The 
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practicality and validity of this approach will permit use in larger populations such as 
larger prospective cohort studies. The 4-DFD proved to be an accurate approach for 
estimate of short-term polyphenol intake as demonstrated by associations with urine 
polyphenols detected by a more sensitive LC-MS/MS method. However, serious 
consideration must be taken for the use of those two methods in a large scale study, 
since its burden and cost might be excessive where a simple indicator of compliance to 
dietary advice is required.    
Healthy (free of overt CVD, T2D and other clinically significant chronic diseases) and 
probably health-conscious volunteers participated in the CRESSIDA study. Further 
changes in dietary patterns and other beneficial health effects may have been achieved 
in a less health-conscious population adhering to UK dietary guidelines. Nevertheless 
following dietary guidelines did indeed lead to increases in specific polyphenols that 
have been associated with health benefits (e.g. anthocyanins, isoflavones and lignans), 
despite the fact that the majority of polyphenol intakes were supplied by tea, coffee, 
wine and chocolate in this UK population. This suggests that consuming at least 5 
portions F&V per day and >50 % of cereal intake as wholegrain will lead to a 
significant enrichment in polyphenol intakes above and beyond the large amounts of 
polyphenols supplied by hot beverages, wine and chocolate. This may not have been the 
case if participants had chosen predominantly F&V, which are low in polyphenols 
(Chong et al., 2012). In particular estimated anthocyanidin intakes (not easily detected 
in urine) were increased in both dietary estimation methods, and these have been 
associated with reduced risk of T2D (Jennings et al., 2014), and acute randomised 
controlled trials have shown that anthocyanin-rich berry consumption reduces 
glycaemia (Törrönen et al., 2010, Törrönen et al., 2012c, Törrönen et al., 2012a). 
However, what component of the berries is responsible is not entirely clear. 
 
Consideration in establishing dietary reference intake (DRI) for polyphenols is a 
growing interest, although there is still debate in how the process should be managed, 
models suggests an approach to reach optimal intake values by recommendation of 
polyphenol-rich F&V (5-a-day) (Williamson and Holst, 2008) and establish values to 
improve health or prevent disease risk in different life stages (Lupton et al., 2014). 
Although many considerations must be taken into account (as stability, bioavailability, 
absorption, etc.) our data suggest that an additional specific guideline, indicating high 
polyphenol subclass-rich foods may be worth consideration since some polyphenols that 
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have been associated with health benefits increased there were others associated with 
cardiovascular protection that did not show an increased intake, such as flavan-3-ols 
estimated by 4-DFD. A specific recommendation would be useful for the food industry 
as well; targeting affordable functional foods that supply polyphenols that are less 
accessible to specific populations. However, further research is required to provide 
robust interventional evidence for any refinement to current “5-a-day” guidelines, since 
the relative health impact of other non-nutrient bioactives and fibre contained in low-
polyphenol fruits and vegetables is only partially understood. Furthermore, in the light 
of the fact that NDNS survey data suggest that the UK population are not meeting 
current recommendations then it would be futile, and possibly counter-productive, to 







Acute effects of anthocyanin-rich blackcurrant extract 
and polyphenol-rich apple extracts on postprandial 
glucose, insulin and gut hormones concentrations and 
vascular function in healthy men and women. The GLU-








3.1 Introduction  
According to the World Health Organization (WHO), 9 % of the world’s population 
suffers from type 2 diabetes (T2D) and the number is predicted to reach exceptional 
levels (WHO, 2016). Regular exposure to diets with a high glycaemic load (a measure 
of the overall blood glucose-raising effect of a serving of a food) and containing high 
amounts of free sugars may contribute to postprandial hyperglycaemia, a risk factor for 
T2D (Schulze, 2004, Sluijs et al., 2010, de Koning et al., 2011). Strategies to control 
chronic postprandial hyperglycaemia by optimising the functionality of foods would 
strengthen efforts to reduce the risk for T2D. Fruit polyphenols may help to delay 
glucose absorption and thereby control glucose levels following a carbohydrate-
containing meal or beverage. In vitro studies suggest that some berry anthocyanins and 
apple polyphenols are effective inhibitors of digestive enzymes, α-amylases and α-
glucosidases (Adisakwattana et al., 2004, Tadera et al., 2006, Adisakwattana et al., 
2009, Akkarachiyasit et al., 2010, Pereira et al., 2011). Additional in vitro experiments 
have shown inhibition of intestinal glucose transporters SGLT1 and GLUT2 by berry 
anthocyanins and apple polyphenols (Johnston et al., 2005, Kwon et al., 2007, Manzano 
and Williamson, 2010, Alzaid et al., 2013, Schulze et al., 2014). Human data is limited; 
however randomised controlled trials (RCTs) have supported the in vitro results of 
berry anthocyanins and apple polyphenols lowering postprandial plasma glucose 
concentrations. Administration of different apple products (Johnston et al., 2002, 
Schulze et al., 2014, Makarova et al., 2015) and a mixture of whole strawberries, 
bilberries, lingonberries, chokeberries and blackcurrants (Törrönen et al., 2010, 
Törrönen et al., 2012a, Törrönen et al., 2012c, Törrönen et al., 2013) have been shown 
to significantly reduce postprandial glucose concentrations following the consumption 
of either starch, glucose or sucrose loads.  
However, the majority of study designs have varied in their route of administration of 
polyphenols, making difficult to identify the relative effects of the polyphenols per se. 
Confounding factors from the degree of mastication to variability in the food matrix 
could influence the release of polyphenols. In addition, the effect of whole fruits or 
purées used in RCTs could be confounded by the presence of other components as fibre 
which is known to delay gastric emptying (Jenkins et al., 1978) and thus could be 




In the present series of RCTs, drinks containing a highly purified anthocyanin-rich 
blackcurrant extract, highly purified polyphenol-rich apple extract or the combinations 
of both were tested in reducing the postprandial glycaemia following a carbohydrate-
rich meal in a dose-dependent manner, compared with a matched placebo drink. Since 
RCT of anthocyanin-rich whole foods and individual apple flavonoids have been shown 
to influence markers of oxidative stress and endothelial function (Egert et al., 2009, 
Rodriguez-Mateos et al., 2013, Khan et al., 2014, Alvarez-Suarez et al., 2014, Gasper et 




3.2 Aim and objectives  
Aim  
To investigate the extent to which plasma glucose concentrations are reduced following 
different doses of polyphenol-rich fruit extracts derived from blackcurrants and apples 
added to a low sugar beverage when consumed with a high carbohydrate test meal. 
Objectives 
Three randomised controlled crossover trials:  
1) the first two to investigate the effects of consumption of different doses of a 
anthocyanin-rich blackcurrant extract and a polyphenol-rich apple extract 
incorporated into a low sugar drink on postprandial metabolic responses 
following a high-carbohydrate test meal;  
2) the third to investigate the additive/synergistic effects of consumption of 
different doses of a polyphenol-rich apple extract and a single dose of an 
anthocyanin-rich blackcurrant extract incorporated into a low sugar drink on 
postprandial metabolic responses following a mixed carbohydrate (sugar and 
starch) test meal;  
 
Primary outcomes 
Investigate whether there are dose-related differences in peak postprandial glucose 
following consumption of a small volume beverage containing either a blackcurrant or 
apple polyphenol extract together with a high-carbohydrate test meal, compared to a 
placebo drink. 
Secondary outcomes 
Investigate differences in postprandial plasma glucose area under the curve, insulin, C-
peptide, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 
(GLP-1), triacylglycerol (TAG), non-esterified fatty acids (NEFA) and 8-isoprostane-
F2α concentrations and vascular function in order to elucidate potential mechanisms for 
any differences observed in plasma glucose response. 
3.3 Hypothesis  
Hypothesis 1 Acute consumption of an anthocyanin-rich blackcurrant extract and a 
polyphenol-rich apple extract will reduce peak postprandial glucose concentrations 
following a high-carbohydrate meal. 
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Hypothesis 2 Acute consumption of anthocyanin-rich blackcurrant extract and 
polyphenol-rich apple together will have an additive/synergistic effect on peak 
postprandial glucose concentrations following a high-carbohydrate meal. 
3.4 Methodology   
The first study consisted of two phases: Phase 1 took 7 months to run, from August 
2012 to February 2013, Phase 2 took 6 months to run, from April to September 2013. 
The study was sponsored by GlaxoSmithKline Nutritional Healthcare (GSKNH) and 
received approval from the Biomedical Sciences, Dentistry, Medicine and Natural and 
Mathematical Sciences Research Ethics Subcommittee from King’s College London 
(REC reference: BDM/11/12-88). This study abided by the principles outlined in the 
Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 
2013) and was registered at clinicaltrials.gov as NCT01706653.   
The second study took 7 months to run, from January to July 2015 and was sponsored 
by King’s College London and received approval from the Biomedical Sciences, 
Dentistry, Medicine and Natural and Mathematical Sciences Research Ethics 
Subcommittee from King’s College London (REC reference: BDM/14/15-10). This 
study abided by the principles outlined in latest version of the Declaration of Helsinki 
and was registered at clinicaltrials.gov as NCT02340039.   
The lead researcher was Dr Wendy Hall and study investigators included research 
assistant Ms Leanne Smith, Mr Robert Gray, BSc Nutrition student Najmeh Kamali, 
BSc Nutrition medical students Stephanie G Stone and Jonathan E Mok, MSc Nutrition 
students Rhia K Mhajan, Chi Ieng Fu and Georgia Lenihan-Geels. The author’s 
participation in the first study (two phases) comprised assistance in screening and study 
days as well as blood sample handling and storage following the protocol established by 
GSK NH and laboratory analysis of 8-isoprostane-F2α concentrations by gas 
chromatography mass spectrometry (GC-MS). In the second study the author’s 
participation consisted in the preparation of the application for ethical approval and 




3.4.1 Study design  
First study  
Phase 1 (GLU-BERRY study): A randomised, controlled, double-blind, cross over 
design was used to allow subjects receive each of the following interventions in random 
order at 4 separate study visits: 0, 150, 300 and 600 mg of blackcurrant anthocyanins 
delivered in a blackcurrant extract dispersed in a low sugar fruit drink. At least 7 days 
wash-out period were required between study days. After baseline measurements and 
blood samples were taken the test drink and meal were consumed within 5 min, total 
carbohydrate provided including the drink was 67 g. Drink was consumed within 2 
minutes and immediately following consumption of the drink 100 g of white bread 
(Hovis, London, UK) with 32 g of a low polyphenol apricot jam (Hartley’s, Hain 
Daniels Group, Leeds, UK), providing 1127 kJ and 62 g carbohydrate; 39 g starch and 
23 g as sugars, were consumed. Further blood samples were collected at 10 min 
intervals for the first 30 min and then quarter-hourly until t 90 min and at t 120 min 
(Figure 3.1).  
Phase 2 (GLU-APP study): A randomised, controlled, double-blind, cross over design 
was used to allow subjects receive each of the following interventions in random order 
at 3 separate study visits: 0, 300 and 600 mg of apple polyphenols delivered in an apple 
extract dispersed in a low sugar fruit drink. At least 7 days wash-out period were 
required between study days. After baseline measurements and blood samples were 
taken the test drink and meal were consumed within 5 minutes. Immediately after 
consumption of the test drink, a mixture of 250 ml water and 82.5 g of dextrose 
monohydrate (OneOn Nutrition, UK), to provide 75 g of dissolved glucose, was 
consumed. The study procedure thereafter was identical to Phase 1.  
Second study 
GLU-FRU study: A randomised, controlled, double-blind, cross over design was used 
to allow subjects receive each of the following interventions in random order at 3 
separate study visits: 0 mg of polyphenols, 1200 mg of apple polyphenols and 600 mg 
apple polyphenols + 600 mg blackcurrant anthocyanins delivered in an apple and a 
blackcurrant extract dispersed in a low sugar fruit drink. At least 7 days wash-out period 
were required between study days. After baseline measurements and blood samples 
were taken the test drink and meal were consumed within 5 min, total carbohydrate 
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provided including the drink was 75 g. Drink was consumed within 2 minutes and 
immediately following consumption of the drink 100 g of white bread (Hovis, London, 
UK) with 30 g of a low polyphenol apricot jam (Hartley’s, Hain Daniels Group, Leeds, 
UK), providing 1284 kJ and 63 g carbohydrate; 41 g starch and 22 g as sugars, were 
consumed. The study procedure was identical to the first study. 
 
Figure 3.1 Study day timings and procedures 
 
3.4.2 Test drinks and high carbohydrate meals  
Highly purified extracts instead of whole fruits were used in test drinks so to avoid the 
confounding effect of fruit fibre on gastric emptying rate (Ulmius et al., 2009).  
GLU-BERRY study 
The blackcurrant extract (BerryPharma® by Iprona AG, Lana, Italy) for GLU-BERRY 
study contained 2822 mg total anthocyanins per 100 ml (5775 mg total polyphenols per 
100 ml) and 2.3 g of carbohydrates per 100ml, analysed by RSSL The Lord Zuckerman 
Research Centre (Reading, UK). Study drinks were formulated by GlaxoSmithKline 
Nutritional Healthcare R&D (Coleford, UK) and Döhler (Milton Keynes, UK) and 
standardised to contain 0, 150, 300 or 600 mg anthocyanins. The placebo drink did not 
have blackcurrant extract added to it, but tannins (polymeric polyphenols, such as 
proanthocyanidins) were added to lower-concentration drinks and placebo to make sure 
each of the drinks had comparable astringency/bitterness in taste. Each test drink 
consisted of a “no added sugar” fruit drink providing 90 kJ, <0.1 g protein, <5 g 





Table 3.1 Energy, nutrient and polyphenol composition of the test drinks for GLU-
BERRY study 
Per 200 ml 600 mg  300 mg  150 mg  0 mg  
ACN ACN ACN ACN 
Energy and nutrients     
Energy (kJ) 92 90 90 95 
Carbohydrate (g) 4.6 4.5 4.5 4.8 
Glucose (g) 0.2 0.2 0.2 0.2 
Fructose (g) 0.2 0.2 0.2 0.2 
Sucrose/Lactose/Maltose (g) <0.1 <0.1 <0.1 <0.1 
Starch (g) 4.0 4.0 5.0 4.0 
Fat (g) 0.4 0.4 0.4 0.4 
Protein (g) <0.1 <0.1 <0.1 <0.1 
Total dietary fibre (AOAC) (g) <0.5 <0.5 <0.5 <0.5 
Vitamin C (mg) <0.5 <0.5 <0.5 <0.5 
Vitamin E (mg) <0.2 <0.2 <0.2 <0.2 
Sodium (mg) <3 <3 <3 <3 
Potassium (mg) 15.7 7.8 3.9 <3 
Magnesium (mg) 2.3 1.1 0.6 <0.4 
Calcium (mg) 6.5 3.3 <3 <3 
Phosphorus (mg) <2 <2 <2 <2 
Zinc (mg) <0.1 <0.1 <0.1 <0.3 
Polyphenols     
Total phenolics (mg)1,2 1596 810 460 207 
Total anthocyanins (mg)1 599 322 131 46 
Delphinidin-3-rutinoside (mg)3 260 140 57 20 
Cyanidin-3-rutinoside (mg)3 209 113 46 16 
Delphinidin-3-glucoside (mg)3 76 41 17 6 





phenolic and anthocyanin content estimated from direct analysis of drinks by Folin -Ciocalteau 
method and HPLC respectively.  
2 
Tannins added as an ingredient (600 mg ACN 0 mg, 300 mg ACN 60 mg, 150 mg ACN 90 mg, 0 mg 
ACN 150 mg per 200 ml drink) to render drinks equivalent in bitter/astringent taste for blinding 
purposes. 
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The apple extract for GLU-APP (JF-NATURAL, Tianjin Jianfeng Natural Product 
R&D Co., Ltd, China) contained 73 g of total polyphenols per 100 g of extract, analysed 
by RSSL The Lord Zuckerman Research Centre (Reading, UK) (Appendix 1). The 
apple extract was ~7% phlorizin and ~63% flavan-3-ols. For GLU-APP study drinks 
were formulated by GlaxoSmithKline Nutritional Healthcare R&D (Coleford, UK) and 
standardised to contain 0, 300 or 600 mg of apple polyphenols. Analysis of drinks is 
pending from Lucozade Ribena Suntory previously GSK.  
GLU-FRU study 
The blackcurrant extract (BerryPharma® by Iprona AG, Lana, Italy) contained 1.8% 
anthocyanins (3.6% total polyphenols). The apple extract (Appl’InTM by DIANA 
FOOD, Antrain, France) contained 67% total polyphenols as analysed DIANA FOOD 
and confirmed by author using Folin-Ciocalteu method (Singleton and Rossi, 1965). Of 
total polyphenols 40% were flavonoids (40% flavan-3-ols, 36% dihydrochalcones, 13% 
flavonols and 11% hydroxycinnamic acids) and extract contained 8.5 g of carbohydrates 
per 100 g as reported by Diana FOOD (personal communication, confidential 
information). For GLU-FRU study drinks were formulated by the author and BSc 
students and standardised to contain 0 mg polyphenols, 1200 mg apple polyphenols and 
600 mg apple polyphenols + 600 mg blackcurrant anthocyanins. The extracts were 
dispersed in a very low-polyphenol double concentrate apple and blackcurrant squash 
(Robinson’s, United Kingdom) made up with water; drinks were matched in 
macronutrient and energy content. Each test drink consisted of a fruit drink providing 
220 kJ, 0.2 g protein and 12 g carbohydrate, see Table 3.2. Test drinks (200 ml) were 
blinded in identical black bottles by an external research technician. 
Mixed carbohydrate meal 
The standardised high carbohydrate meal consumed on each study visit was freshly 
prepared on study days previous to baseline measurements, and consisted of 100 g thick 
sliced white bread (Hovis, London, UK) and Hartley’s smooth apricot jam (Hain 
Daniels Group, Leeds, UK), both high carbohydrate foods are low in polyphenols 




Table 3.2 Energy, nutrient and polyphenol composition of the test drinks for GLU-FRU 
study  
 
Per 200 ml  AE AE + BE CON 
Energy and nutrients    
Energy (kJ)  222 227 219 
Carbohydrate (g)  12.2 12.2 12.1 
Starch (g)  - - - 
Sugars (g)  12.2 12.2 12.1 
of which sucrose (g)  6 6 6 
Fat (g)  - - - 
Protein (g)  0.1 0.2 - 
Fibre (g) 0.1 0.4 - 
Soluble fibre (g)  0.1 - - 
Polyphenols    
Total phenolics (mg) 1 1200 1800 4 
Total flavonoids (mg) 1  480 840 2 
Flavan-3-ols (mg)1  192 96 - 
Flavonols (mg) 1  62.4 31.2 - 
Quercetin (mg)1 15.6 7.8  
Dihydrochalcones (mg)1  172.8 86.4 0.4 
Phlorizin (mg)1  100 50 - 
Hydroxycinnamic acids (mg)1  52.8 26.4 1.6 
Chlorogenic acids (mg)1 31.7 15.9 - 
Anthocyanins (mg)1  - 600 - 
Other polyphenols (mg)1  720 960 - 
CHO; carbohydrate, AE; 1200 mg of apple polyphenols, AE+BE; 600 mg of 
blackcurrant anthocyanins + 600 mg apple polyphenols, CON; 0 mg of blackcurrant 
anthocyanins and apple polyphenols.   
1 




3.4.3 Sample Size  
Biostatistics department GSKNH determined the sample size of the first study, it was 
established that with 18 subjects, it would be possible to detect a 1.6 mmol/L difference 
in glucose incremental Cmax, assuming 80% power, a standard deviation of differences 
of 1.878, estimated from a similar study (Törrönen et al., 2012a) using a paired t-test with 
a 0.017 (Bonferoni adjustment allowing for 3 treatment comparisons). This was later 
revised to a sample size of 22 for optimal statistical power.  
For the second study, power calculations were done from plasma glucose concentrations 
obtained from GLU-BERRY study. A sample size of 26 subjects has 80% power to detect 
a difference between average mean area over baseline values 0-30 min of 0.35 mmol/L·h 
between test drinks with a significance level of α=0.01 (two-tailed), calculated from a 
0.44 mmol/L standard deviation of the difference.  
3.4.4 Subjects 
Different strategies were used for advertisement of the clinical trials; circular emails 
within King’s College London (KCL), social networking website, poster advertising at 
KCL, fitness centres and community centres (Appendices 2, 3, 4), online advertising 
agency and nutrition focus groups at community centres. A participant information 
sheet (Appendix 5) or a pdf file was provided to volunteers who expressed interest. 
Respondents were initially interviewed over the telephone and if eligible (Appendix 6), 
were invited to a screening visit in the Metabolic Research Unit at the Diabetes & 
Nutritional Sciences Division, King’s College London in a fasting state. Screening visit 
consisted of the measurement of height, weight, waist circumference, % body fat 
(TanitaTM Body Composition Analyser), supine blood pressure and digital volume 
pulse. Blood samples were taken, by a trained phlebotomist, for liver function tests, 
haematology, plasma glucose and lipid profile, written informed consent was given by 
participants (Appendix 7) and a small remuneration was given for participation in the 
studies. Blood samples were analysed in the Clinical Biochemistry department, King’s 
College Hospital, United Kingdom by Tracy Dew and results were received within one 
week. A unique screening number identify each subject screened for study participation. 
Screening numbers were assigned in ascending numerical order as each subject signed 
their consent form and keep it as the study ID if participant complied with inclusion 
criteria and did not report any of the exclusion criteria.  
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3.4.4.1 Inclusion criteria were:  
 Male and post-menopausal female aged 20-60 y 
 Healthy (free of diagnosed diseases in the exclusion criteria) 
 BMI 18-35 kg/m2 
 Able to understand the information sheet and willing to comply with study 
protocol 
 Able to give informed written consent 
3.4.4.2 Exclusion criteria were: 
 Diagnosed with phenylketonuria,  
 Known or suspected food intolerances, allergies or hypersensitivity  
 Women who are known to be pregnant or who are intending to become pregnant 
over the course of the study   
 Women who are breast feeding 
 Participation in another clinical trial 
 Donated blood within 3 months of the screening visit and participants for whom 
participation in this study would result in having donated more than 1500 
millilitres of blood in the previous 12 months.  
 Full blood counts and liver function test results outside of the normal range. 
 Pre-menopausal women due to the potential influence of cyclical changes in 
reproductive hormones on insulin sensitivity 
 Current smokers, or reported giving up smoking within the last 6 months  
 History of substance abuse or alcoholism 
 Reported history of CVD, diabetes (or fasting glucose ≥ 7.1 mmol/L), cancer, 
kidney, liver or bowel disease, gastrointestinal disorder or use of drug likely to 
alter gastrointestinal function 
 Unwilling to restrict consumption of specified high polyphenol foods for 24 h 
before the study 
 Weight loss >3 kg in preceding 2 months and body mass index <18 or >35 
kg/m2 
 Blood pressure ≥160/100 mmHg 




 Medications that may interfere with the study such as alpha-glucosidase 
inhibitors (acarbose: Glucobay), insulin-sensitising drugs (metformin: 
Glucophage, Glucophage SR, Eucreas, Janume; thiazolidinediones: Actos, 
Competact), sulfonylureas (Daonil, Diamicron MR, Glibenese, Minodiab, 
Amaryl Tolbutamide), and lipid-lowering drugs (statins, nicotinic acid, 
colestyramine anhydrous, ezetimibe, fibrates). Other medications should be 
reviewed by medical representative from KCL on a case by case basis. 
 Nutritional supplements that may interfere with the study such as higher dose 
vitamins/minerals (>200 % reference nutrient intake (RNI)), B vitamins, vitamin 
C, calcium, copper, chromium, iodine, iron, magnesium, manganese, 
phosphorus, potassium and zinc. Subjects already taking vitamin or minerals at a 
dose around 100 % or less up to 200 % of the RNI, or evening 
primrose/algal/fish oil supplements will be asked to maintain habitual intake 
patterns, ensuring that they take them every day and not sporadically. They will 
be advised not to stop taking supplements or start taking new supplements 
during the course of the study. 
3.4.5 Randomisation procedure 
The lead investigators reviewed all criteria and signed the case report form to confirm 
the subject’s eligibility to participate in the study. Subjects who meet all inclusion and 
exclusion criteria were randomised according to the randomisation schedule. 
Randomisation numbers were assigned in ascending numerical order as each subject 
was determined to be fully eligible. The randomisation schedule for GLU-BERRY and 
GLU-APP studies were provided by the Biostatistics Department, GSKNH and the 
randomisation schedule for GLU-FRU study was created using Research Randomizer 
software (https://www.randomizer.org). The allocation of treatment was blinded from 
the investigators, laboratory technicians, statisticians and the study participants by 
independent contracted parties within GlaxoSmithKline Nutritional Healthcare at GLU-
BERRY and GLU-APP studies and by external research technician at GLU-FRU study. 
The blinding could only been broken in an emergency where it was essential to know 
which treatment a subject received in order to give the appropriate medical care. 
Randomisation number was in the format starting FPA001 for GLU-BERRY and GLU-
APP studies and GFS001 for GLU-FRU study. The format of randomisation number 
was used to labelling tubes, vials and cryovials used along studies (Table 3.3). All 
randomised subjects were recorded on the participant identification log.   
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Table 3.3 Randomisation number and labelling format of cryovials 
 
STUDY NAME SUBJECT VISIT TIME POINT 
FPA/GFS 001 1/v1 0 
 VACUTAINER/TEST  
 Ser/NEFA  
 DATE  
 20/09/2012  
 
3.4.6 Study day 
On the day previous to each study visit, participants were told not to participate in 
strenuous exercise and to avoid alcohol, caffeine, oily fish, high polyphenol foods (from 
a list provided) and foods high in fat. Participants were asked to consume a low-fat meal 
the evening before each visit and to fast 12 h before, avoid eating or drinking anything 
except for water until the morning of the study visit. Detailed dietary and lifestyle 
guidance was provided to each participant before commencing the study period. 
Participants attended the Metabolic Research Unit at King’s College London between 
08.00 and 11.00 h. On arrival to study days, participants reported any deviations from the 
protocol, if any deviation they were weighed and rested in the supine position for ten 
minutes. Digital volume pulse (DVP) and blood pressure (BP) measurements were recorded 
for triplicate. For blood sampling a venous cannula was inserted in the forearm vein by a 
trained phlebotomist and baseline samples for analysis of glucose, insulin, triacylglycerol 
(TAG), non-esterified fatty acids (NEFA), glucose-dependent insulinotropic polypeptide 
(GIP) and glucagon-like-peptide-1 (GLP-1) were collected. Glucose baseline samples were 
taken in duplicate (at -10 and -5 min) and isoprostanes samples were taken at baseline and 
endpoint min for GLU-BERRY and GLU-APP studies. After baseline measurements and 
blood sampling participants consumed the drink immediately before a high-carbohydrate 
meal. Following the consumption of the test meal, blood samples were taken at minutes 10, 
20, 30, 45, 60, 75, 90 and 120. BP and DVP measurements were taken again at min 120 and 
two more time points were added for GLU-FRU study at 60 and 90 min. See Fig 3.1 for 





3.4.7.1 Dietary intake analysis 
For GLU-FRU study participants were asked to complete a 4-day food diary (4-DFD) 
previous to the first visit day. Baseline macronutrient intake was assessed using 
Nutritics software (Nutritics, version 3.5. Northern Ireland) and polyphenol intake was 
assessed using the database created for the polyphenol intake analysis of 4-DFD of 
participants in the CRESSIDA study (Chapter 2). 
3.4.7.2 Blood pressure 
Blood pressure was measured at the brachial artery using a calibrated automated blood 
pressure monitor (Omron 705IT, Omron Healthcare Europe B.V.). Participants were 
allowed to rest quietly, in supine position, at a comfortable room temperature for ten 
minutes before the measurements were performed. Participants were not drinking, 
eating or talking at the time that the blood pressure was measured. The arm that the 
measurement was taken from was comfortably supported to heart level. The cuff was 
place and the bladder of the cuff was 2-3 cm above the antecubital fossa in the brachial 
artery (around the participants’ upper arm). The cuff was wrapped snugly around the 
arm, making sure that the cuff index line fell within the marked ranges allowing space 
for a finger between the participants’ arm and the cuff. The cuff was placed so that the 
participants’ artery was aligned with the cuff arrow marked ‘artery’. The start/stop 
button was pressed allowing the reading to take place. Readings for systolic and 
diastolic blood pressure were written down in the case report form (CRF), as well as the 
heart rate readings. Repeated measurements of blood pressure were done two more 
times at two - five minute intervals, and the first one was discarded. 
3.4.7.3 Digital volume pulse measurements 
Arterial tone was measured using the digital volume pulse (DVP). The DVP was 
obtained by photoplethysmography (PulseTrace PCA 2, Micro Medical Ltd, Kent, UK) 
and used to calculate stiffness index (DVP-SI, m/s) and reflection index (DVP-RI, %). 
DVP-SI is related to large artery stiffness and correlates closely with large artery pulse 
wave velocity (PWV) (Millasseau et al. 2002). Although DVP-SI is a measure of 
arterial stiffness which increases with age, it is also sensitive to small changes in 
vascular tone induced by vasodilators (for example, glycerol trinitrate), and it has been 
demonstrated to be sensitive to short-term fluctuations in vessel tone postprandially 
(Hall et al 2008). DVP-RI is more strongly related to vascular tone of small arteries and 
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is markedly sensitive to drugs influencing vasomotor tone (Chowienczyk et al., 1999; 
Millasseau et al., 2002). DVP-RI shows marked changes in response to vasoconstrictors 
and vasodilators. The DVP was measuring using an infra-red probe that clips on the 
finger/thumb of any hand (preferably index finger of the non-dependant hand). 
Participants were allowed to rest quietly, in supine position, at a comfortable room 
temperature for ten minutes before the measurements were performed. The 
measurements were done three times, using the equipment default settings, separated by 
30-45 seconds. The three values for SI were within 10-15% of each other. If one was 
clearly irregular was be discarded. Values were registered in the cases report form.   
 3.4.7.4 Blood sampling   
For blood sampling, an 18 or 20 G IV catheter (BD VenflonTM Pro Safety Shielded, Cat 
no. 393226 (green) or 393224 (pink)) was inserted, ideally, into a vein in the antecubital 
fossa of the arm. If those veins were not suitable then the cannula was inserted into the 
cephalic vein of the lower forearm. The catheter was held in place with an IV dressing 
(BD Veca IV dressing, Cat no. 392020), blood was drawn using a 3-way tap (BD 3-way 
taps Cat no. 344995). The 2 h blood samples were collected by a trained phlebotomist 
using 5 or 20 ml syringes according to the blood collection protocol outlined in Fig 3.1. 
A baseline blood sample was taken for the measurement of plasma glucose, insulin, C-
peptide, TAG, NEFA, GIP and GLP-1 and isoprostanes. Further blood samples for 
plasma glucose, insulin, C-peptide, TAG, NEFA, GIP and GLP-1 were taken at 10, 20, 
30, 45, 60, 75, 90 min and additional for isoprostanes at 120 min (Fig 3.1). Blood 
samples were collected into fluoride/oxalate tubes (BD Vacutainer Cat no. 368921) for 
glucose analysis, into SSTTM serum tubes (BD Vacutainer Cat no. 367954) for insulin, 
C-peptide, TAG and NEFA analysis, into K2EDTA tubes for GIP and GLP-1 (BD 
Vacutainer Cat no. 367839). Tubes for GLP-1 analysis had 10 µl per ml blood 
dipeptidyl peptidase IV inhibitor added (Millipore, MO, USA). Blood samples for 8-
isoprostane-F2α analysis were collected into chilled citrated tubes (BD Vacutainer Cat 
no. 367691) and chilled fresh indomethacin (cyclooxygenase inhibitor) was 
immediately added (final concentration 15 μmol/L). The sample was kept on ice 30 min 
prior to centrifugation. Prior to centrifugation BHT was added (final concentration 20 
μmol/L) and the samples were snap frozen in liquid N2. Participants were provided with 




3.4.7.5 Sample analysis 
Following collection into vacutainers tubes and prior to centrifugation, samples were 
placed in ice. After centrifugation at 1300 g , 4 ° C for 15 min samples were aliquot into 
their correspondent labelled cryovial (Table 3.3) and frozen at -40 or -80 ° C for their 















































RT CENTRIFUGE SEPARATION ANALYTES ANALYSIS STORAGE 
Fasting (-10 min) 
(4 ml) 
Fasting (-5 min) 
(21 ml) 
 
4 ml fluoride oxalate 
(grey) 
1 ICE 15min X 1300g @ 4OC 1 ml Glucose KCL – ILAB -40 o C 
1 ml Spare  -40 o C 
4 ml fluoride oxalate  
(grey) 
1 ICE 15min X 1300g @ 4OC 1 ml Glucose KCL – ILAB -40 o C 
1 ml Spare  -40 o C 
5 ml serum  1 ICE 15min X 1300g @ 4OC 0.5 ml TAG KCL – LAB -40 o C 
(gold) 0.5 ml Insulin KCH -40 o C 
 0.5 ml NEFA KCL - LAB -40 o C 
 0.5 ml spare  -40 o C 
4 ml EDTA + DPP IV  inhibitor   2 ICE 15min X 1300g @ 4OC 0.5 ml GIP KCH -80 o C 
(lavender) 0.5 ml GLP-1 KCH -80 o C 
1 ml spare  -80 o C 
2 x 4 ml pre-chilled citrate  3 ICE 15min X 1300g @ 4OC 
(+snap freeze) 
2.2 ml Isoprostanes KCL -80 o C 
(blue) 2.2 ml Isoprostanes KCL -80 o C 
TEST MEAL (0 min) 
Postprandial (10, 20, 30, 
45, 60, 75, 90 min) 
(13 ml) 
 
4 ml fluoride oxalate  
(grey) 
1 ICE 15min X 1300g @ 4OC 1 ml Glucose KCL – ILAB -40 o C 
1 ml Spare  -40 o C 
4 ml serum  2 ICE 15min X 1300g @ 4OC 0.5 ml TAG KCL – ILAB  -40 o C 
(gold) 0.5 ml Insulin KCH -40 o C 
 0.5 ml NEFA KCL – ILAB  -40 o C 
 0.5 ml spare  -40 o C 
5 ml EDTA + DPP IV  inhibitor   3 ICE 15min X 1300g @ 4OC 0.5 ml GIP KCH -80 o C 
(lavender) 0.5 ml GLP-1 KCH -80 o C 
1 ml spare  -80 o C 
Postprandial (120 min) 
(21 ml) 
 
4 ml fluoride oxalate  
(grey) 
1 ICE 15min X 1300g @ 4OC 1 ml Glucose KCL – ILAB -40 o C 
1 ml Spare  -40 o C 
4 ml serum  2 ICE 15min X 1300g @ 4OC 0.5 ml TAG KCL – ILAB  -40 o C 
(gold) 0.5 ml Insulin KCH -40 o C 
 0.5 ml NEFA KCL – ILAB  -40 o C 
 0.5 ml spare  -40 o C 
5 ml EDTA + DPP IV inhibitor 
(lavender) 
3 ICE 15min X 1300g @ 4OC 0.5 ml GIP KCH -80 o C 
0.5 ml GLP-1 KCH -80 o C 
1 ml spare  -80 o C 
2 x 4 ml pre-chilled citrate  4 ICE 15min X 1300g @ 4OC 
(+snap freeze) 
2.2 ml Isoprostanes KCL -80 o C 
(blue) 2.2 ml Isoprostanes KCL -80 o C 
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CENTRIFUGE SEPARATION ANALYTES ANALYSIS STORAGE 
Fasting (-10 min) 
(4 ml) 
 
4 ml fluoride oxalate 
(grey) 
1 ICE 15min X 1300g @ 4OC 1 ml Glucose KCL – ILAB -40 o C 
1 ml Glucose KCL– ILAB -40 o C 
1 ml Spare  -40 o C 
Fasting (-5 min) 
(13 ml) 
 
4 ml fluoride oxalate 
(grey) 
1 ICE 15min X 1300g @ 4OC 1 ml Glucose KCL – ILAB -40 o C 
1 ml Glucose KCL – ILAB -40 o C 
1 ml Spare  -40 o C 
5 ml serum (gold) 2 RT(10’) 15min X 1300g @ 4OC 0.5 ml Insulin KCH -40 o C 
0.5 ml TAG KCL – ILAB -40 o C 
0.5 ml NEFA KCL – ILAB -40 o C 
0.5 ml Spare  -40 o C 
0.5 ml Spare  -40 o C 
4 ml EDTA +  DPP IV 
inhibitor  (lavender) 
3 ICE 15min X 1300g @ 4OC 0.5 ml GIP KCH -80 o C 
0.5 ml GLP-1 KCH -80 o C 
1 ml Spare  -80 o C 
1 ml Spare  -80 o C 
TEST MEAL (0 min) 
Postprandial 
(10, 20, 30, 45, 60, 75, 
90 and 120 min) 
(13 ml) 
4 ml fluoride oxalate 
(grey) 
1 ICE 15min X 1300g @ 4OC 1 ml Glucose KCL – ILAB -40 o C 
1 ml Glucose KCL – ILAB      -40 o C 
1 ml Spare  -40 o C 
5 ml serum (gold) 2 RT(10’) 15min X 1300g @ 4OC 0.5 ml Insulin KCH -40 o C 
0.5 ml TAG KCL – ILAB -40 o C 
0.5 ml NEFA KCL – ILAB -40 o C 
0.5 ml Spare  -40 o C 
0.5 ml Spare  -40 o C 
4 ml EDTA + DPP IV  
inhibitor (lavender) 
3 ICE 15min X 1300g @ 4OC 0.5 ml GIP KCH -80 o C 
0.5 ml GLP-1 KCH -80 o C 
1 ml Spare  -80 o C 
1 ml Spare  -80 o C 
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3.4.7.5.1 Plasma glucose 
Plasma glucose concentrations were analysed at KCL on the ILab 650 chemistry 
analyser. The IL Glucose Oxidase reagent was supplied ready to use (ILTM Test Cat No. 
0018259140). Glucose was measured using the enzymes glucose oxidase and 
peroxidase. In the first step glucose was converted to gluconic acid and hydrogen 
peroxide. The hydrogen peroxide then reacts, in the presence of peroxidase, 4-
aminophenazone and phenol to produce a red quinoneimine dye. The increase in 
absorbance generated by the red dye was proportional to the glucose concentration in 
the sample. Primary measurements were taken at 510 nm, and a blanking reading was 
taken at 600 nm. Precision: the coefficient of variation for two quality control serum 
samples 7.0-15.2 mmol/L was not be greater than 2% within run and total.  
3.4.7.5.2 Insulin 
Plasma insulin concentrations were analysed at KCH by immunoassay. Insulin reagent 
supplied by Siemens Medical Solutions Diagnostics Europe Ltd. The Siemens Advia 
Centaur assay is a two-site sandwich immunoassay using direct chemiluminometric 
technology, which uses constant amounts of two antibodies. Sample is incubated with 
two insulin-specific antibodies. The first is in the Lite reagent, is a monoclonal mouse 
anti-insulin antibody labelled with acridinium ester. The second antibody, in the solid 
phase, is a monoclonal mouse anti-insulin antibody, which is covalently coupled to 
paramagnetic particles. Insulin forms a sandwich between the two antibodies. After the 
incubation a magnetic field is applied causing the solid phase (including the sandwich) 
to be held at the site of the reaction cuvette while the liquid phase is aspirated. The 
cuvette is then washed with deionised water. Acid reagent (containing hydrogen 
peroxide) is then added to the cuvette to begin the light emission reaction with the 
acridinium ester. The cuvette is then moved to the luminometer and base reagent is 
added to enhance the light reaction. Light intensity is measured immediately and 
converted to relative light units. This has a direct proportional relationship with the 
insulin concentration. Sensitivity: Minimum detectable concentration of 0.5 mU/L. 





Plasma C-peptide concentrations were analysed at KCH by immunoassay. This was a 
sandwich ELISA based assay. Biotinylated monoclonal and horseradish peroxidase 
(HRP) labelled antibodies were used; both have high affinity and specificity for 
different epitopes of C-Peptide. Reaction between the C-Peptide antibodies and native 
C-Peptide occurred without competition or steric hindrance forming a soluble sandwich 
complex. After incubation and washing TMB substrate solution was added to be 
catalysed by HRP and produce blue coloration. The reaction was terminated adding stop 
solution, which stopped the blue colour development and produced a yellow colour. The 
intensity of signal was measured at 450 nm and was directly proportional to the amount 
of C-peptide in the sample. The detection limit was 25 pmol/L. 
3.4.7.5.4 Triacylglycerol (TAG)  
Plasma TAG concentrations were analysed at KCL on the ILab 650 autoanalyser, 
utilising an in vitro enzymatic colorimetric method (ILTM Triglycerides, Cat No. 
0018258740) for the quantification of the red pigment that is produced, which is 
proportional to the concentration of TAG. The red quinoneimine is produced by a multi-
enzymatic cascade reaction, using enzymes; lipase, glycerol kinase, glycerophosphate 
oxidase and peroxidise to degraded triglycerides to the red pigment. Primary 
measurements were taken at 510 nm, and a blanking reading was taken at 700 nm. 
Precision: the coefficient of variation for two quality control serum samples 1.12-3.0 
mmol/L, was not be greater than 2 % within run and total.  
3.4.7.5.5 Total non-esterified fatty acids (NEFA) 
Plasma NEFA concentrations were analysed at KCL on the ILab 650 autoanalyser, 
utilising an in vitro enzymatic colorimetric method (NEFA, Randox Cat. No. FA 115) 
for the quantification of the purple pigment that is produced, which is proportional to 
the concentration of NEFA. The purple adduct is produced by a multi-enzymatic 
cascade reaction, using enzymes; Acyl-CoA synthetase, Acyl-CoA oxidase and 
peroxidise to degraded NEFA to the purple pigment. Precision: the coefficient of 
variation for two quality control serum samples 0.58-1.46 mmol/L, was not be greater 
than 3 % within run and total.  
151 
 
3.4.7.5.6 Plasma GIP and GLP-1 
Plasma GIP and GLP-1 concentrations were analysed by immunoassay at the Clinical 
Biochemistry laboratory, Kings College Hospital by Dr Tracy Drew. The dual-
monoclonal, sandwich immunoassay was used for GIP, and the high sensitivity GLP-1 
active ELISA kit, chemiluminescent for GLP-1. 
Plasma GIP 
Linco Research. 6 Research Park Dr St Charles, Missouri 63304 USA. This kit is for 
non-radioactive quantification of human GIP in human serum, plasma, tissue extract 
and cell culture samples. This kit has 100 % cross reactivity to human GIP (1-42) and 
GIP (3-42). This assay is a Sandwich ELISA based, sequentially, on: 1) capture of 
human GIP molecules from samples to the wells of a microtiter plate coated by a pre-
titered amount of anti-GIP monoclonal antibodies, 2) wash away of unbound materials 
from samples, 3) binding of a second biotinylated anti-GIP polyclonal antibody to the 
captured molecules, 4) wash away of unbound materials from samples, 5) incubation of 
streptavidin-horseradish peroxidase conjugate to bind to the immobilized biotinylated 
antibodies, 6) wash away of free enzyme conjugates, and 7) quantification of 
immobilized antibody-enzyme conjugates by monitoring horseradish peroxidase 
activities in the presence of the substrate 3,3’,5,5’ tetramethylbenzidine. The enzyme 
activity was measured spectrophotometrically by the increased absorbency at 450 nm, 
corrected from the absorbency at 590 nm, after acidification of formed products. Since 
the increase in absorbency is directly proportional to the amount of captured human GIP 
in the unknown sample, the latter can be derived by interpolation from a reference curve 
generated in the same assay with reference standards of known concentrations of human 
GIP. Sensitivity: The minimal detectable GIP concentration was 4.2 pg/ml.  
 
Plasma GLP-1 
Linco Research. 6 Research Park Dr St Charles, Missouri 63304 USA. This kit is for 
non-radioactive quantification of biologically active forms of Glucagon-Like Peptide-1 
[i.e. GLP-1 (7-36 amide) and GLP-1 (7-37)] in plasma and other biological media. It is 
highly specific for the immunologic measurement of active GLP-1 and do not detect 
other forms of GLP-1 (e.g. 1-36 amide, 1-37, 9-36 amide or 9-37). The GLP-1 sequence 
is highly conserved between the species, with no sequence variation occurring in all 
mammals. This assay is based, sequentially, on: 1) capture of active GLP-1 from the 
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sample by a monoclonal antibody, immobilised in the wells of a microwell plate, that 
binds specifically to the N-terminal region of active GLP-1 molecule, 2) washing to 
remove unbound materials, 3) binding of an anti-GLP-alkaline phosphatise detection 
conjugate to the immobilised GLP-1, 4) washing off unbound conjugate, and 5) 
quantification of bound detection conjugate by adding MUP (methyl umbelliferyl 
phosphate) which in the presence of alkaline phosphatise forms the fluorescent product 
of umbelliferon. Since the amount of fluorescence generated is directly proportional to 
the concentration of active GLP-1 in the unknown sample, the latter can be derived by 
interpolation from a reference curve generated in the same assay with reference 
standards of known concentrations of active GLP-1. Sensitivity; the minimal detectable 
GLP-1 concentration was 1.5 pM.  
3.4.7.5.7 Plasma isoprostanes  
Isoprostanes (8-isoprostane F2α) were analysed using immunoaffinity gas 
chromatography negative chemical ionization mass spectrometry (GC-NCI-MS) with 
prior immunoaffinity purification. In the isoprostanes analysis the research technician 
Robert Gray advised in the development of the protocol and was in charge of the GC-
NCI-MS equipment. Material and reagents are listed in Table 3.5; the protocol followed 




Table 3.5 Material, reagents and solutions details for Isoprostanes (8-isoprostane F2α) 
analysis 
 
Material, reagent or solution  Concentration Supplier details 
8-Isoprostane affinity column (4ml)  Cayman Chemical Company, 
cat. no.400058 
Eicosanoid affinity column buffer solution 
(EACB): 13.3 g K2HPO4, 3.22 g KH2PO4, 0.5 
g NaN3 and 29.2 g NaCl in a final volume of 1 
L and pH of 7.4 
0.1 M  




8-iso-PGF2α (working standard solution) 10 µg/ml Santa Cruz Biotechnology, 
cat. no. sc-203219 
8-iso-PGF2α-D4 (internal standard solution) 50 ng/ml Santa Cruz Biotechnology, 
cat. no. sc-205468 
Potassium hydroxide (KOH) 15 % w/v  
Potassium dihydrogen phosphate (KH2PO4) 1 M  
N,N-diisopropylethylamine (DIPEA) in 
acetone 
10 % v/v Sigma-Aldrich; cat. no. 
7887685 




As supplied Sigma-Aldrich, cat. no. 
33024 












Determination of total (free and esterified) 8-isoprostane F2α in plasma by GC-
NCI-MS. 
 
a) Alkaline hydrolysis protocol 
Two millilitres aliquots of plasma sample were subjected to alkaline hydrolysis by 
adding 1 ml of KOH solution in the presence and 1 ng of 8-iso-PGF2α-D4 internal 
standard, incubating mixture for 1 h at 60 ° C.  
b) Purification protocol 
Hydrolysate was then neutralised with 3-4 ml of KH2PO4 solution to give a final pH of 
7-7.4 and then buffered with 2 ml of EACB. To extract the total 8-isoprostane F2α of the 
plasma sample, the buffer mixture was applied to the 8-isoprostane immunoaffinity 
column and column was washed with 2 ml of EACB, followed by 2 ml of ultrapure 
water. Washing was done under gravity alone and the washing product discarded. Total 
8-isoprostane F2α was eluted by adding 2 ml of ES into the column. Elute was collected 
in a 2 ml amber vial (VWR International Chromacol Cat no. CRMA2-SVWAST-CPK) 
and evaporated to dryness using a vacuum centrifugal concentrator at 60°C (Eppendorf 
concentrator 5301).  
c) Regeneration of columns 
Columns were used 3 times, after each purification protocol columns were regenerated 
by washing them with 5 ml of ultrapure water followed by 5 ml of EACB. The columns 
were store at 4°C with 2 ml of EACB to prevent column packing material to becoming 
dry.  
d) Derivatisation protocol 
To the dried sample obtain from the purification protocol was added 25 μL of DIPEA 
and 25 μL of PFBBr,  gently vortex, incubated for 10 min at 60°C and evaporated to 
dryness under a stream of nitrogen at room temperature. The pentafluoryl benzoyl 
derivatives formed were then supplemented with 25 μL of BSTFA and 5 μL of DIPEA, 
gently vortex, incubated for 3 min at 60°C and evaporated to dryness under a nitrogen 
stream at room temperature. To the trimethyl silyl derivatives formed in these step were 
added 20 μL of isooctane, vortex and transferred to a GC vial amber fixed insert (Essex 





e) Preparation of calibration standards  
Serial dilutions of the 8-iso-PGF2a working standard solution, adding 1 ng of internal 
standard solution (8-iso-PGF2α-D4) were prepared for plotting the calibration curve. 
Concentration points were; 0 ng (blank), 0.05 ng, 0.1 ng and 1.0 ng. Standards solutions 
were evaporated to dryness at 60°C using a vacuum centrifugal concentrator and 
derivatised in accordance with the derivatisation protocol. 
f) GC-NCI-MS analysis.  
The trimethyl silyl derivatives of standards and samples were analysed by GC-MS in 
negative chemical ionization mode with methane as reagent gas on an Agilent 
Technologies 6890N/5673 gas chromatograph mass spectrometer. Each standard or 
sample produces the m/z 569 ion current chromatogram (8-iso-PGF2α) and the m/z 573 
ion current chromatogram (8-iso-PGF2α-D4). 
g) Calculations 
A calibration curve was constructed of the ratio of peak area of 8-iso-PGF2α to that of 
the internal standard in the standards against concentration of 8-iso-PGF2α in the 
standards. 8-iso-PGF2α concentration in the samples was calculated by using the peak 
area ratios (8-iso-PGF2α to internal standard) in the linear regression equation generated 






3.4.8 Statistical analysis 
GLU-BERRY and GLU-APP studies: GSK statisticians were responsible for the data 
management and final statistical analysis. Data was analysed by analysis of variance 
with covariates. The model included factors for subject (a random effect), period, 
treatment and two baseline terms as covariates; (i) the subject-level baseline-number of 
valid responses calculated as the mean baseline across all periods within a subject, and 
(ii) the period level baseline (glucose or insulin concentration) minus the subject-level 
baseline. The residual variance from the model was used to construct confidence 
intervals for the difference between test treatment and the reference treatment.  
GLU-BERRY study:  
A linear mixed effects model was used to analyse incremental Cmax and area over 
baseline (AOB) using PROC MIXED in SAS software (Marlow, UK). AOB was 
calculated as the positive incremental area or the AUC above baseline (Allison et al., 
1995). Main effects of treatment and treatment x time interactions for the change from 
baseline at each time point were calculated by linear mixed effects modelling using 
SPSS Statistics version 21 (IBM, UK). The models included subject as a factor (a 
random effect), fixed factors were treatment (and time and treatment x time interaction 
where appropriate) and period. Baseline values, and two baseline terms were included 
as covariates: (i) subject-level baseline; the number of valid responses calculated as the 
mean baseline across all periods within a subject, and (ii) the period-level baseline 
minus the subject-level baseline. P-values were adjusted using Dunnett’s procedure for 
the comparison against a control (reference) product, either using SAS for incremental 
Cmax, Tmax and AOB, or using 2-way repeated measures ANOVA in GraphPad Prism 
version 6.00 for Windows (GraphPad software, CA, USA) for treatment and treatment x 
time effects (since SPSS does not provide Dunnett’s multiple testing adjustment in the 
linear mixed model facility with repeated measures). The assumption of normality and 
homogeneity of variance was investigated. Violation of these assumptions were 
overcome where appropriate using natural logarithmic transformation or performing a 
non-parametric test. Tmax data was analysed by Friedman’s non-parametric test using 







GLU-FRU study: Area under the curve (AUC) and incremental area under the curve 
(iAUC) were calculated using the trapezoidal rule. iAUC was calculated by subtracting 
baseline values from all subsequent time-point values (Allison et al., 1995). Statistical 
analysis was performed using Statistical Package for the Social Sciences (SPSS) v.21. 
Normality of data distribution was evaluated by inspection of histograms and normal Q-
Q plots. Non-normally distributed data was natural logarithmic converted and analysed. 
Two-way repeated measures analysis of variance (ANOVA) were used for treatment 
and treatment x time interactions, iAUC 0-120 min, iAUC 0-30 min and Cmax. A non-
parametric Friedman’s test was used to detect a significant difference in Tmax between 
the treatments. P-values were adjusted using two-way repeated measures ANOVA with 
post hoc analysis by Tukey’s adjustment for treatment and treatment x time interactions 







 3.5.1 GLU-BERRY study  
A total of 30 healthy men and postmenopausal women aged 20 to 60 years attended 
screening sessions, 26 meet all inclusion criteria and therefore were found eligible to 
participate in the study. Participants were randomised to treatment and 22 subjects 
completed the GLU-BERRY study. Details of study stages are shown on the consort 
diagram (Figure 3.2) and characteristics of the 22 participants who completed the study 





































    
 
Assessed for eligibility 
(n=62) 
Excluded (n=32) 
  Not meeting inclusion criteria 
   (n=30) 
  Declined to participate 
   (n=2) 























Randomised to treatment order 
(n=22) 
 
Subjects withdrew before 
randomisation (n=4) 
Cannulation problems  (n=3) 




Requested information (n=107) 
 
Consented and attended 
screening visit (n=30) 
 
Excluded (n=4) 
Not meeting inclusion criteria 
 (n=4) 
   
Lost at recruitment stage 
(n=45) 




































Met inclusion criteria and 






Table 3.6 Characteristics of GLU-BERRY study population (n=22) 
 
Variable 1  
Age (y) 45.4 (13.7) 
Sex (male to female ratio) 13:9 
Body Mass Index (kg/m2) 25.5 (3.8) 
Systolic blood pressure (mmHg) 122.7 (14.1) 
Diastolic blood pressure (mmHg) 77.2 (10.8) 












Fasting plasma glucose (mmol/L) 5.4 (0.5) 
Fasting plasma triacylglycerol (mmol/L) 1.2 (0.5) 
Fasting plasma total cholesterol (mmol/L)  4.9 (1.0) 
Fasting plasma LDL cholesterol (mmol/L) 2.8 (0.8) 







Values are means (SD) 
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There was an overall treatment effect on change from baseline of (Ln)glucose 
concentrations 0-120 min (P <0.05), with no statistically significant treatment x time 
interaction for postprandial glucose response (P=0.16) (Figure 3.3). Following 600 mg 
ACN treatment glucose concentrations were inhibited during the initial 30 min of the 
postprandial period, see Table 3.7 for details; AOB 0-120 min were not significantly 
different between treatments. Post hoc pairwise comparisons showed there were 
significantly lower glucose concentrations following 600 mg ACN compared to 0 mg 
ACN at 10-30 min post-drink, and there was a statistically significant increase in 
glucose following 600 mg ACN at 75 min relative to 0 mg ACN (mean difference in 
change from baseline values was 0.72 mmol/L (0.18, 1.25; P <0.01). Cmax (adjusted 
for baseline) was not significantly different between treatments. Tmax was slightly 
greater following 600 mg ACN (mean at 55 min, 95% CI 48, 62) compared to 300 mg 
ACN, 150 mg ACN and 0 mg ACN (means were 46 min, 39, 62; 49 min, 42, 57; 48 
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Figure 3.3 Postprandial plasma glucose concentrations 
Mean (±SEM) plasma glucose concentrations following ingestion of 4 low sugar fruit drinks 2 
minutes before consuming a mixed carbohydrate meal, in randomised order (n=22). All data 
were natural log transformed before mixed model analysis. There was an overall treatment 
effect on changes from baseline (P<0.001). Post hoc analysis of time-point differences in 
change from baseline in glucose compared to 0 mg ACN with Dunnett’s adjustment: aP < 0.05 
for the difference between 600 mg ACN and 0 mg ACN and 300 mg ACN and 0 mg ACN; 
b
P < 
0.005 for the difference between 600 mg ACN and 0 mg ACN; 
c
P < 0.01 for the difference 





There was a statistically significant treatment effect (P <0.001) and treatment x time 
interaction (P <0.05) for (Ln)insulin 0-120 min, and a treatment x time interaction (P 
<0.05) for the change from baseline in (Ln)insulin 0-120 min. Post hoc analysis showed 
significantly lower insulin concentrations following 600 mg ACN compared to 0 mg 
ACN, at 10, 20 and 30 min, and higher concentrations at 75 and 90 min (Figure 3.4). 
The mean difference in AOB 0-30 min between 600 mg ACN and 0 mg ACN (95% CI) 
was -8.77 mU/L.h (-13.86, -3.68), P <0.005 (Table 3.7). There were no differences in 
Cmax, Tmax and AOB 0-120 min for insulin.  
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Figure 3.4 Postprandial plasma insulin concentrations 
Mean (±SEM) insulin concentrations following ingestion of 4 low sugar fruit drinks 2 minutes 
before consuming a mixed carbohydrate meal, in randomised order (n=22). All data were 
natural log transformed before mixed model analysis. There was a treatment effect (P < 0.001) 
and a treatment x time interaction on raw values and changes from baseline (P < 0.001). Post 
hoc analysis of time-point differences in change from baseline in insulin with Dunnett’s 
adjustment: 
a
P < 0.005 for the difference between 600 mg ACN and 0 mg ACN; 
b
P < 0.01 for 
the difference between 600 mg ACN and 0 mg ACN; 
c
P < 0.05 for the difference between 600 






Table 3.7 Effects of blackcurrant extract and placebo test drinks on area over baseline 






Mean    
difference 
95% CI1 P –value1 
Glucose 
(mmol/L·h) 
600 mg ACN – 0 mg ACN -0.34 -0.56, -0.11 0.0049 
600 mg ACN – 150 mg ACN -0.41 -0.63, -0.18 0.0005 
600 mg ACN – 300 mg ACN -0.18 -0.41, 0.04 0.1066 
Insulin 
(mU/L·h) 
 600 mg ACN – 0 mg ACN   -8.77 -13.86, -3.68 0.0011 
600 mg ACN – 150 mg ACN -7.34 -12.08, -2.59 0.0031 
600 mg ACN – 300 mg ACN  -4.17 -8.86, 0.52 0.0801 
1
Confidence interval and P-value adjusted by Dunnett's procedure for multiple comparisons 
against a control group (0 mg ACN). There were no significant differences between the lower 
doses (300, 150 mg anthocyanins) relative to placebo. AOB (0-30 min; mmol/L.h) for glucose, 
0 mg ACN 0.77 (0.58, 0.96), 150 mg ACN 0.84 (0.66, 1.03), 300 mg ACN 0.62 (0.43, 0.81), 
600 mg ACN 0.44 (0.25, 0.63); for insulin, 0 mg ACN 16.56 (11.76, 21.36), 150 mg ACN 





There was statistically significant treatment effect (P<0.0000001) and treatment x time 
interaction (P<0.005) on (Ln)GIP 0-120 min and change from baseline of (Ln)GIP 0-
120 min (treatment effect P<0.00005). Plasma GIP changes from baseline concentration 
were significantly reduced during the overall postprandial period following 600 mg 
ACN compared to 0 mg ACN, with a decrease in Cmax (mean difference -64.4 ng/L; -
95,5, -33.4; P <0.0005) and AOB 0-120 min (P <0.0001). Post hoc pairwise 
comparisons with Dunnett’s adjustment for multiple comparisons showed reduced 
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Figure 3.5 Postprandial plasma GIP concentrations 
Mean (±SEM) plasma GIP concentrations following ingestion of 4 low sugar fruit drinks 2 
minutes before consuming a mixed carbohydrate meal, in randomised order: 600 mg ACN 
(n=17); 300 mg ACN (n=20); 150 mg ACN (n=20); 0 mg ACN (n=19). All data were natural 
log transformed before mixed model analysis. There was an overall treatment effect on raw 
values (P < 0.0000001) and changes from baseline (P < 0.00005), and a treatment x time 
interaction on raw values (P < 0.005). Post hoc analysis of time-point differences in change 
from baseline with Dunnett’s adjustment: aP < 0.0001 for the difference between 600 mg ACN 
and 0 mg ACN, and 
b
P < 0.001 for the difference between 150 mg ACN and 0 mg ACN; 
c
P < 
0.0005 for the difference between 600 mg ACN and 0 mg ACN; 
d
P < 0.005 for the difference 
between 600 mg ACN and 150 mg ACN and 600 mg ACN and 300 mg ACN; 
e
P < 0.05 for the 
difference between 600 mg ACN and 0 mg ACN; and 
f
P < 0.0005 for the difference between 
600 mg ACN and 0 mg ACN.  
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Plasma GLP-1 concentrations were reduced at later time points by 600 mg ACN 
(Figure 3.6), with a statistically significant treatment effect on changes from baseline of 
(Ln)GLP-1 (P<0.0005), but no significant treatment x time interaction. Post hoc 
pairwise comparisons showed reduced plasma GLP-1 concentrations relative to baseline 
following 600 mg ACN compared to 0 mg ACN and 150 mg ACN anthocyanins at 90 
min. There were no differences in Cmax, Tmax and AOB 0-120 min for GLP-1. 
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Figure 3.6 Postprandial plasma GLP-1 concentrations 
Mean (±SEM) plasma GLP-1 concentrations following ingestion of 4 low sugar fruit drinks 2 
minutes before consuming a mixed carbohydrate meal, in randomised order: 600 mg ACN 
(n=20); 300 mg ACN (n=22); 150 mg ACN (n=21); 0 mg ACN (n=22). All data were natural 
log transformed before mixed model analysis. There was an overall treatment effect on raw 
values and changes from baseline (P < 0.001). Post hoc analysis of time-point differences in 
change from baseline with Dunnett’s adjustment: aP < 0.05 for the difference between 600 mg 









Plasma TAG concentrations ((Ln)TAG up to 120 min) were significantly different 
according to treatment but this was due to a significant difference at baseline (P<0.005) 
and the changes from baseline (Ln)TAG did not differ (Figure 3.7). There was no effect 
of treatment on plasma NEFA concentrations (Figure 3.8).  
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Figure 3.7 Postprandial plasma TAG concentrations 
Mean (±SEM) plasma TAG concentrations following ingestion of 4 low sugar fruit drinks 2 
minutes before consuming a mixed carbohydrate meal, in randomised order (n=22). All data 
were natural log transformed before mixed model analysis. There was a treatment effect (P < 
0.0000001) on raw values but not for changes from baseline and no treatment x time 
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Figure 3.8 Postprandial plasma NEFA concentrations 
Mean (±SEM) plasma NEFA concentrations following ingestion of 4 low sugar fruit drinks 2 
minutes before consuming a mixed carbohydrate meal, in randomised order (n = 22). All data 
were natural log transformed before mixed model analysis. There were no statistically 






Vascular function and isoprostanes  
There were no differences between treatments for changes from baseline in DVP-RI, 







Table 3.8 Effects of blackcurrant extract and placebo test drinks on digital volume pulse (DVP), systolic and diastolic blood pressure (SBP and 


























Values are mean baseline values and changes from baseline measured 120 min after the test drink and mixed carbohydrate meal, (95% CI), n=22.  
2
Values are geometric mean baseline values and log ratios of changes from baseline measured 120 min after the test drink and mixed carbohydrate 
meal, (95% CI), n=22. For example, the log ratio of change from baseline in 8-isoprostanes F2 following placebo was 1.13, equating to a 13% 
increase from baseline. 
3 
n=20 due to sample loss 
Variable1  0 mg 150 mg 300 mg 600 mg 
DVP-RI (%)  Baseline 74.4 (69.5, 79.2) 70.4 (64.8, 76.1) 72.9 (67.1, 78.6) 72.8 (68.0, 77.5) 
 
Δ 120 min -0.57 (-5.35, 4.21) 3.80 (-0.93, 8.54) 0.15 (-4.26, 4.56) 1.38 (-3.28, 6.04) 
DVP-SI (m/s) Baseline 8.57 (7.75, 9.40) 8.50 (7.63, 9.37) 8.44 (7.64, 9.25) 8.71 (7.62, 9.80) 
 
Δ 120 min -0.75 (-1.44, -0.05) -0.23 (-1.05, 0.59) -0.57  (-1.21, 0.07) -0.55 (-1.54, 0.45) 
SBP (mmHg) Baseline 120.8 (116.1, 125.2) 120.9 (115.6, 126.0) 120.7 (116.0, 125.5) 118.3 (113.7, 122.9) 
 
Δ 120 min -4.5 (-8.8, -0.1) -1.0 (-6.8, 4.9) -5.2 (-8.9, -1.5) -1.7 (-6.7, 3.3) 
DBP (mmHg) Baseline 74.6 (71.2, 78.1) 75.3 (71.7, 78.9) 74.5 (71.3, 77.8) 73.6 (70.8, 76.4) 
 
Δ 120 min -0.6 (-4.3, 3.2) 1.7 (-2.0, 5.4) -1.1 (-3.6, 1.3) 0.5 (-2.5, 3.5) 
Plasma isoprostane (pmol/L)2 Baseline 86.4 (68.8, 108.4)3 123.7 (96.6, 158.3) 3 100.5 (80.8, 125.1) 98.4 (76.6, 126.2) 
8-isoprostanes F2α Δ 120 min 1.13 (1.01, 1.27) 0.94 (0.81, 1.09) 1.02 (0.91, 1.14) 0.97 (0.85, 1.11) 
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3.5.2 GLU-APP study  
A total of 27 healthy men and postmenopausal women aged 20 to 60 years attended 
screening sessions; all of them met inclusion criteria and therefore were found eligible 
to participate in the study. Twenty two participants were randomised to treatment and 
22 completed the GLU-APP study. Details of study stages are shown on the consort 
diagram (Figure 3.9) and characteristics of the 22 participants who completed the study 
are shown in Table 3.9.    












































Assessed for eligibility 
(n=55) 
Excluded (n=28) 
  Not meeting inclusion criteria 
   (n=13) 
   Lost to follow up  
   (n=13) 
   Declined to participate 
   (n=2) 























Randomised to treatment order 
(n=22) 
 
Subjects withdrew before 
randomisation (n=5) 
Declined to participate  
(n=2)    
Did not attend first visit  
(n=1) 





Requested information (n=90) 
 
Consented and attended 
screening visit (n=27) 
 
Lost at recruitment stage  
(n=35) 
Not meeting inclusion criteria 
 (n=14) 




































Met inclusion criteria and 
contacted to participate in study 
(n=27) 
Subjects withdrew after 
randomisation (n=1) 




Table 3.9 Characteristics of GLU-APP study population (n=22)  
 
Variable 1  
Age (y) 41.5 (13.3) 
Sex (male to female ratio) 14:8 
Body Mass Index (kg/m2) 24.9 (3.7) 
Systolic blood pressure (mmHg) 118.6 (18.0) 
Diastolic blood pressure (mmHg) 79.7 (10.4) 












Fasting plasma glucose (mmol/L) 5.0 (0.4) 
Fasting plasma triacylglycerol (mmol/L) 1.2 (0.9) 
Fasting plasma total cholesterol (mmol/L)  5.3 (1.2) 
Fasting plasma LDL cholesterol (mmol/L) 3.2 (0.9) 











There was no effect of treatment on plasma glucose and plasma insulin concentrations. 
Plasma concentrations of glucose and insulin 0-120 min are shown in Figures 3.10 and 
3.11. There were no differences for change from baselines, Cmax, Tmax or AOB 
(Table 3.10) on plasma glucose and plasma insulin concentrations. The analysis of 
time-points suggested no dose response effect over time.  
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Figure 3.10 Postprandial plasma glucose concentrations 
Mean (±SEM) plasma glucose concentrations following ingestion of 3 low sugar fruit drinks 2 
minutes before consuming a high carbohydrate meal, in randomised order (n=22). There were 
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Figure 3.11 Postprandial plasma insulin concentrations 
Mean (±SEM) plasma insulin concentrations following ingestion of 3 low sugar fruit drinks 2 
minutes before consuming a high carbohydrate meal, in randomised order: 600 mg APP, 600 
mg of apple polyphenols; 300 mg APP, 300 mg of apple polyphenols and 0 mg APP, 0 mg 
apple polyphenols (control), (n=22). There were no statistically significant differences in insulin 

















There was no effect of treatment on plasma GIP and GLP-1 concentrations in 0-120 min 
postprandial period. There were no differences for changes from baseline concentrations 
for any of the plasma concentrations. However post hoc pairwise comparisons showed 
elevated plasma GLP-1 concentration relative to baseline following 600 mg APP 
compared to 0 mg APP at 20 min (Figure 3.12). There were no differences in Cmax, 
Tmax and AOB 0-120 min for GIP and GLP-1 (Table 3.10).    
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Figure 3.12 Postprandial plasma GIP concentrations 
Mean (±SEM) plasma GIP concentrations following ingestion of 3 low sugar fruit drinks 2 
minutes before consuming a high carbohydrate meal, in randomised order (n=22). There were 
no statistically significant differences in GIP concentrations between treatments. 
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Figure 3.13 Postprandial plasma GLP-1 concentrations 
Mean (±SEM) plasma GLP-1 concentrations following ingestion of 3 low sugar fruit drinks 2 
minutes before consuming a high carbohydrate meal, in randomised order (n=22). There were 
no statistically significant differences in GIP concentrations between treatments. Post hoc 
analysis with Dunnet’s adjustment: aP= 0.048 for the difference between 600 mg APP and 0 mg 








There was no effect of treatment on plasma TAG and NEFA concentrations in 0-120 
min postprandial period. There were no differences for changes from baseline 
concentrations for any of the plasma concentrations. There were no differences in 
Cmax, Tmax and AOB 0-120 min for TAG and NEFA (Table 3.10).    
 
Table 3.10 Effects of apple extract and placebo test drinks on area over baseline (AOB) 
0-120 min for plasma glucose, insulin, GIP, GLP-1, TAG and NEFA concentrations in 




Treatment Mean 95% CI1 
Glucose (mmol/L·min) 
0 mg APP 0.98 (0.42, 1.54) 
300 mg APP 0.88 (0.40, 1.36) 
600 mg APP 1.19 (0.46, 1.92) 
Insulin (mU/L·min) 
0 mg APP 34.7 (27.8, 41.6) 
300 mg APP 36.8 (29.5, 44.0) 
600 mg APP 32.9 (25.3, 40.6) 
GIP (ng/L·min) 
0 mg APP 127.5 (101.9, 153.2) 
300 mg APP 135.2 (108.2, 162.2) 
600 mg APP 139.8 (107.4, 172.2) 
GLP-1 (pmol/L·min) 
0 mg APP 2.22 (1.12, 3.32) 
300 mg APP 2.71 (1.43, 3.99) 
600 mg APP 2.93 (1.73, 4.13) 
TAG (mmol/L·min) 
0 mg APP -0.08 (-0.19, 0.03) 
300 mg APP -0.03 (-0.07, 0.01) 
600 mg APP -0.04 (-0.08, 0.00) 
NEFA  (mmol/L·min) 
0 mg APP -0.29 (-0.37, -0.21) 
300 mg APP -0.32 (-0.39, -0.25) 
600 mg APP -0.31 (-0.39, -0.23) 
600 mg APP, 600 mg of apple polyphenols; 300 mg APP, 300 mg of 
apple polyphenols; 0 mg APP, 0 mg apple polyphenols (control).  
1 
From ANCOVA model with treatment and period as fixed factors, 




Vascular function and isoprostanes  
There were no differences between treatments for changes from baseline in DVP-RI, 
DVP-SI and systolic and diastolic blood pressure (Table 3.11). Isoprostanes were not 






Table 3.11 Effects of apple extract and placebo test drinks on digital volume pulse (DVP) and systolic and 




0 mg 300 mg 600 mg 
DVP-RI (%)  Baseline 59.3 (54.4, 64.2) 57.1 (50.1, 64.1) 58.6 (51.2, 66.0) 
 
Δ 120 min 1.14 (-2.92, 5.20)  -1.21 (-6.40, 3.99) 0.01 (-4.23, 4.25) 
DVP-SI (m/s) Baseline 6.7 (6.1, 7.4) 6.8 (6.1, 7.6) 7.0 (6.3, 7.8) 
 
Δ 120 min 0.02 (-0.21, 0.25) -0.11 (-0.43, 0.21) 0.08 (-0.19, 0.35) 
SBP (mmHg) Baseline 118.9 (113.9, 123.9) 120.5 (114.5, 126.6) 122.5 (117.2, 127.8) 
 Δ 120 min -0.52 (-3.54, 2.49) -1.06 (-3.90, 1.78) 1.51 (-0.18, 3.21) 
DBP (mmHg) Baseline 72.6 (69.5, 75.7) 74.3 (70.4, 78.3) 73.5 (69.5, 77.5) 
 
Δ 120 min -0.10 (-1.54. 1.34) 0.41 (-2.08, 2.90) -0.29 (-2.04, 1.46) 
There were no differences between treatments for changes from baseline 
1
Values are mean baseline values and changes from baseline measured 120 min after the test drink and mixed 




3.5.3 GLU-FRU study  
A total of 42 healthy men and postmenopausal women aged 20 to 60 years attended 
screening sessions, 34 meet all inclusion criteria and therefore were found eligible to 
participate in the study. Participants were randomised to treatment and 25 subjects 
completed the GLU-FRU study. Details of study stages are shown on the consort 
diagram (Figure 3.14) and characteristics of the 25 participants who completed the 
study are shown in Table 3.12.     

































    
 
Assessed for eligibility 
(n=69) 
Excluded (n=27) 
  Not meeting inclusion criteria 
   (n=17) 
   Lost to follow up  
   (n=7) 
   Declined to participate 
   (n=3) 























Randomised to treatment order 
(n=34) 
 
Subjects withdrew after 
randomisation (n=9) 
   Unable to comply protocol (n=2) 
   Adverse effects (n=4) 




Requested information (n=180) 
 
Consented and attended 
screening visit (n=42) 
 Excluded (n=8) 
 Not meeting inclusion criteria 
 (n=6) 
 Withdrew participation 
  (n=2) 
 
Lost at recruitment stage  
(n=111) 
Not meeting inclusion criteria 
 (n=61) 




































Met inclusion criteria and 






Table 3.12 Characteristics of GLU-FRU study population (n=25) 
 
Variable 1  
Age (y) 32.3 (14.4) 
Sex (male to female ratio) 20:5 
Body Mass Index (kg/m2) 23.5 (2.8) 
Systolic blood pressure (mmHg) 112.2 (10.8) 
Diastolic blood pressure (mmHg) 69.2 (7.9) 












Fasting plasma glucose (mmol/L) 5.1 (0.3) 
Fasting plasma triacylglycerol (mmol/L) 1.1 (0.9) 
Fasting plasma total cholesterol (mmol/L)  4.3 (1.0) 
Fasting plasma LDL cholesterol (mmol/L) 2.6 (0.9) 














There was an overall treatment effect for the change from baseline of glucose 
concentrations 0-120 min (P=0.003), with statistically significant treatment x time 
interaction for postprandial glucose response (P=0.000). As Figure 3.15 illustrates, 
AE+BE treatment inhibited glucose concentrations during the 120 min of the 
postprandial period, change from baseline 0-120 min mean difference AE+BE vs CON 
(95% CI) -0.52 mmol/L (-0.86,-0.18), P=0.002. iAUC 0-120 min was significantly 
different between treatments, mean differences AE+BE vs CON (95% CI) -51.6 
mmol/L.min (-93.8, -9.4), P=0.014. iAUC 0-30 min was statistically significant 
different between treatments, AE+BE and AE treatments significantly lower glucose 
concentrations compared to CON, see Table 3.14 for details. Post hoc analysis with 
Tukey’s adjustment, showed significantly lower glucose concentrations following AE 
and AE+BE compared to CON at 10, 20 and 30 min post-drink, and lower glucose 
concentration for AE at 60 min. Cmax was significantly different between treatments, 
AE and AE+BE had a lowering effect on maximal plasma glucose concentration when 
compared to CON. Cmax mean difference AE vs CON (95% CI) -0.7 (-1.3, -0.1), 
P=0.023; Cmax mean difference AE+BE vs CON (95% CI) -0.9 (-1.6, -0.3), P=0.002. 
Tmax was significantly different between treatments, was greater following AE+BE 
(median at 60 min, IQR 45, 75, P=0.000) compared to AE and CON (medians were 45 
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Figure 3.15 Postprandial glucose concentrations  
Mean (±SEM) plasma glucose concentrations following ingestion of 3 low sugar fruit drinks 2 
minutes before consuming a mixed carbohydrate meal, in randomised order (n = 25). AE; 1200 
mg of apple polyphenols, AE+BE; 600 mg of apple polyphenols + 600 mg blackcurrant 
anthocyanins, CON; 0 mg of blackcurrant anthocyanins and apple polyphenols.  There was an 
overall treatment effect on changes from baseline (P=0.003). Post hoc analysis of time-point 
differences in change from baseline in glucose with Tukey’s adjustment: aP < 0.05 for the 
difference between CON and AE and AE+BE; 
b
P<0.0001 for the difference between CON and 
AE and AE+BE; 
c
P < 0.001 for the difference between AE and AE+BE and CON; 
d
P < 0.05 for 
the difference between AE and AE+BE; 
e

















There was an overall treatment effect for the change from baseline of (Ln)insulin 
concentrations 0-120 min (P<0.0005), with a statistically significant treatment x time 
interaction for postprandial insulin response (P<0.0001) (Figure 3.16). Both treatments, 
AE+BE and AE inhibited insulin concentrations during the 120 min of the postprandial 
period, change from baseline 0-120 min mean difference AE+BE vs CON (95% CI) -
0.40 mIU/L (-0.64,-0.16), P<0.0005, and mean difference AE vs CON (95% CI) -0.27 
mIU/L (-0.51,-0.03), P<0.05.  iAUC 0-120 min was significantly different between 
treatments, mean difference AE+BE vs CON (95% CI) -1109.7 mIU/L·min (-1642.2, -
577.2), P=0.000 and mean difference AE vs CON (95% CI) -872.7 mIU/L·min (-
1734.4,-11.1), P=0.047. iAUC 0-30 min was statistically significantly different between 
treatments, both AE+BE and AE treatments significantly lowered insulin concentrations 
compared to CON, see Table 3.14 for details. Post hoc analysis for multiple 
comparisons with Tukey’s adjustment, showed significantly lower (Ln)insulin 
concentrations following AE and AE+BE compared to CON at 10, 20, 30 and 45 min 
post-drink and AE vs CON at 120 min. Cmax was significantly different between 
treatments, AE+BE had a lowering effect on maximal plasma (Ln)insulin concentration 
when compared to CON. Cmax mean difference AE+BE vs CON (95% CI) -16.8 (-
33.5, -0.11), P=0.048. Tmax was significantly different between treatments, being 
greater following AE+BE (median at 75 min, IQR 67, 75, P=0.000) compared to AE 
and CON (medians were 60 min, 45, 75 and 45 min, 25, 60, respectively), see Table 
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Figure 3.16 Postprandial insulin concentrations  
Mean (±SEM) plasma insulin concentrations following ingestion of 3 low sugar fruit drinks 2 
minutes before consuming a mixed carbohydrate meal, in randomised order (n = 25). AE; 1200 
mg of apple polyphenols, AE+BE; 600 mg of apple polyphenols + 600 mg blackcurrant 
anthocyanins, CON; 0 mg of blackcurrant anthocyanins and apple polyphenols. There was an 
overall treatment effect on changes from baseline (P < 0.001). Post hoc analysis of time-point 
differences in change from baseline in insulin compared with Tukey’s adjustment: aP < 0.0001 
for the difference between CON and AE and AE+BE; 
b
P<0.005 for the difference between AE 
and AE+BE; 
c
P<0.0001 for the difference between CON and AE+BE; 
d
P<0.05 for the 
















There was an overall treatment effect for the change from baseline of (Ln)C-peptide 
concentrations 0-120 min (P<0.0001), with statistically significant treatment x time 
interaction for postprandial C-peptide response (P<0.0001) (Figure 3.17). Treatments, 
AE+BE and AE suppressed C-peptide concentrations during the 120 min of the 
postprandial period, change from baseline 0-120 min mean difference AE+BE vs CON 
(95% CI) -0.29 pmol/L (-0.40,-0.18), P<0.0001, and mean difference AE vs CON (95% 
CI) -0.16 pmol/L (-0.27,-0.05), P=0.004.  iAUC 0-120 min was significantly different 
between treatments, mean difference AE+BE vs CON (95% CI) -33779.1 pmol/L·min 
(-48831.4, -18726.9), P=0.000. iAUC 0-30 min was statistically significant different 
between treatments, both AE+BE and AE treatments significantly lower C-peptide 
concentrations compared to CON, see Table 3.14 for details. Post hoc analysis with 
Tukey’s adjustment for multiple comparisons, showed significantly lower C-peptide 
concentrations following AE and AE+BE compared to CON at 10, 20, 30 and 45 min 
post-drink and AE+BE vs CON at 60 min.  Cmax was not significantly different 
between treatments. Tmax was greater following AE+BE and AE (medians were 75 
min, IQR 60, 90, and 60 min, 60, 105, respectively, P=0.000) compared to CON 
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Figure 3.17 Postprandial C-peptide concentrations  
Mean (±SEM) plasma C-peptide concentrations following ingestion of 3 low sugar fruit drinks 
2 minutes before consuming a mixed carbohydrate meal, in randomised order (n = 25). AE; 
1200 mg of apple polyphenols, AE+BE; 600 mg of apple polyphenols + 600 mg blackcurrant 
anthocyanins, CON; 0 mg of blackcurrant anthocyanins and apple polyphenols. There was an 
overall treatment effect on changes from baseline (P<0.0001). Post hoc analysis of time-point 
differences in change from baseline in C-peptide with Tukey’s adjustment: aP < 0.0001 for the 
difference between CON and AE and AE+BE; 
b
P<0.05 for the difference between AE and 
AE+BE; 
c
P<0.0001 for the difference between AE and AE+BE; 
d
P<0.0005 for the difference 
between AE and AE+BE; 
e
P<0.005 for the difference between CON and AE+BE; 
f
P<0.05 for 






Plasma GIP changes from baseline concentration were significantly reduced during the 
whole postprandial period by treatments AE and AE+BE compared to CON, with a 
statistically significant treatment effect (P=0.0001) and treatment x time interaction 
(P<0.0001) on change from baseline of (Ln)GIP 0-120 min (Figure 3.18). Treatments, 
AE+BE and AE inhibited plasma GIP concentrations along the 120 min of postprandial 
period, change from baseline 0-120 min mean difference AE+BE vs CON (95% CI) -
0.55 ng/L (-0.83,-0.26), P=0.000, and  mean difference AE vs CON (95% CI) -0.36 
ng/L (-0.65,-0.07), P=0.010. iAUC 0-120 min was significantly different between 
treatments, mean difference AE+BE vs CON (95% CI) -6097.2 ng/L·min (-7742.5, -
4451.9), P=0.000; mean difference AE vs CON (95% CI) -4038.1 ng/L·min (-5467.5 -
2608.8), P=0.000. iAUC 0-30 min was statistically significant different between 
treatments, both AE+BE and AE treatments significantly lower GIP concentrations 
compared to CON, see Table 3.14 for details. Post hoc analysis with Tukey’s 
adjustment for multiple comparisons, showed significantly lower GIP concentrations 
following AE and AE+BE compared to CON at all timepoints up to 75 min.  There was 
a significant decrease in Cmax following AE+BE and AE vs CON (mean differences -
45.5 ng/L; (95% CI) (-73.6, -17.5), P=0.003 and -32.7 ng/L; (-54.1, -11.4), P=0.005). 
Tmax was greater following BE+AE (median at 90 min, IQR 82, 120, P=0.000) 
compared to AE and CON (medians were 90 min, 75, 120 and 60 min, 45, 75, 
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Figure 3.18 Postprandial GIP concentrations 
Mean (±SEM) plasma GIP concentrations following ingestion of 3 low sugar fruit drinks 
immediately before consuming a mixed carbohydrate meal, in randomised order (n = 25). AE; 
1200 mg of apple polyphenols, AE+BE; 600 mg of apple polyphenols + 600 mg blackcurrant 
anthocyanins, CON; 0 mg of blackcurrant anthocyanins and apple polyphenols. There was an 
overall treatment effect on changes from baseline (P=0.0001). Post hoc analysis of time-point 
differences in change from baseline with Tukey’s adjustment: aP<0.0001 for the difference 
between CON and AE and AE+BE; 
b
P<0.05 for the difference between AE and AE+BE, 
c
P<0.0001 for the difference between AE and AE+BE; 
d
P<0.0001 for the difference between 
CON and AE+BE; 
e
P<0.05 for the difference between CON and AE; 
f
P<0.05 for the difference 















Incremental area under the curve (iAUC) 0-30 min for plasma glucose, insulin, C-
peptide and GIP were significantly different between treatments. Both treatments AE 
and AE+BE decreased the early response of variables involved in the glycaemic 
response when compared with control. Due to technical problems with the GLP-1 assay 








Table 3.13 Incremental area under the curve (iAUC), maximum concentration (Cmax) 
and time of maximum concentration (Tmax) for plasma glucose, insulin, C-peptide and 
GIP concentrations following consumption of apple, apple and blackcurrant and placebo 
test drinks and a starch and sucrose meal (n=25).  
  
 Glucose Insulin C-peptide GIP 
iAUC
1
 (0-30 min) mmol/L∙min mIU/L∙min pmol/L∙min ng/L∙min 
CON 42.16 (16.3) 845.6 (468.6) 14660.4 (6337.1) 1745.7 (640.5) 
AE 19.03 (9.5) 297.3 (304.8) 6749.8 (4569.5) 502.3 (347.0) 
AE+BE 11.23 (8.0) 220.4 (159.9) 3713.4 (3137.3) 66.9 (324.3) 
P (main treatment 
effect) <0.0001 <0.0001 <0.0001 <0.0001 
iAUC
1
 (0-120 min) mmol/L∙min mIU/L∙min pmol/L∙min ng/L∙min 
CON 119.40 (117.8) 4423.2 (2544.1) 116419.2 (40664.0) 14336.4 (4748.3) 
AE 103.90 (101.9) 3758.5 (3119.2) 104543.1 (50677.6) 10331.6 (3705.3) 
AE+BE 76.26 (101.9) 3476.8 (2019.3) 87006.0 (33614.1) 8406.5 (4245.6) 
P (main treatment 
effect) 0.029 0.028 <0.0001 <0.0001 
Cmax
1 
 mmol/L mIU/L pmol/L ng/L 
CON 8.2 (1.3) 80.0 (47.2) 1895.2 (684.2) 210.9 (79.9) 
AE 7.6 (1.2) 69.6 (54.0) 1871.2 (739.9) 180.4 (67.7) 
AE+BE 7.3 (1.2) 69.0 (35.1) 1728.1 (531.9) 170.4 (64.5) 
P (main treatment 
effect) <0.0001 0.240 0.135 0.001 
Tmax
2
 (min)   
  
CON 30 (20, 30) 45 (25, 60) 60 (45, 75) 60 (45, 75) 
AE 45 (37, 60) 60 (45, 75) 75 (60, 105) 90 (75, 120) 
AE+BE 60 (45, 75) 75 (60, 75) 75 (60, 90) 90 (82, 120) 
P (main treatment 
effect) <0.0001 <0.0001 <0.0001 <0.0001 
1 
All values are Mean (SD) 
2 
All valueas are Median (IQR) 
Two-way repeated measures analysis of variance (ANOVA) were used to test for statistically significant 





Table 3.14 Effects of apple, apple and blackcurrant and placebo test drinks in 
incremental area under the curve (iAUC) 0-30 min for plasma glucose, insulin, C-








95% CI1 P -value1 
Glucose 
(mmol/L·min) 
AE – CON -26.3 -34.9, -17.7 0.000 
AE+BE – CON -31.5 -40.8, -22.2 0.000 
AE+BE – AE -5.2 -9.8, -0.6 0.023 
Insulin 
(mU/L·min) 
AE – CON  -613.1 -771.6, -454.6 0.000 
AE+BE – CON -675.3 -915.1, -435.5 0.000 
AE+BE – AE  -62.2 -203.0, 78.6 0.782 
C-peptide 
(pmol/L·min) 
AE – CON  -9221.9 -11031.5, -7142.3 0.000 
AE+BE – CON -11881.4 -15099.3, -8663.6 0.000 
AE+BE – AE  -2659.5 -4817.5, -501.6 0.013 
GIP  
(ng/L·min) 
AE – CON  -1272.7 -1568.3, -977.2 0.000 
AE+BE – CON -1735.3 -1998.1, -1472.6 0.000 
AE+BE – AE  -462.6 -617.2, -307.9 0.000 
AE; 1200 mg of apple polyphenols, AE+BE; 600 mg of apple polyphenols + 600 mg 
blackcurrant anthocyanins, CON; 0 mg of blackcurrant anthocyanins and apple polyphenols. 
1
 From two-way analysis of variance, confidence interval and P-value adjusted by Bonferroni’s 






Plasma TAG concentrations are showed in Figure 3.19; there were no differences 
between treatments for raw data and change from baseline 0-120 min following the 
consumption of the test meals.   
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Figure 3.19 Postprandial triacylglycerol concentrations  
Mean (±SEM) plasma TAG concentrations following ingestion of 3 low sugar fruit drinks 
immediately before consuming a mixed carbohydrate meal, in randomised order (n=25). AE; 
1200 mg of apple polyphenols, AE+BE; 600 mg of apple polyphenols + 600 mg blackcurrant 
anthocyanins, CON; 0 mg of blackcurrant anthocyanins and apple polyphenols. There was no 







Decreases in plasma NEFA concentrations relative to baseline were significantly 
reduced during the whole postprandial period by treatment AE+BE compared to CON, 
with a statistically significant treatment effect (P<0.005) and treatment x time 
interaction (P<0.0001) on change from baseline of NEFA 0-120 min (Figure 3.20). 
Treatment AE+BE inhibited the decreases in plasma NEFA concentrations along the 
120 min of postprandial period, change from baseline 0-120 min mean difference 
AE+BE vs CON (95% CI) 0.12 mmol/L (0.03, 0.20), P=0.004. iAUC 0-120 min was 
significantly different between AE+BE and CON, mean difference (95% CI) 17.2 
mmol/L.min (7.2, 27.3), P=0.001. Post hoc analysis with Tukey’s adjustment for 
multiple comparisons, showed significantly higher NEFA concentrations following AE 
and AE+BE compared to CON from 20 min up to 120 min. There was a significant 
increase in Cmax following AE+BE vs CON (mean differences -0.14 mmol/L; (95% 
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Figure 3.20 Postprandial non-esterified fatty acids concentrations  
Baseline values (mmol/L): AE 0.47±0.05 AE+BE 0.40±0.04, CON 0.54±0.04. Mean (±SEM) 
plasma NEFA concentrations following ingestion of 3 low sugar fruit drinks immediately before 
consuming a mixed carbohydrate meal, in randomised order (n = 25). AE; 1200 mg of apple 
polyphenols, AE+BE; 600 mg of apple polyphenols + 600 mg blackcurrant anthocyanins, CON; 
0 mg of blackcurrant anthocyanins and apple polyphenols. There was an overall treatment effect 
on changes from baseline (P=0.000). Post hoc analysis of time-point differences in change from 
baseline in NEFA with Tukey’s adjustment: aP<0.0005 for the difference between CON and 
AE+BE; 
b
P<0.05 for the difference between CON and AE, 
c
P<0.0001 for the difference 
between CON and AE and AE+BE, 
d
P<0.05 for the difference between AE and AE+BE; 
e
P<0.0001 for the difference between CON and AE+BE, 
f
P<0.0005 for the difference between 
CON and AE; 
g













There were no differences between treatments on SBP and DBP for raw data or changes 
from baseline 0-120 min (Figure 3.21).  
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Figure 3.21 Postprandial systolic and diastolic blood pressures values    
Mean (±SEM) SBP and DBP values following ingestion of 3 low sugar fruit drinks immediately 
before consuming a mixed carbohydrate meal, in randomised order (n = 25). AE; 1200 mg of 
apple polyphenols, AE+BE; 600 mg of apple polyphenols + 600 mg blackcurrant anthocyanins, 
CON; 0 mg of blackcurrant anthocyanins and apple polyphenols. There was no statistically 




There were no differences between treatments for DVP-SI for raw data and change from 
baseline (Figure 3.22).  
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Figure 3.22 Postprandial changes from baseline on stiffness index values   
Baseline values (m/sec): AE 6.2, AE+BE 6.5, CON 6.4. Mean (±SEM) DVP-SI values 
following ingestion of 3 low sugar fruit drinks immediately before consuming a mixed 
carbohydrate meal, in randomised order (n=25). AE; 1200 mg of apple polyphenols, AE+BE; 
600 mg of apple polyphenols + 600 mg blackcurrant anthocyanins, CON; 0 mg of blackcurrant 
















There were no differences in raw data for reflection index values, however changes 
from baseline values were significantly reduced during the whole postprandial period by 
treatment AE compared to CON, with a statistically significant treatment effect 
(P=0.01) and significant effect on treatment x time interaction 0-120 min (P=0.05) 
(Figure 3.23). Post hoc analysis with Tukey’s adjustment for multiple comparisons, 
showed treatments AE and AE+BE reduced reflection index at 90 and 120 min of 
postprandial period. Change from baseline 0-120 min mean difference AE vs CON 
(95% CI) -7.04 m/sec (-12.3, -1.8), P=0.007.   
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Figure 3.23 Postprandial changes from baseline on reflection index values  
Baseline values (%): AE 67, BE+AE 65, CON 63. Mean (±SEM) DVP-RI values following 
ingestion of 3 low sugar fruit drinks immediately before consuming a mixed carbohydrate meal, 
in randomised order (n=25). AE; 1200 mg of apple polyphenols, AE+BE; 600 mg of apple 
polyphenols + 600 mg blackcurrant anthocyanins, CON; 0 mg of blackcurrant anthocyanins and 
apple polyphenols. There was an overall treatment effect on changes from baseline (P=0.05) 
following ingestion of treatment AE. Post hoc analysis of time-point differences in change from 
baseline in DVP-RI with Tukey’s adjustment: aP<0.0001 for the difference between AE and 
CON; 
b
P<0.05 for the difference between CON and AE+BE; 
c
P<0.05 for the difference between 





3.6 Discussion  
3.6.1 GLU-BERRY study 
An inhibitory effect on postprandial glycaemia and insulinaemia was observed 
following consumption of the highest dose of blackcurrant extract contained in a no 
added sugar fruit drink. Medium and lowest dose treatments did not show any effect. 
Early postprandial (0-30 min) plasma glucose and insulin response was decreased by 
the 600 mg of blackcurrant anthocyanins (600 mg ACN) treatment although a rebound 
effect was observed at 75 and 90 min. These results coincide with previous findings on 
studies consuming whole berry meals or berry nectars (juices) rich in anthocyanins, 
including strawberries, bilberries, cranberries and blackcurrants and showing plasma 
glucose and insulin concentrations inhibition in the first 30 min following consumption 
(Törrönen et al., 2012a, Törrönen et al., 2013, Törrönen et al., 2012c, Törrönen et al., 
2010, Törrönen et al., 2012b). The present data also agrees with previous work that 
shows that berries consumed along with a starch-containing test meal have a more 
marked effect in suppressing insulin concentrations than they do on glucose 
concentrations (Törrönen et al., 2013).  
The rebound effect on blood glucose and insulin concentrations observed at 75 and 90 
min might be explained by effects on digestive processing of starch and sucrose 
contained in our test meal. Diverse polyphenol-rich extracts have been shown to inhibit 
digestive enzymes involved in the metabolism of complex carbohydrates. Polyphenolic 
compounds of blackcurrant extract such as proanthocyanidins may reduce pancreatic α-
amylase activity in the duodenum (Grussu et al., 2011), anthocyanins and other 
blackcurrant polyphenols may reduce intestinal brush border α-glucosidases activities 
(maltase and sucrase) (Akkarachiyasit et al., 2010). Polyphenol-induced delayed 
digestive processing is likely to have resulted in partially digested carbohydrates 
possibly flowing further down the small intestine. This may have increased the 
proportion of glucose that was absorbed later (75-90 min) relative to control accounting 
for the crossover in glucose and insulin profiles, and this also is in agreement with 
glycaemic/insulinaemic profiles observed previously (Törrönen et al., 2012a, Törrönen 
et al., 2012c, Törrönen et al., 2010). Since the 0, 150 and 300 mg ACN intervention 
drinks also contained added tannins, a polyphenolic compound, in order to match the 




amylase across all test drinks. Thus, the differences observed here are more likely to be 
related to the other flavonoids contained in the blackcurrant extract.  
Concentrations of secondary outcome variables, plasma GIP and GLP-1, were also 
decreased by the 600 mg ACN treatment throughout the postprandial period (120 min). 
Medium and lowest dose treatments did not show any effect. The strong inhibition of 
plasma GIP concentrations suggests that secretory regulation of this incretin is highly 
sensitive to glucose absorption rates. Intestinal sodium/glucose co-transporter SGLT1 
has been shown to be closely related with the expression of GIP and GLP-1 in 
individual enteroendocrine cells of murine jejunal crypts. Studies in Sglt1-/- (knocked 
out) mice have shown the essential role of SGLT1 as a glucose sensor for gut incretins 
GIP and GLP-1 secretion (Gorboulev et al., 2012), although intestinal facilitated 
glucose transporter GLUT2 may also be an important regulator of incretin response 
(Mace et al., 2012). These findings showing inhibition of GIP and GLP-1 secretion by 
blackcurrant polyphenols agree with a previous report on inhibited glucose induced 
SGLT1-mediated incretin secretion by apple polyphenol phlorizin (Moriya et al., 2009), 
a dihydrochalcone well-known for its SGLT1 inhibitory effects (Smith et al., 1992, 
Wright et al., 2011). The suppression of plasma GLP-1 concentrations by the highest 
dose of blackcurrant extract at 90 min paradoxically coincided with the time point 
where plasma insulin concentrations were increased relative to placebo. Our data 
support the role of incretins as sensitive biomarkers for the rate of glucose transport into 
enterocyte, since GIP, GLP-1 and insulin profiles were not in alignment along the 
postprandial period as it might be expected given the association between insulin and 
glucose concentrations. GLP-1 is secreted from L cells in the distal small intestine 
within minutes of nutrient ingestion via neuroendocrine signalling, but the inhibition by 
the 600 mg ACN treatment occurred around the time that the meal contents would be 
reaching the part of the small intestine where the secretory cells are located suggesting 
an inhibition by direct blackcurrant polyphenols contact with the L-cells (Baggio and 
Drucker, 2007). The inhibition of plasma GLP-1 secretion in the second half of the 
postprandial period contradicts a previous study of a mixed berry meal consumed with 
sucrose, showing plasma GLP-1 concentrations increased in the first hour following 
consumption of the meal (Törrönen et al., 2012c). Opposite findings might mirror 
differences in study design such as the solid state of the carbohydrate load, and mixed 
composition (sucrose and starch) of the test meal in the present study. Differences in 




previous study showing a return to insulin baseline concentrations following their 
reference meal (sucrose and water) (Törrönen et al., 2012a), while plasma insulin 
concentrations in our study remained markedly elevated following control and 
blackcurrant extract treatments.  
Our findings suggest that the consumption of the highest dose of blackcurrant extract 
caused a slower rate of glucose absorption in the small intestine. Inhibition of digestive 
enzymes and intestinal glucose transporters (e.g. SGLT1, GLUT2) are the main 
proposed mechanisms by which blackcurrant polyphenols might act on glycaemic 
response (Williamson, 2013, Kwon et al., 2007, McDougall, 2008). A third mechanism 
suggest that as well as glucose anthocyanins can be transported into the enterocyte using 
intestinal glucose transporters, and competition for this route following an anthocyanin-
rich meal might reduce the rate of glucose absorption (Kamiloglu et al., 2015).  
Other variables related to lipids, blood pressure, vascular function and oxidative stress 
were not affected by the 600 mg ACN treatment or any other treatment. Contrary to 
expectations the insulin-mediated suppression of circulating NEFA concentrations was 
not different in the current study, our data disagree with a previous study showing an 
inhibition of the upwards return to baseline in plasma NEFA concentrations around 90-
120 min following blackcurrant puree and blackcurrant juice, reflecting insulin 
concentrations at these times points in comparison to the reference meal (Törrönen et 
al., 2012a). As for vascular function variables, our results are consistent with previous 
observations following berry polyphenols using similar methodology (Rodriguez-
Mateos et al., 2013), or Laser Doppler imaging with iontophoresis to measure 
microvascular function (Jin et al., 2011). Possibly a more specific method such as flow-
mediated dilatation of the brachial artery by ultrasound is necessary in order to detect an 
effect of blackcurrant polyphenols on endothelium-dependent vasodilation (Rodriguez-
Mateos et al., 2013). Since anthocyanins are rapidly absorbed and cleared, and their 
plasma concentrations are very low, they are unlikely to have a significant impact on 
vascular function in the early postprandial period (Rechner et al., 2002). However 
blackcurrant phenolic acids that peak around 2 h post-ingestion and their colonic 
metabolites, conjugated phenolic acids, which would be expected to appear in the 
circulation 4-12 h post-ingestion might be associated with some improvement in 
endothelial function (Rodriguez-Mateos et al., 2013, Czank et al., 2013). In order to 




of longer duration is required and a larger sample size to allow for inter-individual 
variability in colonic gut microflora profiles. A decreased glycaemia induced by the 
highest dose of blackcurrant phenolics might be expected to reduced endothelial 
oxidative stress and therefore improve vascular function (Del Bo et al., 2015). The 
deterioration in vascular function variables at 120 min were unaffected by treatment and 
this may be because the differences in glycaemic response between placebo and highest 
dose, although statistically significant, were not marked enough to affect vascular 
function.       
Previous data shows that anthocyanins may have an antioxidant effect. However in the 
present study blackcurrant polyphenols did not influence plasma concentrations of F2-
isoprostanes, which are peroxidation products of arachidonic acid arising from reactive 
oxygen species production and a sensitive marker of cellular oxidative damage. This 
result suggests that it is unlikely that a reduction of oxidative stress via a direct route 
has also occurred in the relatively short timeframe for absorption of phenolics into the 
circulation, although a longer postprandial measurement period might have detected 
differences at later timepoints. Plasma isoprostanes concentrations increased at 90 min 
after an OGTT in T2D patients (Sampson et al., 2002), therefore it might be possible 
that analysis at 120 min in the current study missed an earlier effect.       
These results combined provide a unique dataset showing that a highly purified liquid 
blackcurrant extract (5.4% weight total phenolic content, without fibre and low in other 
confounding nutrients) not only decreased glucose and insulin concentrations but also 
inhibits gut incretins GIP and GLP-1 secretion.  
The strengths of this study include the adherence to the highest standards of conducting 
a randomised clinical trial: fully blinded until the final statistical analysis had been 
completed, randomisation and allocation concealment conducted at a remote site by an 
independent party and the control treatment fully matched to the intervention drinks for 
taste, appearance, and nutrient composition. Our results could be applicable to the 
general population since the study was performed in a broad cross-section of healthy 
men and postmenopausal women, although for reasons of avoiding the confounding 
effects of cyclical fluctuations of reproductive hormones on glycaemia and insulinaemia 
premenopausal women were excluded (Brennan et al., 2009). Furthermore, the highest 




blackcurrant anthocyanins could be easily achieved in a normal diet by consuming ~100 
g of fresh blackcurrant fruit (Rothwell et al., 2013) and the prototype drinks formulated 
for the study could feasibly be developed into functional drinks and made available to 
all consumers. 
Limitations of the GLU-BERRY study include the addition of tannins as a taste-
blinding to the control and lower doses of blackcurrant extract drinks in order to match 
the bitter/astringent taste of the highest dose of blackcurrant extract. Given that it is 
impossible to find a bitter/astringent taste additive that is not a bioactive compound 
there is not an alternative for a replacement for tannins, which are likely to bind to 
proteins including digestive enzymes. Tannins are complex flavonoid polymers 
(proanthocyanidins) that have shown in vitro inhibitory activity on α-amylase and α-
glucosidase (Schafer and Hogger, 2007, Grussu et al., 2011, McDougall et al., 2005), 
mechanisms which may reduce glucose absortion in gut lumen. Tannins have also been 
associated with stimulation of the incretin GLP-1 activity and insulin secretion by 
pancreatic beta cells, mechanisms involved in glucose homeostasis (Blade et al., 2016). 
Although we observed significant inhibition of glycaemia, insulinaemia and incretin 
secretion, the true size of the effect may have been larger if the stringent adherence to 
taste-matching the placebo and lower doses had not necessitated the addition of tannins. 
The use of a blackcurrant extract rather than a purified blackcurrant anthocyanins source 
means that it is not possible to attribute with any certainty the effects on glucose 
homeostasis entirely or even partially to blackcurrant anthocyanins, as there are other 
polyphenols present in the blackcurrant extract that may have been responsible. 
Although we did not carry out analysis of other polyphenols in the blackcurrant extract, 
proanthocyanidins and phenolic acids are most likely to account for the remaining 997 
mg (highest dose), 428 mg (medium dose), and 239 mg (lower dose) phenolic content 









3.6.2 GLU-APP study  
The aim of this study was to show an inhibitory effect on postprandial glycaemia and 
insulinaemia after the consumption of two different doses of apple polyphenols 
(approximately 7% phlorizin) contained in no added sugar fruit drinks. It was 
hypothesised that a dose response effect would be observed following the intake of test 
drinks immediately before a carbohydrate (glucose, in the form of dextrose 
monohydrate) load equivalent to an oral glucose tolerance test. A glucose load was used 
instead of a starch and sucrose meal because of the known inhibitory effects of the 
apple-specific dihydrochalcone, phlorizin, on SGLT1-mediated transport of glucose, 
explained below. Results showed no effect of apple extract on circulating concentrations 
of glucose, insulin, GIP, GLP-1, TAG, or NEFA, or on blood pressure and vascular 
function. Our data differ from other clinical trials using apple-derived products, like 
apple juice and apple extract (Johnston et al., 2002, Schulze et al., 2014), which showed 
a delay in early glucose and insulin response.  
Although the apple extract was analysed, the drinks composition analysis has not been 
provided by the industrial collaborators at the time of writing. It is likely that the same 
protocol was followed as for GLU-BERRY drinks formulation where tannins were 
added to the placebo and lower dose to match drinks for astringent/bitter taste. The 
addition of tannins (proanthocyanidins) to the control (0 mg APP) and lowest dose (300 
mg APP) drinks could possibly mask the potential effects of the apple extract treatment 
on postprandial glycaemia. Since the test meal provided was a liquid load of glucose 
devoid of starch or sucrose and there were no action of digestive enzymes that could be 
inhibited, it might be expected that the main effect of apple polyphenols were exerted at 
the gut luminal interface, by inhibition of glucose transporters (SGLT1 and GLUT2). 
The apple extract used was rich in flavan-3-ols (~63%) mainly catechin and epicatechin, 
proanthocyanidins (~30%) and phlorizin (~7%) (Table 4.3). Phlorizin is a well-known 
competitive inhibitor of SGLT1 (Wright et al., 2011) and large polymers such as 
proanthocyanidins have shown non-specific binding with plasma membrane 
phospholipids forming complexes that could cover transmembrane proteins 
(Tarahovsky, 2008) like glucose transporters, hindering their function. Furthermore, 
covalent and non-covalent interactions are likely to occur between phenolic compounds 




However other phenolic compounds present in considerable quantities in GLU-APP test 
drinks as catechin (39%) and epicatechin (16.5%) when tested in the Caco-2 in vitro 
system did not show an inhibitory total glucose uptake (SGLT1- and GLUT-mediated) 
(Shimizu, 2000) but did show a significant decrease on GLUT-mediated glucose uptake 
(Johnston et al., 2005), opposing results may due to concentrations tested and 
mechanism involved in transporters inhibition.  
Previous clinical trials using apple extracts and liquid glucose meal have showed 
reduced early postprandial glucose response in healthy volunteers, however the 
phlorizin content in the apple extracts used, 315 mg (Makarova et al., 2015) and 448 mg 
(Schulze et al., 2014) highly exceed the phlorizin contents in GLU-APP drinks, 21 and 
42 mg in the lowest and highest dose, respectively. High concentrations of catechin and 
epicatechin, 234 and 99 mg in the GLU-APP top dose, did not improve the inhibitory 
effect as might be expected if compared with Makarova study (Makarova et al., 2015) 
where 63.5 and 53 mg of catechin and epicatechin were contained in the extract 
supplied. Alternatively a human trial using clear and apple juices containing small 
amounts of phlorizin, 12 and 26 mg, respectively, and a load of sucrose, fructose and 
glucose showed a significant effect in early glucose response (Johnston et al., 2002), 
although the complete phenolic profile of the apple juices were not provided, apple juice 
is estimated to contained significant amounts of proanthocyanidins (Rothwell et al., 
2013), which are likely to have contributed to the significant effects on glucose uptake 
by inhibiting digestive enzymes and limiting glucose availability in the gut lumen. 
These results suggest that the concentrations of phlorizin contained in GLU-APP drinks, 
expected to be the major responsible of decreased glucose uptake, were not sufficient to 
show an inhibitory effect on glucose response and that the inhibition of digestive 
enzymes may be play a central role in the decreasing of postprandial hyperglycaemia. 
Limitations in the GLU-APP study might be the use of a liquid test meal (glucose + 
water) in contrast to a solid, mixed-carbohydrate meal as used in the GLU-BERRY 
protocol. Although the glucose meal was chosen in order to induce a higher 
postprandial glycaemia, and because the phlorizin in the apple extract was expected to 
be the most bioactive component in directly inhibited SGLT1 transporter, administering 
a glucose meal instead of a starch/sucrose meal removed the digestive enzyme (α-
amylase and α-glucosidase) component of the total inhibitory effect (Barbosa et al., 




might have equalled the proanthocyanidins contained in the highest dose therefore 
diminished the difference in glucose uptake in gut lumen between treatments and it 
subsequent effects. Alternatively, the doses chosen, equivalent to 150 and 300 g of 
whole raw dessert apples (Rothwell et al., 2013) may have been too low to inhibit 
postprandial glycaemia and a higher dose may have been more efficacious. The doses 
tested 300 and 600 mg of polyphenols (mainly flavonoids) agreed with the average 
daily intake in Mediterranean countries as France, Italy, Spain and are even lower than 
estimated intakes in Northern European countries as UK, Netherlands and Denmark 
(Zamora-Ros et al., 2015); therefore consumption of 600 mg of polyphenols not 
exclusively derived from apple might be a daily goal that is easy to achieve.  
The use of a liquid load of pure glucose does not represent a typical real life meal and 
therefore the use of a solid meal containing different type of carbohydrates and other 
macronutrients as protein and fat represent a closer approach to daily life. Since the 
doses of apple extract used have had no effect on glycaemia response after the glucose 
meal and apple extract was 7% phlorizin, our results questions the relative importance 
of SGLT1 inhibition in vivo relative to the potential inhibition of digestive enzyme 
activity by polyphenols if disaccharides or polysaccharides are included in the test meal. 
Previous studies suggests that phlorizin, as inhibitor of SGLT1, need to be in greater 
concentrations if only glucose is provided as meal. In addition the used of disaccharides 
and/or polysaccharides might allow to see a positive effect with small amounts of 
phlorizin but a significant quantity of polyphenols contained in extracts.  
   






3.6.3 GLU-FRU study  
In this clinical trial we showed an inhibitory effect on postprandial glycaemia and 
insulinaemia by both treatments; apple polyphenol and the combination of apple 
polyphenols and blackcurrant anthocyanins, with the combination of both extracts 
having a more potent effect. The mixed extract drink treatment (AE+BE) reduced by 
73% the early glucose response (iAUC 0-30 min) compared to a 63% reduction with the 
apple extract only treatment (AE). Results from different trials testing acute and chronic 
hypoglycaemic effect of acarbose, an α-glucosidase inhibitor used in the treatment of 
T2D, have shown a decreased postprandial glycaemia (AUC) between 12 and 48% 
(Joshi et al., 2015, Nawawi et al., 2000). Although we did not test chronic effects, given 
the acute effects showed in our clinical trials it seems likely that the fruit extracts could 
act in a similar manner than acarbose.  
A similar response was found for the gut incretin, GIP; an overall effect was showed 
after consumption of both treatments with a stronger inhibition following the AE+BE 
treatment. As might be expected the insulin-mediated postprandial inhibition of plasma 
NEFA concentrations mirrors the insulin response across treatments, with higher NEFA 
concentrations following the consumption of AE+BE drink compared to AE and CON. 
Plasma TAG concentrations, blood pressure and vascular function DVP-SI did not 
differ between treatments. However, vascular function DVP-RI was decreased over the 
study period (2 h) by the AE treatment indicating a reduction in systematic arterial 
resistance.   
To our knowledge this is the first study testing the combination of apple extract and 
blackcurrant extract in a randomised controlled trial. Previously we showed in the GLU-
BERRY study that a drink containing 600 mg of blackcurrant anthocyanins (1600 mg 
total phenolics) inhibit plasma glucose and insulin early response. Results in GLU-FRU 
study clearly show an increased overall effect on the glucose homeostasis mechanism 
along the postprandial period by combining 600 mg of apple polyphenols and 600 mg 
of blackcurrant anthocyanins (1200 mg total blackcurrant polyphenols) in a test drink.  
 
Plasma glucose concentrations were reduced following the AE and AE+BE treatments 
in the early stage as measured by iAUC (0-30 min). Our results agree with previous 
reports of clinical trials where consumption of cloudy apple juice and apple extracts 




response (Johnston et al., 2002, Schulze et al., 2014, Makarova et al., 2015). The apple 
extract used in GLU-FRU study was rich in phlorizin (8.4%), giving a total of 100 and 
50 mg in the AE and AE+BE drinks, respectively. In comparison, the apple extract used 
in GLU-APP although similar in phlorizin content (7%) was lower in total 
dihydrochalcones, hydroxycinnamic acids and proanthocyanidins. In previous reports a 
cloudy apple juice containing 26 mg of phlorizin, 25 g glucose and 30.7 g fructose 
significantly lowered plasma glucose in human volunteers compared to a control drink, 
as demonstrated by a lower glucose iAUC from 0-30 and 30-90 mins (Johnston et al., 
2002). Furthermore, a dose of 2.8 g of an apple extract that appeared to be derived from 
apple pomace, containing a very large dose (448 mg) of phlorizin, reduced plasma 
glucose iAUC between baseline and 15, 30 and 45 mins in healthy human subjects 
following a 75 g glucose load (Schulze et al., 2014), and 25 g of unripe apple extract, 
derived from apple pomace, containing 315 mg of phlorizin reduced postprandial 
glucose response in healthy volunteers following by a 50 g glucose load (Makarova et 
al., 2015). However the magnitude of the inhibition found in our study was clearly 
greater than previous reports, which might be explained by differences in the 
carbohydrate load, i.e. the solid state of the meal allowing the inhibitory effect more 
time to take effect, and the mixed carbohydrate composition, starch and sucrose, in the 
present study versus a liquid load of glucose, fructose, and sucrose in the studies 
reported by Schulze et al. and Makarova et al., and glucose only in the GLU-APP study. 
In vitro studies have shown inhibitory effects on the activity of digestive enzymes -
amylase and -glucosidases (maltase and sucrase) by flesh and peel apple extracts 
(Barbosa et al., 2010), flavonol quercetin (Tadera et al., 2006), proanthocyanidins 
(Grussu et al., 2011) and other apple polyphenols compounds as chlorogenic acids 
(Hanhineva et al., 2010).  
The apple extract used here was rich in phlorizin as well as in proanthocyanidins and 
chlorogenic acid in addition small amounts of other characteristic polyphenols as 
monomeric flavan-3-ols and flavonols were contained. In addition to potential 
polyphenol-induced delayed digestive breakdown of carbohydrates, inhibition of 
glucose transporters (SGLT1 and GLUT2) by apple extracts and phlorizin (Manzano 
and Williamson, 2010, Schulze et al., 2014) as well as quercetin glycosides (Ader et al., 
2001) as showed in in vitro systems, may explain the marked effect of postprandial 




phlorizin-containing apple extracts and juice may lower the postprandial glucose curve. 
However, the previously mentioned studies in humans have utilised extracts or juices 
that contain additional polyphenols from apple. Therefore, it is unlikely that these 
effects are played out entirely by phlorizin. In a study using mice everted jejunal rings 
pure phlorizin (4.1μM) proved to be less effective in inhibiting sugar absorption when 
compared with phlorizin contained in an apple extract (3.2 μM) (Schulze et al., 2014). 
Although phlorizin was the most effective inhibitor, other polyphenols contained in the 
apple extract showed inhibitory effects in lower degree.  
The polymeric proanthocyanidin, component of apple polyphenols estimated using 
Phenol Explorer (Rothwell et al., 2013) to constitute 300 and 600 mg of the AE+BE and 
AE drinks respectively, and consisting of monomer and dimers (~18%), oligomers (3-
10 mers) (~52%) and polymers (>10 mers) (30%) has previously shown inhibition of 
glucose and insulin at 10 and 30 min at doses of 95 and 285 mg when consumed 
together with a high carbohydrate meal (Sapwarobol et al., 2012). In vitro enzymatic 
studies have suggested non-specific inhibition of α-amylase by direct contact between 
proanthocyanidins (PA) and the enzyme (McDougall et al., 2005). Interactions between 
polyphenols might show an additive effect when PA are combined with other phenolic 
compounds, such as anthocyanins (Akkarachiyasit et al., 2011) or flavonols and 
flavones (Lo Piparo et al., 2008) which also inhibit the enzyme by a different 
mechanism as interaction with the active site. Or a synergistic effect when α-amylase 
inhibitors are in presence of α-glucosidase inhibitors as chlorogenic acid, a 
hydroxycinnamic acid (McDougall, 2008) or cyanidin-3-glucoside, an anthocyanin 
(Adisakwattana et al., 2004).  
Other human studies showing inhibition of glucose and/or insulin using apple 
polyphenols have used higher quantities of individual polyphenols than those in the 
current AE and AE+BE drinks. For example one gram of chlorogenic acid (van Dijk et 
al., 2009) vs 32 and 16 mg in AE and AE+BE drinks, and 400 mg of quercetin vs 16 
and 8 mg in AE and AE+BE drinks (Hussain et al., 2012) which made the current 
concentrations of these individual polyphenols too low to play a highly significant 
effect on glucose homeostasis by themselves. However, the present data further confirm 
the inhibitory actions of polyphenol-rich apple and anthocyanin-rich blackcurrant 




and/or synergistic effects of the different polyphenols present in the extracts might 
explain the overall results on glucose homeostasis.  
Plasma insulin concentrations follow the glucose response, with a decreased 
concentration following consumption of AE and AE+BE treatments up to 45 min, 
compared to control and a marked effect following the mixed extract treatment. Since 
insulin concentrations are not only subject to pancreatic secretion rates, but also to the 
rate of hepatic extraction, we also analysed C-peptide concentrations, which is a 
polypeptide originated in the β-cells and is removed from the proinsulin molecule to 
produce insulin. Is secreted in equal concentrations as insulin into portal circulation 
from where a percentage of insulin is retained by liver but no C-peptide is extracted and 
reaches plasma circulation representing a better marker of glucose induced β-cell 
secretion. Concentrations and plasma kinetics of C-peptide therefore indicate rate of 
insulin secretion more accurately than plasma insulin concentrations (Hoekstra et al., 
1982). Plasma concentrations of C-peptide were reduced following the AE and AE+BE 
treatments up to 60 min, with a pronounced inhibition by AE+BE treatment.     
In concordance with the data on insulin secretion, plasma concentrations of the incretin, 
GIP, were also decreased by treatments AE and AE+BE throughout the 2 hours 
postprandial period. There was a marked effect in early response following the AE+BE 
as measured by iAUC 0-30 min. As observed in the GLU-BERRY study the strong 
inhibition of plasma GIP concentrations suggests that secretory regulation of this 
incretin is highly sensitive to glucose absorption rates. Intestinal sodium/glucose co-
transporter SGLT1 has been shown to be physically and physiologically related with the 
expression of GIP, and SGLT1 may act as a glucose sensor for GIP secretion 
(Gorboulev et al., 2012).  GIP is secreted in the proximal section of small intestine by 
K-cells only minutes after carbohydrate and fat intake (Baggio and Drucker, 2007). GIP 
secretion was decreased up to 75 min of the postprandial period corresponding to the 
time that meal content should take to transit along the upper intestine (duodenum and 
jejunum); it is possible that decreased stimulation of GIP secretion results from direct 
inhibitory phlorizin contact with K-cells (Smith et al., 1992, Wright et al., 2011), as 
well as synergistic inhibition by blackcurrant polyphenols in the case of AE+BE, which 
contained half the dose of phlorizin and showed a greater effect on GIP secretions than 
AE. Our results agree with a previous report of inhibition of glucose-induced SGLT1-




experiments using a rat model suggests GLUT2 might also play a role as glucose sensor 
for glucose induced incretin secretion (Mace et al., 2012) and this presents an additional 
mechanism whereby polyphenols such as phloretin, a GLUT2 inhibitor, may influence 
gut hormone secretion. Although phloretin was only present in low amounts in this 
apple extract, phlorizin could be rapidly cleaved by the enzyme lactase phlorizin 
hydrolase (LPH) to release the aglycone phloretin.      
Plasma NEFA concentrations followed the expected insulin-mediated suppression 
following treatment AE and AE+BE, concentrations were higher following AE and 
AE+BE treatments compared to CON, with a marked effect for AE+BE mirroring 
plasma insulin and GIP concentrations, effect was observed throughout the postprandial 
period. There are no previous studies showing effects on non-esterified fatty acids 
concentrations by apple extracts or apple juices, but our results suggests an evident 
influence of both treatments on circulating NEFA concentrations after ingestion of 
apple and blackcurrant extracts and a high carbohydrate meal, as a side-effect of 
reduced insulin secretion, and ultimately inhibition of intestinal glucose absorption. 
Other variables related to plasma lipids and blood pressure were not affected by any 
treatment.  
This study hypothesised that an improvement in vascular function measured as digital 
volume pulse stiffness and reflection index would be observed following the AE and 
AE+BE treatment, with a more marked effect after AE+BE treatment. Our results show 
no effect on DVP-SI (mainly reflecting stiffness of larger arteries) across treatments; 
however the increase from baseline for DVP-RI (indicating vascular resistance of small 
to medium-sized arteries) was suppressed following AE throughout the postprandial 
period. There was a tendency for decreased values following the AE+BE treatment but 
the difference did not reach statistical significance. This result is an agreement with 
GLU-BERRY study where the same amount of anthocyanins (600 mg) did not show an 
improvement in vascular function. The additive effects of apple and blackcurrant extract 
observed in glucose homeostasis variables did not have a highly significant effect on 
vascular function, suggesting that the reductions in pulse wave reflection were directly 
related to the post-absorptive effects of absorbed polyphenols on the vascular wall 
rather than an indirect effect via reduced postprandial glycaemia-induced oxidative 




Our results are in agreement with previous reports showing an improvement in vascular 
function measured by flow mediated dilation of the brachial artery, a more specific 
methodology, following a high-quercetin and high-epicatechin apple treatment 
(Bondonno et al., 2012). Our data also agree with human studies supporting the putative 
mechanisms of apple polyphenols on endothelial function improvement, mainly by 
increasing the bioavailability and bioactivity of nitric oxide (NO) in circulating plasma, 
a main regulator of vasodilation (Bondonno et al., 2012, Hollands et al., 2013, Gasper 
et al., 2014). Several in vitro studies have shown the potential pathways involved 
including activation of endothelial NO synthase (eNOS) by quercetin and quercetin 
metabolites (Shen et al., 2012), increase eNOS expression by catechins compounds 
(Appeldoorn et al., 2009), inhibition of NADPH oxidase by Orto-methylated flavan-3-
ols and chlorogenic acids (Steffen et al., 2008) causing a decrease in reactive oxygen 
superoxide formation. A human study showed that ~3% of an ingested dose of 
chlorogenic acids were absorbed in the 0-2 h period after intake (Stalmach et al., 2009) 
therefore it is probable that chlorogenic acids contained in the test drink and absorbed 
within the 2 h postprandial period may have contributed to increase NO bioavailability. 
Although the polyphenols showing a significant effect in in vitro studies were in our 
apple extract, quantities contained in drinks are too low in comparison with effective 
doses in vitro; an additive effect might explain the vasculo-protective effect of AE 
treatment. An explanation of possible cause-effect relationships need to be further 
explored, since differing rates of absorption and metabolic fates of the combined 
polyphenols may have a relation with the observed improvement in vascular function as 
has been suggested by a previous report (Rodriguez-Mateos et al., 2013).  
Strengths of this study, as for GLU-BERRY and GLU-APP, include the robust study 
design and the use of highly purified fruit extracts removing the confounding factor of 
fruit fibre and ensuring the homogenous polyphenol content in the drinks, eliminating 
the variability in polyphenol content on fruits due to species and cultivars and genetic, 
agricultural and environmental factors as well as storage and processing conditions (de 
Pascual-Teresa et al., 2007, Tabart et al. 2006, Basu et al., 2014).  
 
The dose of blackcurrant extract used is within achievable levels, since intake of 600 
mg of blackcurrant anthocyanins could be easily achieved in a normal diet by 
consuming ~100 g of fresh blackcurrant fruit. However, intake of 600 mg of apple 




plausible but challenging to have in one sitting. Furthermore, the apple extract used was 
especially high in phlorizin, which is more concentrated in apple stem (pedicel), seeds 
and skin (exocarp). Treatment AE+BE contained ~50 mg of phlorizin which represents 
the amount contained in 18 medium dessert unpeeled apples (1800g) (Rothwell et al., 
2013).  
The drinks were matched for their content on apple polyphenols and blackcurrant 
anthocyanins rather than blackcurrant polyphenols, which lead to a higher amount of 
total phenolics content on the AE+BE than in the AE drink, although due to the diverse 
nature and functional properties of polyphenols then it is arguable that this is not a 
hindrance to interpretation of the results. The combination of extracts and the potential 
presence of un-identified polyphenols contained within them, makes it difficult to 
attribute the effects on glucose homeostasis and vascular function entirely or even 
partially to blackcurrant anthocyanins or specific apple phenolic acids or flavonoids, as 
there are other polyphenols present in the extracts that may have been responsible. 
Intake of 1200 mg of apple polyphenols as used in AE treatment is achievably in a 
normal diet by consuming ~600 g of fresh apple fruit which is unrealistic unless pureed 
and concentrated. Further studies on the dose-response relationship are needed to 
identify the minimum effective dose required in order to achieve the same clinical 
effects.  
 
3.6.4 Conclusion  
In conclusion, the ingestion of blackcurrant and apple polyphenol-rich extracts 
decreased the plasma levels of glucose following starch and sucrose containing meals 
(but not following a glucose meal in the case of apple), and inhibited the secretion of 
insulin, GIP and to a smaller extent GLP-1. Although blackcurrants are likely to be 
consumed only sporadically in the general population and its availability is 
geographically limited, other berries more widely consumed like redcurrants, 
strawberries, grapes, raspberries, blackberries, blueberries, bilberries and cranberries 
contain different profiles of anthocyanins and proanthocyanidins. The consumption of a 
large dose of apple polyphenols also decreased circulating NEFA concentrations and 
improved markers of vascular function within the 2 h postprandial timeframe following 
a starch/sucrose meal. A mixture of apple and blackcurrant polyphenols attenuated in a 




blackcurrant polyphenols did on their own. Intakes of apple polyphenols in equivalent 
doses to that used in our study is challenging to achieve by consumption of fresh fruit, 
but since apple is consumed frequently in the general population and is extensively 
available, then the cumulative impact of daily small inhibitory effects on postprandial 
glycaemia could potentially still have an impact on health in the long term. Therefore 
regular consumption of berries, apples or a combination of both as main meals or with 
snack foods may help lowers postprandial glycaemia and insulinaemia. A more gradual 
and sustained insulinaemic response could potentially increase satiety during intermeal 
intervals (Blaak et al., 2012) and a lowered postprandial glycaemia is likely to protect 
the optimum functionality of pancreatic beta cells and may help to reduce the vascular 
burden of glucose-induced oxidative stress and endothelial dysfunction (Williams et al., 
1998, Ceriello et al., 2008) associated with the development of atherosclerosis. See 
Table 3.15 for a summary of effects on glucose homeostasis and vascular function 
showed by GLU-BERRY and GLU-FRU studies.      
 
Table 3.15 Summary table of GLU-BERRY and GLU-FRU studies outcomes 
Outcome 
GLU-BERRY 
(600 mg ACN) 
GLU-FRU 
(600 mg AE 
+ 600 mg ACN) 
GLU-FRU 
(1200 mg AE) 
Glucose  ↓ AOB 0-30 min ↓ iAUC 0-120 min    ↓ iAUC 0-30 min 
Insulin  ↓ AOB 0-30 min ↓ iAUC 0-120 min    ↓ iAUC 0-120 min 
C-peptide  NA ↓ iAUC 0-120 min    ↓ iAUC 0-30 min 
GIP  ↓ AOB 0-120 min ↓ iAUC 0-120 min    ↓ iAUC 0-120 min 
NEFA  NS ↑ iAUC 0-120 min NS 
DVP-RI  NS NS    ↓ Δ 60, 90, 120 min 
ACN, anthocyanin; AE, apple extract; AOB, area over baseline; iAUC, incremental area under 
the curve; NA, not analysed; GIP, glucose-dependent insulinotropic; polypeptide NS, no 










Given the concentrations of polyphenols used in the RCTs, incorporation of individual 
or blended blackcurrant and apple extracts into novel food or drink products, such as no 
added sugar fruit drinks, cereal bars, wholegrain crackers, breads and pasta, offers a 
potential avenue of functional food development that could target consumers (healthy or 
with T2D) who are interested in controlling their blood glucose concentrations. 
However, there may be significant technical challenges for the food and drink industry 
in formulating products with the desired characteristics in terms of physical and 
chemical stability (Woodward et al., 2011), bioavailability (Gonzales et al., 2015) and 
palatability (Drewnowski and Gomez-Carneros, 2000). Most phenolic compounds are 
known and even prized (particularly in the case of tea, coffee and wine) for their 
astringency and bitterness, but these properties are not always desirable in other foods 
so additional ingredients can sometimes be added to overcome these sensory challenges, 
for example, gums and pectins (Laaksonen et al., 2015). However, it is possible that 
addition of polysaccharides would enable the polyphenols to bind to these instead of the 
digestive enzymes, thus diminishing their glycaemia-lowering effects, and considerable 
efforts would be required by the food industry to develop acceptable novel products 
fortified with fruit extracts. 
 
The scientific evidence presented here supports current dietary guidelines that 
consumption of meals rich in fruits and vegetables and wholegrains may help prevent 
T2D and CVD, and suggests one of many routes by which cardio-metabolic protection 
can occur. Further mechanistic investigations into the polyphenol subclasses and/or 
individual polyphenols that are responsible for these clinical effects would strengthen 
current knowledge in the area. Elucidation of mechanisms involving glucose 
transporters expressed in in vitro systems is the next step in this research project, where 
blackcurrant and apple extracts used in RCTs were tested for their inhibitory effect on 











Acute effects of anthocyanin-rich blackcurrant extract 
and polyphenol-rich apple extracts on glucose transport 
in human intestinal cell line Caco-2/TC7 and Xenopus 





4.1 Introduction  
Consumption of foods with high content of polyphenols has been associated with 
reduced risk for type 2 diabetes. Epidemiological studies have shown an association 
between flavonoids and phenolics acids and lower risk of T2D (Zamora-Ros, 2013, 
Wedick et al., 2012) and randomised controlled trials have shown inhibition of 
postprandial glycaemia after consumption of polyphenol-rich meals or drinks (Törrönen 
et al., 2012c, Törrönen et al., 2012a, Schulze et al., 2014, Johnston et al., 2002). In our 
clinical trials, we have shown a decrease in postprandial glycaemia after consumption of 
drinks containing an anthocyanin-rich blackcurrant extract and a proanthocyanidin- and 
chlorogenic acid-rich apple extract. Potential mechanisms for hypoglycaemic effect of 
polyphenols include inhibition of digestive enzymes, decrease of intestinal glucose 
absorption, and stimulation of insulin secretion and protection of pancreatic β-cells.  
During digestion of carbohydrates, digestive enzymes, α-amylases and α-glucosidases, 
play a central role degrading polysaccharides and oligosaccharides into shorter-chain 
oligosaccharides, disaccharides and ultimately, monosaccharides. Certain polyphenols 
such as anthocyanins, flavonols, flavan-3-ols, proanthocyanidins and phenolic acids 
may inhibit α-amylases and α-glucosidases activity (Adisakwattana et al., 2004, 
McDougall et al., 2005, Tadera et al., 2006, Adisakwattana et al., 2009, Akkarachiyasit 
et al., 2010, Pereira et al., 2011, McDougall, 2008), slowing the accumulation of free 
glucose in the small intestine. Once free glucose is released, it is ready for transporter-
mediated uptake into enterocytes; however in vitro experiments have shown that certain 
polyphenols such as anthocyanins, flavan-3-ols, flavonols and dihydrochalcones may 
directly inhibit intestinal glucose transporters SGLT1 and GLUT2 (Johnston et al., 
2005, Kwon et al., 2007, Manzano and Williamson, 2010, Alzaid et al., 2013, Schulze 
et al., 2014), slowing the rate of glucose influx into enterocytes and subsequent efflux to 
the blood stream. Although there is a considerable number of studies showing 
polyphenol effects on intestinal glucose transporters, results should not be generalised. 
Effective concentrations and mechanisms of action vary widely between polyphenols, 
moreover concentrations tested have not always agreed with in vivo conditions limiting 
biologically significant conclusions.  
Therefore the aim of the present project was to identify the mechanisms of glucose 




used in our randomised clinical trials, on intestinal sugar transport using Caco-2/TC-7 
cells and Xenopus laevis oocytes systems.   
4.2 Hypothesis 
Anthocyanin-rich blackcurrant extract, individual major blackcurrant anthocyanins, and 
polyphenol-rich apple extracts inhibit glucose uptake in a dose-responsive way in 
human intestinal cell line Caco-2/TC7 and Xenopus laevis oocytes injected to express 
sodium-dependent glucose transporter 1 (SGLT1). 
A secondary hypothesis was that, should the blackcurrant extract be shown to inhibit 








In vitro experiments were completed under supervision of Dr Christopher P Corpe and 
with the assistance of postgraduate research students, Dr Patrick O’Brien, Dr Hoi Man 
Cheung and Diana C Munoz Sandoval. 
4.3.1. Polyphenol-rich fruit extract profiles   
Three different polyphenol-rich fruit extracts used in randomised clinical trials (Chapter 
3) were tested in the Caco-2/TC7 and Xenopus oocyte systems. Details on extracts 
composition and concentrations used in the in vitro assays are shown below.  
4.3.1.1 Anthocyanin-rich blackcurrant extract (BE) 
The anthocyanin-rich blackcurrant extract (BE) (BerryPharma® by Iprona AG, Lana, 
Italy) used in GLU-BERRY and GLU-FRU studies contained 2822 mg total 
anthocyanins per 100 ml (5775 mg total polyphenols per 100 ml), analysed by RSSL 
The Lord Zuckerman Research Centre (Reading, UK) (Table 4.1).  









Total polyphenols 5775 
Total carbohydrates 2300 
Glucose 100 
Fructose 100 






Individual anthocyanins and anthocyanidins in BE 
The four main anthocyanins present were glycoside compounds of delphinidin and 
cyanidin. Is has been proposed that anthocyanin glycosides may be cleaved by lactase 
phlorizin hydrolase inserted in enterocytes provoking the release of free aglycones of 
the parental compounds, in this case delphinidin and cyanidin. Therefore the four main 
anthocyanins present in the blackcurrant extract and the two parental aglycones 
(anthocyanidins) were tested (Table 4.2) as well as combination of the four glycosides 
and combination of the two aglycones.  
Table 4.2 Anthocyanins and anthocyanidins tested in Caco-2 cell system 
Individual compound Supplier details Solvent used1 
Cyanidin-3-glucoside  
(Kuromanin chloride) 





Santa Cruz Biotechnology, 




Santa Cruz Biotechnology, 




Santa Cruz Biotechnology, 








Company cat no. 11012 
DMSO 
1





4.3.1.2 Polyphenol-rich apple extract (AE1) 
Polyphenol-rich apple extract (AE1) used in GLU-APP study (JF-NATURAL, Tianjin 
Jianfeng Natural Product R&D Co., Ltd, China) contained 73 g of total polyphenols per 
100 g of extract, analysed by RSSL The Lord Zuckerman Research Centre (Reading, 
UK) (Table 4.3).  
 





   Phloretin  110 
   Phlorizin 4992 
Flavonols  
   Quercetin  103 
Hydroxycinnamic acids  
   Gallic acid < 30  
Flavan-3-ols (monomers)  
   Catechin  28479 
   Epicatechin 12010 
   Epigallocatechin 5467 
   Gallocatechin    < 1 
   Epigallocatechin gallate  < 10 
   Gallocatechin gallate < 100  
   Epicatechin gallate 182 
Proanthocyanidins 21839 
Total polyphenols 73000 






4.3.1.3 Polyphenol-rich apple extract (AE2) 
The polyphenol-rich apple extract (AE2) (Appl’InTM by DIANA FOOD, Antrain, 
France) used in GLU-FRU study contained 67% phenolics as analysed by DIANA 
FOOD and confirmed by author using Folin-Ciocalteu method (Singleton and Rossi, 
1965) (Table 4.4).  
 




   Phlorizin 5360 
Flavonols 3350 
   Quercetin 670 
Hydroxycinnamic acids 2680 
   Chlorogenic acid 2010 
Flavanols  10720 
   Epicatechin 134 
   Procyanidins 10586 
Proanthocyanidins 40200 
Total polyphenols 67000 
Total carbohydrates 8500 
Glucose 1300 
Fructose   3000 
All values were derived from HPLC analysis of 
raw extract 
 
4.3.1.4 Estimation of physiological concentrations of BE, AE1 and AE2 
Estimation of physiological concentrations of blackcurrant polyphenols, blackcurrant 
anthocyanins and apple polyphenols present in gut lumen after ingestion of test drinks 
in clinical trials were based on the milligrams of total polyphenols or anthocyanins 




of the maximum volume of gastrointestinal fluid within which drinks would be diluted 
after ingestion (up to 2 L) with a solid meal (Kong and Singh, 2008; Schiller et al., 
2005).  
Concentration of blackcurrant polyphenols and blackcurrant anthocyanins present in test 
drinks used in GLU-BERRY were described in Table 3.1, test drinks contained 460, 
810 and 1596 mg of polyphenols. The total volume where polyphenols dissolved was 
predicted to be 2.2 L. Therefore estimated physiological concentrations of blackcurrant 
polyphenols in gut lumen after consumption of test drinks were 0.21, 0.34 and 0.73 
mg/ml. For practical reasons concentrations in vitro were tested as 0.2, 0.4 and 0.8 
mg/ml, additional lower and higher concentrations were also tested.  
Concentrations of individual blackcurrant anthocyanins tested corresponded with 
estimated physiological concentrations of individual compounds present in gut lumen 
after consumption of the top dose drink; 600 mg ACN for details in calculation see 
Table 4.5.  
Table 4.5 Estimated physiological concentrations of anthocyanins and anthocyanidins 
tested in Caco-2 cells 
Individual compounds 













 33 0.015 485 0.03 
Cyanidin-3-rutinoside
1
 209 0.095 631 0.15 
Delphinidin-3-glucoside
1
 76 0.035 501 0.07 
Delphinidin-3-rutinoside
1
 260 0.118 647 0.18 










 336 0.153 339 0.25
4
 
ACNs, anthocyanins/anthocyanidins; MW, molecular weight; mM, millimolar.  
1
 Concentrations estimated from the analysis of the raw extract and not from drinks analysis.  
2 
Values estimated from glycosides concentrations in raw extract.   
3
 Averaged molecular weight of main anthocyanins. 
4





Concentrations of apple polyphenols present in test drinks used in GLU-APP and GLU-
FRU studies were described in section 3.4.2 and Table 3.2, respectively. Test drinks 
contained 300, 600 and 1200 mg of apple polyphenols, the total volume where apple 
polyphenols dissolved was predicted to be 2.2 L, therefore estimated physiological 
concentrations of apple polyphenols in gut lumen after consumption of 300, 600 and 
1200 mg of apple polyphenols were 0.14, 0.27 and 0.54 mg/ml, respectively. For 
practical reasons concentrations in vitro were tested as 0.15, 0.3 and 0.5 mg/ml, 
respectively. Additional lower and higher concentrations were also tested in the in vitro 
systems.  
4.3.2 Human intestinal Caco-2/TC7 cells system  
4.3.2.1Cell culture conditions  
The human intestinal Caco-2 cell line TC7 subclone was obtained from Dr Paul 
Sharp/Christopher Corpe’s laboratory at KCL. Cells were grown, maintained and 
subcultured following procedure previously reported (Kwon et al., 2007). Caco-2/TC7 
cells were seeded in T-25 cell culture flasks (Corning, Sigma-Aldrich), cells were 
grown in high-D-glucose (25 mM) with glutamine Dulbecco’s modified Eagle’s 
medium (DMEM) (Sigma-Aldrich, UK), containing 10% fetal bovine serum (FBS; 
Sigma-Aldrich), 50 units penicillin and 50 µg streptomycin (Pen/Strep; Sigma-Aldrich), 
0.1 mM MEM non-essential amino acids (Life Technologies, UK), additional 2 mM L-
Glutamine (Life Technologies, UK) and 5 µg/ml Plasmocin (InvivoGen, USA), referred 
as complete media in the following sections. Cells were cultured at 37oC in a humidified 
incubator (BIOHIT, HealthCare, UK) in a 5% CO2-95% air atmosphere. Complete 
medium was changed every other day and cells were split once a week when 80 % 
confluence was reached. For detaching cells the monolayer in T25 flask was washed 
twice with 4 ml of sterilised 37 o C PBS, subsequently 1.5 ml of TrypLETM Select (Life 
Technologies, UK) were added and flask was incubated 15 min at 37 o C. After 
detaching the cells, a suspension was made adding 8.5 ml of complete medium and 
centrifuged at 1000 rpm for 5 min at 23 o C. Supernatant medium was discarded and the 
cell pellet was re-suspended in 10 ml of complete medium. For counting cells 15 μl of 
the cell suspension was loaded on the haemocytometer, a cover slide was place before 
in order to add the suspension by capillarity. For passaging cells were seeded at 6000 




density in 24-well dishes (NUNC, DK) and grown for 21 days, cells were used between 
passages 45-53 in all experiments.  
4.3.2.2 Glucose uptake assays 
Conditions for glucose uptake assays were previously established in the laboratory 
during the doctoral program of Dr Patrick O’Brien (O'Brien, 2015). For glucose 
transport assays uptake media contained 10 mM D-glucose or 10 mM L-glucose and 0.1 
µCi/ml Glucose D-[14C(U)] or 0.1 µCi/ml Glucose L-[1-14C] as tracer (Table 4.6). 
Krebs buffer solution (KBS) containing 30 mM HEPES, 130 mM NaCl, 4 mM 
KH2PO4, 1 mM MgSO4·7H20, 1 mM CaCl2, dH2O and adjusted pH 7.4 was used as 
wash media, for sodium-free conditions NaCl was replaced with KCl. Sodium-
containing and sodium-free KBS supplemented with 0.2% bovine serum albumin (BSA) 
was used as pre-incubation and uptake media. Times for pre-incubation and uptake in 
all experiments, unless specified, were 15 and 10 minutes, respectively. Throughout 
assays pre-incubation started by aspirating complete media, washing cells with KBS 
and adding 500 µl of pre-incubation media. Uptake was initiated by removing pre-
incubation media and adding 500 µl of uptake media and terminated by aspirating 
uptake media and washing cells three times with 500 µl of ice cold 1 M phosphate 
buffer solution (PBS). Subsequently 500 µl of 0.2% sodium dodecyl sulphate (SDS) 
were added to each well and plates were incubated one hour at 37 °C for cellular lysis. 
After incubation aliquots of 200 µl of cell lysate were added to 5 mL of Ecoscint A 
Scintillation Cocktail (National Diagnostic) and radioactivity count was measured on a 
Liquid Scintillation Counter (Beckman Coulter, Inc. LS6500). Calculations for glucose 
uptake were made taking into account the specific activity of uptake media, glucose 
uptake was corrected for simple diffusion of L-glucose. 
4.3.2.2.1 Inhibitors of glucose transporters  
To ensure the Caco-2/TC7 system was functioning as expected specifics inhibitors of 
sugar transporters were tested. Glucose uptake experiments were performed under 
sodium-dependent and sodium-independent conditions; phlorizin (Pz) 0.5 mM was used 
as specific inhibitor of SGLT1, phloretin (Pt) 0.5 mM as specific GLUT2 inhibitor and 
cytochalasin B (CB) 0.01 mM as GLUTs inhibitor. Since inhibitors were dissolved in 
dimethyl sulfoxide (DMSO) a final concentration of 0.1% DMSO was present in the 




pre-incubation medium (control) and pre-incubation media. After removing pre-
incubation media, uptake was initiated by adding 500 µl of uptake media (control) or 
uptake media containing Pz, Pt, CB or DMSO. Uptake was terminated by washing cells 
three times with ice cold PBS. Cells were treated for radioactivity count as procedure 
described in section 4.3.2.3 Inhibitors of glucose transporters were tested throughout the 
in vitro Caco-2/TC7 cells assays.  
 
Table 4.6 Reagents details for cell culture assays 
Reagent Supplier details 
D-(+)-glucose BDH Laboratory Supplies, cat. no. 101174Y 
L-(-)-glucose Santa Cruz Biotechnology, cat. no. sc-221793A 
Glucose, D-[14C(U)] Perkin Elmer, cat. no. NEC042X050UC 
Glucose, L-[1-14C] Perkin Elmer, cat. no. NEC478050UC 
HEPES Sigma Aldrich, cat. no. H3375 
CaCl2 1 M AMRESCO, LLC. cat. no. E506 
BSA (bovine serum albumin) Sigma Aldrich, cat. no. A9647 
PBS (phosphate buffer solution) Severn Biotech, 20-7400-10 
SDS (sodium dodecyl sulphate) Fisher, cat. no. 02674-25 
Ecoscint A Scintillation Cocktail National Diagnostics, LS-273 
Phlorizin  Cayman Chemical Company, cat. no.11576 
Phloretin Santa Cruz Biotechnology, cat. no. sc-3548 
Cytochalasin B Santa Cruz Biotechnology, cat. no. sc-3519 
DMSO (dimethyl sulfoxide) Fisher Scientific CAS-No 67-68-5 
Methanol  Fisher Scientific CAS-No 67-56-1 







4.3.2.2.2 Time course assay 
Before starting experiments Caco-2/TC7 cells were pre-incubated with complete media 
containing 3.2 mg/ml of blackcurrant polyphenols, times for pre-incubation were 0 
(controls), 1 and 30 min and 3 hours. Following pre-incubation, complete media was 
removed and cells were washed once with room temperature KBS. Uptake was initiated 
by adding 500 µl of BE-free uptake media (control) or uptake media containing 3.2 
mg/ml of blackcurrant polyphenols, after 10 min uptake was terminated by aspirating 
uptake media and washing the cells three times with 500 µl of ice cold PBS. 
Subsequently 500 µl of 0.2% SDS were added to each well and plates were incubated 
one hour at 37 °C for cellular lysis. Aliquots of 200 µl of cell lysate were added to 5 ml 
of scintillation liquid (National Diagnostic, Ecoscint A, LS-273) and radioactivity count 
was measured on a Liquid Scintillation Counter (Beckman Coulter, Inc. LS6500). 
Calculations for glucose uptake were made taking into account the specific activity of 
uptake media. Total glucose uptake was corrected for simple diffusion of L-glucose.  
4.3.2.2.3 Dose response assays  
Glucose uptake experiments were performed under sodium-dependent and sodium-
independent conditions in order to identify acute effects of the fruit extracts on total 
glucose uptake (SGLT1- and GLUT-mediated) and GLUT-mediated glucose uptake. 
Before uptake started complete media was aspirated and cells were washed once with 
room temperature KBS. Cells were pre-incubated for 15 min with pre-incubation media; 
uptake was initiated by replacing pre-incubation media with uptake media. Uptake 
media contained, except for controls, increasing concentrations of blackcurrant or apple 
polyphenols. After 10 min the uptake media was aspirated and the transport process was 
stopped by washing three times each well with ice cold KBS, cells were treated for 
radioactivity count as previously described in this document.     
4.3.2.2.4 Individual anthocyanins and anthocyanidins 
Individual anthocyanins contained in the anthocyanin-rich blackcurrant extract and 
derived anthocyanidins (aglycones) were tested at estimated physiological (Table 4.3) 
concentrations and at 0.1 mM against 10 mM D-glucose and 1 mM D-glucose, 
respectively.  
In the first set of experiments concentrations tested correspond with estimated 




consumption of the top dose drink used in GLU-BERRY study (600 mg ACN) (Table 
4.4). Before uptake started complete media was aspirated and cells were washed once 
with room temperature KBS. Cells were pre-incubated for 15 min with pre-incubation 
media; uptake was initiated by replacing pre-incubation media with uptake media 
containing, except for control, different concentrations of individual anthocyanins, 
anthocyanidins, and solvents, combination of glycosides or combination of aglycones. 
After 10 min the uptake media was aspirated and the transport process was stopped by 
washing three times each well with ice cold KBS, cells were treated for radioactivity 
count as previously described in this document.  
Further concentrations of individual compounds were tested in the Caco-2/TC7 system; 
in order to increase the anthocyanins/glucose ratio in uptake media different assay 
conditions were settled. Glucose concentration in uptake media was decreased to 1 mM 
and individual compounds in uptake media were tested at 0.1 mM given a ratio 1:10. 
Before uptake started complete media was aspirated and cells were washed once with 
room temperature KBS. Cells were pre-incubated for 15 min with pre-incubation media 
containing, except for control, 0.1 mM of individual anthocyanins, anthocyanidins or 
different concentrations of solvents. Uptake was initiated by replacing pre-incubation 
media with uptake media containing, except for control, 0.1 mM of individual 
anthocyanins, anthocyanidins or different concentrations of solvents. After 2 min the 
uptake media was aspirated and the transport process was stopped by washing three 
times each well with ice cold KBS, cells were treated for radioactivity count as 
previously described in this document.  
4.3.3 Xenopus laevis oocytes injected to express SGLT1 system 
4.3.3.1 In vitro synthesis of cRNA encoding rSGLT1  
4.3.2.1.1 Linearising cDNA  
Insertion of complementary DNA (cDNA) clones of rat SGLT1 (rSGLT1, ID: 7129017) 
into the pExpress-1 vector was previously done and verified in Dr Corpe’s laboratory; 
full details were reported in the thesis of MSc Reshma Suresh. Analysis of the rSGLT1 
plasmid generated showed the rSGLT1 clone inserted identical to published sequence 
and a plasmid mass of 6.5 kb, including 2.4 kb for the rSGLT1 inserted clone and 4.1 kb 




To obtain linearized DNA, rSGLT1-pExpress-1 cDNA was digested using the XhoI kit 
(New England BioLabs Inc) following supplier’s protocol. Mixtures were made up to 
a final volume of 50 μl with RNase-free water and incubated two hours in a bath water 
at 37 o C. Precipitation of linearized sample was done by adding 2.5 μl of EDTA (0.5 
M), 5 μL of ammonium acetate (5 M) and 100 μl of ethanol (100%). Mixture was 
chilled at -20 o C for 30 min and centrifuged at 4 o C, 13000 rpm for 15 min. Supernatant 
was discarded, and 10 min were allowed for ethanol evaporation before pellet were re-
suspended in 10 μL of RNase-free water. Linearized DNA concentration was measured 
using a NanoDrop 2000 Spectrophotometer (Thermo Scientific, UK).                
Following DNA digestion, linearization of rSGLT1-pExpress-1 cDNA was confirmed 
by agarose gel electrophoresis (Figure 4.1). Agarose gel 1% was made up of UltraPure 
Agarose (Life Technologies, UK), TBE buffer (Table 4.7) and stained with 5 µg 
Ethidium Bromide (Alfa Aesar, UK). 500 ng of cDNA and linearized DNA were 
complemented with 2 µl of Blue/Orange 6X Loading Dye (Promega, UK) and made up 
to 6 µl with RNase-free water. Samples were added to different wells in the 
electrophoresis gel and ran together with 20 µl of 1kb DNA Ladder (Promega) in a TBE 
buffer-filled box at 120 V for 90 min. Gel was visualised on a SynGene Genius 
Bioimaging system using GeneSnap, version 6.00.26 (Synaptics, UK). The 
electrophoresis showed bp size of uncut cDNA and linearised cDNA as expected (6.5 
kb) although uncut cDNA ran lower than expected possible due to the presence of 




         
  
 
Figure 4.1 Electrophoresis of uncut cDNA and linearised cDNA of rSGLT1  
After linearisation of cDNA with restriction enzymes XhoI samples alongside with 1 kb DNA 
ladder were analysed in agarose gel 1% stained with ethidium bromide. Electrophoresis showed 
bp size of uncut cDNA and linearised cDNA as expected (6.5 kb), although uncut cDNA ran 

















4.3.2.1.2 Synthesis of cRNA encoding rSGLT1 for oocyte microinjection 
The transcription kit mMESSAGE mMACHINE SP6 (AmbionTM) was used to 
transcribe linearised DNA of rSGLT1 into complementary RNA (cRNA) encoding 
rSGLT1 according to manufacturer’s protocol. For synthesis of cRNA 7.5 µg of 
linearised DNA were complemented with 3 µl of nuclease-free water, 10 µl of 
NTP/CAP solution, 2 µl of reaction buffer and 2 µl of SP6 enzyme mix. The mixture 
was gently mixed and incubated at 37 o C for 2 hr. For removing DNA template 1 µl of 
TURBO DNase was added to the sample, mixed and incubated at 37oC for 15 min. 
Reaction was stopped by adding 30 µl of nuclease-free water and cRNA was 
precipitated by adding 30 µl of Lithium Chloride Precipitation Solution, mixtures were 
chilled at -20 oC for 45 min and centrifuged at 4 o C and 13000 rpm for 15 min in order 
to pellet the cRNA. After centrifugation the supernatant was carefully discarded by 
decantation and cRNA pellet was washed with 1 ml of 70% ethanol, mixture was 
centrifuged again at 4 o C, 13000 rpm for 15 min, supernatant was discarded and 10 min 
were allowed to ethanol evaporation before the cRNA pellet were re-suspended in 30 µl 
of nuclease-free water. Concentration of cRNA encoding rSGLT1 was measured using a 
NanoDrop 2000 Spectrophotometer (Thermo Scientific, UK); sample was storage at -20 
o C. 
Size and integrity of the cRNA was verified by running a Nano chip electrophoresis 
with the Agilent 2100 Bioanalyzer using the RNA 6000 Nano kit (Agilent 
Technologies, Germany). Samples were analysed by Erick Nasser in the Genomic 
Centre of King’s College London, before analysis sample was diluted to a final 
concentration of ~100 ng/µl. Results in the gel image (Fig 4.2 A) and electropherogram 
(Fig 4.2 B) from the cRNA Nano chip electrophoresis indicate a structure in the 2.4 kb 
range as expected for the rSGLT1 inserted clone. Although results suggest a possible 
secondary structure by the presence of two bands and two peaks instead of a single one, 
validation assays of the system showed the clone works as expected in oocytes injected 
cRNA encoding rSGLT1 (Suresh, 2013, Munoz Sandoval, 2015).    
 
 
















Figure 4.2 Nano chip electrophoresis of rSGLT1 cRNA  
Transcription of linearised cDNA of rSGLT1 into cRNA was analysed for purity and integrity. 
A) Gel image of rSGLT1 cRNA. L, ladder; 1, cRNA of rSGLT1. The presence of two bands 
indicate an incomplete transcription reaction, however the band above 2000 [nt] pinpoint the 
presence of a structure within the expected range (2.4 kb for inserted rSGLT1 clone). B) 
Electropherogram of rSGLT1 cRNA. The presence of two peaks suggests the presence of a 
secondary structure however the peak in the 2000 [nt] range indicate a structure within the 
predicted size.      
 
4.3.3.2 Expression of SGLT1 transporter in oocytes 
4.3.3.2.1 Oocyte isolation  
Batches of Xenopus laevis oocytes were provided by the European Xenopus Resource 
Centre of the University of Portsmouth. After arrival ovary sacs containing oocytes 
were placed in petri dishes and washed two to three times with calcium-free MBS 
media (Table 4.8) before start the manual separation of the ovary lobes and releasing of 
individual using watchmaker forceps. Released individual oocytes were washed three 
times with MBS Ca2+ free-media and incubated in 0.2% Collagenase IV from 
Clostridium Histolitycum (Sigma Aldrich, UK) contained in calcium-free MBS media; 
petri dishes were wrapped in aluminium foil, in order to protect oocytes from light, and 
placed on a shaker at room temperature and 4 rpm for 30 min. After incubation manual 
dissection with forceps was carefully done, subsequently media was removed and 
incubation with collagenase followed by oocyte separation was repeated. After 





MBS media (with Ca2+), in order to stop the collagenase action, and incubated in fresh 
MBS media.  
Selection of healthy oocytes was done using a Pasteur pipette, perfectly spherical 
oocytes with ~1 mm of diameter without any follicular attachment and with a clear 
division of the animal (black) and vegetal (white) pole (Figure 4.3) were selected using 
a Stereo Microscope (Leica StereoZoom GZ6) equipped with a cold light source (Leica 
CLS 100X). After selection oocytes were transferred into 6-well culture plates (NUNC, 
UK) and incubated in MBS media supplemented with 1 mM sodium pyruvate (GE 
Healthcare, UK). Plates were wrapped in aluminium foil and incubated at 19 o C 
(LABCOLD Incubator, UK) until microinjection.  




Figure 4.3 Healthy oocytes  
 
Table 4.7 Solutions used in the oocyte system 
Solution  Composition 
TBE buffer (10X) 0.90 M Tris, 0.89 M Boric acid and 20 M EDTA 
MBS (modified Barth’s 
saline media) 
88 mM NaCl, 1 mM KCl, 0.82 mM MgSO4, 0.33 mM 
Ca(NO3)2, 10 mM HEPES, 0.41 mM CaCl2, 100U/100 
μg penicillin/streptomycin, 0.05 mg/L tetracycline and 
0.1 mg/ml gentamicin.  pH 7.5  
 
 
4.3.3.2.2 Oocyte microinjection 
Before injecting, oocytes were inspected for irregular shaped or damaged oocytes to be 
discarded. Healthy oocytes were collocated in the oocyte chamber, consisting of a petri 
dish filled with MBS media and a polypropylene mesh (0.8 mm pores) attached to the 





Microinjections of cRNA were done with a Nanoject II injector (Drummond Scientific 
Company) with a glass needle attached (Figure 4.4). With help of a Stereo Microscope 
equipped with cold light, 36.8 nL of rSGLT1 cRNA (1.2-1.5 μg/ml) were injected to 
each oocyte. For microinjections glass needles were pulled from capillary glass pipettes 
(Drummond Scientific Company, US) using a P87 Flaming/Brown Micropipette Puller 
(Sutter Instrument Company, US) with the following parameters; heat 749, pull 63, 
velocity 45 and time 210. Prior to injection needles were opened by carefully breaking 
off the tip with forceps, tip needle was 10-15 mm in length. Needles were loaded with 
3.5 μL of cRNA at the bottom of the tip followed by 12 μL of mineral oil in the barrel, 
0.5-20 μL Microloader pipette tips (Eppendorf, US) were used to fill the needles. The 
needle was then attached to the Nanoject II injector and the injector was placed at 40 o 
angle with respect to the oocyte chamber. Injected oocytes and healthy non-injected 
oocytes were transferred to 6-well plates filled with MBS media supplemented with 1 
mM sodium pyruvate, plates were wrapped in aluminium foil and incubated at 19 o C 
until assay day. Oocytes were checked daily and removed into fresh media when 
necessary, transport assays were carried out at fourth day post injection, allowing time 
for the cRNA translation and expression of mature protein (SGLT1 transporter) into the 
oocyte plasma membrane. Non-injected oocytes were used as controls in the uptake 








Figure 4.4 Xenopus oocyte microinjection equipment 
A) Oocyte injection chamber with polypropylene mesh (0.8 mm pores) attached for holding 








4.3.3.3 Glucose transport assays 
Conditions for glucose uptake assays were previously established in the laboratory by 
MSc Reshma Suresh and MRes Diana Munoz Sandoval. Ten oocytes injected to express 
SGLT1 and ten sham oocytes were used for every condition tested. For glucose 
transport assays uptake media contained 10 mM D-glucose and 0.5 µCi/ml Glucose D-
[14C(U)] as tracer (Table 4.1). MBS was used as uptake media and PBS as wash media; 
uptake period in all experiments was 10 minutes. Throughout assays uptake was started 
by aspirating incubation media and adding 500 µl of uptake medium and terminated by 
aspirating uptake media and washing three times with 4 ml of ice cold PBS. 
Subsequently each oocyte was solubilised in 500 µl of 10% SDS contained in a 
scintillation vial prior to the addition of 4 ml of Ecoscint A, vials were vigorously 
shaken by hand before radioactivity count. Radioactivity count was measured on a 
Liquid Scintillation Counter (Beckman Coulter, Inc. LS6500). Calculations for glucose 
uptake were made taking into account the specific activity of uptake media and total 
glucose uptake was corrected for D-Glucose diffusion in sham oocytes.  
4.3.3.3.1 Inhibition assays in oocytes expressing SGLT1 
To ensure the oocyte system was functioning as expected phlorizin (Pz), a well-known 
competitive SGLT1 inhibitor and phloretin (Pt), a non-competitive SGLT1 inhibitor 
were tested on the oocytes injected to express rSGLT1 and sham oocytes. Pz 0.5 mM 
and Pt 0.5 mM were dissolved in dimethyl sulfoxide (DMSO) therefore a concentration 
of 0.1% DMSO was also tested in oocytes. After remove incubation media, uptake was 
initiated by adding 500 µl of uptake medium (control) or uptake media complemented 
with DMSO, Pz or Pt. After 10 min uptake was terminated and oocytes were washed 
and treated as procedure described in section 4.3.2.3. Pz 0.5 mM and 0.1% DMSO were 
tested throughout the in vitro oocytes assays.  
4.3.3.3.2 Dose response assays with anthocyanin-rich blackcurrant 
extract and polyphenol-rich apple extract (AE2) in oocytes expressing 
SGLT1 
Before uptake started incubation medium was aspirated, uptake was initiated by adding 
uptake media. Uptake media contained, except for control, increasing concentrations of 
blackcurrant (BE) or apple extract (AE2), after 10 min the uptake media was aspirated 




PBS. Oocytes were treated for radioactivity count as previously described in section 
4.3.2.3. Concentrations of BE and AE2 tested in the oocyte system were the 
physiological range estimated to be present in the small intestine after ingestion of test 
drinks on human studies and additional higher and lower concentrations.          
4.3.4 Statistical analysis 
All results were expressed as mean ± SEM. Statistical analysis was done using the 
software GraphPad Prism 6 for Windows (GraphPad software, CA, USA). All data was 
tested for normality with D-Agostino & Pearson omnibus test. Experiments with 
normally distributed data were analysed by one-way analysis of variance with Dunnett’s 
multiple comparison post hoc test or by unpaired t-test. Experiments with non-normally 
distributed data were analysed by Kriskal-Wallis test with multiple comparison Dunn’s 
post hoc adjustment or by Mann-Whitney test. IC50 were estimated by non-linear 
regression analysis using the software SigmaPlot 13 for windows (Systat Software Inc. 






Results showed in this section represent pooled data of three or more assay repetitions 
testing anthocyanin-rich blackcurrant extract and polyphenol-rich apple extracts on 
Caco-2 cells and oocytes systems. Validation details of the Caco-2/TC7 cells and 
Xenopus laevis oocytes systems implemented by the research group were reported in the 
theses of Dr Patrick O’Brien (O'Brien, 2015) and MRes Diana C Munoz Sandoval 
(Munoz Sandoval, 2015), respectively.   
 
4.4.1 Effects of glucose transporter inhibitors on Caco-2/TC7 system  
All through the period of experimentation on the Caco-2 cells system specific inhibitors 
of glucose transporters; phlorizin, phloretin and cytochalasin B which inhibit SGLT1, 
GLUT2 and GLUT 1-4, 7, 8 respectively, showed the in vitro system functioning as 
expected. Total glucose uptake was decreased by specific glucose transporter inhibitors 
(P<0.0001): phlorizin decreased total glucose uptake by 23%, phloretin by 22% and 
cytochalasin B by 42% (Figure 4.5 A). Specific glucose transporter inhibitors were also 
tested under sodium independent conditions. As expected GLUT-mediated glucose 
uptake was decreased by GLUTs inhibitors, phloretin and cytochalasin B (P<0.0001), 
but not by phlorizin. Phloretin decreased GLUT-mediated glucose uptake by 14% and 






















































































Figure 4.5 Inhibition of total and GLUT-mediated glucose uptake by phlorizin, 
phloretin and cytochalasin B   
Caco-2/TC7 cells were treated with phlorizin 0.5 mM, phloretin 0.5 mM and cytochalasin B 
0.01 mM contained in uptake media, control was supplemented with dimethyl sulfoxide 0.1 %. 
Values were corrected for simple diffusion by subtracting L-glucose uptake. Data are presented 
as mean ± SEM (n=4-5). One-way analysis of variance followed by multiple comparisons 
against control with Dunnett’s adjustment. A) Total glucose uptake: ****P<0.0001 for the 
difference between control and phlorizin, phloretin and cytochalasin B. B) GLUT-mediated 
glucose uptake: **P<0.005 for the difference between control and phloretin; ****P<0.0001 for 




4.4.2 Effects of anthocyanin-rich blackcurrant extract (BE) on glucose uptake 
4.4.2.1 Time course assay with BE 
Time course assay showed a statistically significant inhibition of total glucose uptake on 
Caco-2/TC7 cells pre-incubated with 3.2 mg of blackcurrant polyphenols (P<0.0001) 
(Figure 4.6). Concentration of blackcurrant polyphenols present in pre-incubation and 
uptake media is fourfold the dose estimated to be present in gut lumen when top dose 
drink (600 mg ACN) was consumed by participants in human study (Chapter 3). There 
was an acute effect of blackcurrant polyphenols on total glucose uptake, uptake was 
significantly decreased after 0, 1, 30 min and 3 h pre-incubation (P<0.0001). Significant 
inhibitory effect following 0 and 1 min pre-incubation treatments served for establishing 
assay conditions for testing acute effects of rich-polyphenols fruit extracts on glucose 
uptake. All the following assays were performed with no fruit extract added in pre-
incubation media.        









































Figure 4.6 Total glucose uptake inhibition after treatment with blackcurrant extract  
Caco-2/TC7 cells were pre-incubated with 3.2 mg/ml of blackcurrant polyphenols before 
glucose uptake, uptake media contained, except for control, 3.2 mg/ml of blackcurrant 
polyphenols. Values were corrected for simple diffusion by subtracting L-glucose uptake. Data 
are presented as mean ± SEM (n=3). One-way analysis of variance followed by multiple 
comparisons against Control with Dunnett’s adjustment: ****P<0.0001 for the difference 




4.4.2.2 Acute effects of BE on glucose uptake 
There was an acute effect of blackcurrant polyphenols on total glucose uptake, 
following 10 min uptake in the presence of different concentrations of blackcurrant 
polyphenols total glucose uptake was inhibited in a dose-responsive manner (P<0.0001) 
(Figure 4.7A). There was a significant reduction on total glucose uptake after treatment 
0.2 mg/ml (P<0.005), and a highly significant reduction following treatments 0.4, 0.8, 
1.6 and 3.2 mg/ml (P<0.0001).  The dose-response assay was performed under sodium-
independent condition in order to assess inhibitory effects by blackcurrant polyphenols 
on GLUT-mediated glucose uptake. There was a dose-response inhibition on GLUT-
mediated glucose uptake, following 10 min uptake in the presence of different 
concentrations of blackcurrant polyphenols (P<0.0001) (Figure 4.7B). There was a 
significant reduction on GLUT-mediated glucose uptake following treatments 0.2, 0.4, 
0.8 and 1.6 mg/ml (P<0.0001). The estimated physiological concentration 
corresponding to the effective dose in the human study (GLU-BERRY study) was 0.8 





















































































Figure 4.7 Acute effects of increasing concentrations of blackcurrant polyphenols on 
total and GLUT-mediated glucose uptake   
Caco-2/TC7 cells were treated with increasing concentrations of blackcurrant polyphenols 
contained in uptake media, except for control (0 mg/ml). Values were corrected for simple 
diffusion by subtracting L-glucose uptake. Data are presented as mean ± SEM (n=3-5). One-
way analysis of variance followed by multiple comparisons against control (0 mg/ml) with 
Dunnett’s adjustment: A) Total glucose uptake: ***P<0.001 for the difference between Control 
and 0.2 mg/ml; ****P<0.0001 for the difference between Control and 0.4, 0.8, 1.6 and 3.2 
mg/ml. B) GLUT-mediated glucose uptake: ****P<0.0001 for the difference between Control 




Concentrations of blackcurrants phenolic necessary to inhibit by half (IC50) total and 
GLUT-mediated glucose uptake were estimated. Blackcurrant polyphenols under 
sodium-dependent conditions showed and IC50= 0.51 ± 0.09 mg/ml (mean ± SE) 
(Figure 4.8A) and under sodium-independent conditions IC50= 0.63 ± 0.07 mg/ml 
(Figure 4.8B). Findings suggest a slightly greater inhibition on total glucose uptake 
than GLUT-mediated glucose uptake by blackcurrant polyphenols. 
Blackcurrant phenolics (mg/ml)
















































































Figure 4.8 Blackcurrant polyphenols IC50 for total and GLUT-mediated glucose uptake  
Effect of blackcurrant polyphenols on total (sodium-dependent) and GLUT-mediated glucose 
uptake (sodium-independent). Nonlinear regression analysis showed different values for IC50s 






4.4.2.3 Acute effect of individual anthocyanins and anthocyanidins 
contained in BE 
Individual anthocyanins and anthocyanidins present in the anthocyanin-rich 
blackcurrant extract and combinations of them did not decrease total glucose uptake (10 
mM D-glucose, 10 min). There was no inhibitory effect when testing physiological 
concentrations estimated to be present in gut lumen after consumption of top dose drink 
in GLU-BERRY study (600 mg ACN) (Figure 4.9). Since individual compounds were 
dissolved in different solvents and therefore their control was not the same data were 






















































































































Figure 4.9 Acute effects of estimated physiological concentrations of individual 
anthocyanins and anthocyanidin on total glucose uptake 
Caco-2/TC7 cells were treated with estimated physiological concentrations of anthocyanins, 
anthocyanidins and combinations contained in uptake media (10 mM D-glucose); except for 
Control (uptake media supplemented with solvent). C3R, cyanidin-3-rutinoside; C3G, cyanidin-
3-glucoside; D3R, delphinidin-3-rutinoside; D3G, delphinidin-3-glucoside. Values were 
corrected for simple diffusion by subtracting L-glucose uptake. Data are presented as 




To test whether increased concentrations of inhibitors related to substrate further 
modifications in glucose uptake medium concentration (1 mM D-glucose, 2 min); 
anthocyanins/anthocyanidins concentrations (0.1 mM) were implemented. However 
increased ratio inhibitor/substrate and adding anthocyanins in pre-incubation media in 
addition to uptake media did not affect the rate of glucose uptake following treatment 
with individual anthocyanins and anthocyanidins (Figure 4.10). There was no decrease 
in total glucose uptake after treatments. Data are presented as normalised means 





























































































Figure 4.10 Acute effects of individual anthocyanins and anthocyanidin 0.1 mM on 
total glucose uptake   
Caco-2/TC7 cells were treated with individual anthocyanins and anthocyanidins (0.1 mM) 
contained in pre-incubation and uptake media (1 mM D-glucose), except for Control (uptake 
media was supplemented with solvent). C3R, cyanidin-3-rutinoside; C3G, cyanidin-3-glucoside; 
D3R, delphinidin-3-rutinoside; D3G, delphinidin-3-glucoside. Values were corrected for simple 
diffusion by subtracting L-glucose uptake. Data are presented as normalised mean expressed as 






4.4.3 Effects of polyphenol-rich apple extract (AE1) on glucose uptake 
There was an acute effect of apple polyphenols (using the extract from the GLU-APP 
study) on glucose uptake, dose response assays in the presence of different 
concentrations of apple polyphenols showed an inhibition in total glucose uptake 
(P<0.0001) (Figure 4.11A). There was a statistically significant inhibition in total 
glucose uptake after treatment 0.15 mg/ml (P<0.05), 0.3 mg/ml (P<0.005), and a highly 
significant reduction following treatments 0.5 mg/ml (P<0.001) and 1.0 mg/ml 
(P<0.0001).  Dose-response assay was performed under sodium-independent condition 
in order to assess inhibitory effects by apple polyphenols (AE1) on GLUT-mediated 
glucose uptake. There was an inhibition on GLUT-mediated glucose uptake following 
treatment with apple polyphenols (P<0.0001) (Figure 4.11B). There was no inhibitory 
effect after 0.07 and 0.15 mg/ml conditions, there was a significant decrease on GLUT-
mediated glucose uptake following treatments 0.3 mg/ml (P<0.05) and 0.5 and 1.0 
mg/ml (P<0.001). The estimated physiological concentration corresponding to the top 
dose in the human study (GLU-APP study) was 0.3 mg/ml and inhibited 30 and 18% of 























































































Figure 4.11 Acute effects of increasing concentrations of apple polyphenols (AE1) on 
total and GLUT-mediated glucose uptake   
Caco-2/TC7 cells were treated with increasing concentrations of apple polyphenols contained in 
uptake media, except for Control (0 mg/ml). Values were corrected for simple diffusion by 
subtracting L-glucose uptake. Data are presented as mean ± SEM (n=3). One-way analysis of 
variance followed by multiple comparisons against Control with Dunnett’s adjustment: A) Total 
glucose uptake: *P<0.05 for the difference between Control and 0.15 mg/ml, **P<0.005 for the 
difference between Control and 0.3 mg/ml; ***P<0.001 for the difference between Control and 
0.5 mg/ml; ****P<0.0001 for the difference between Control and 1.0 mg/ml. B) GLUT-
mediated glucose uptake: *P<0.05 for the difference between Control and 0.3 mg/ml; 




   
4.4.4 Effects of polyphenol-rich apple extract (AE2) on glucose uptake 
There was an acute effect of polyphenols in this second apple extract (used in the GLU-
FRU study) on glucose uptake, dose response assays in the presence of different 
concentrations of apple polyphenols showed an inhibition on total glucose uptake 
(P<0.0001) (Figure 4.12A). There was a highly significant inhibition on total glucose 
uptake following treatments 0.15, 0.3, 0.5, 1.0 and 2.0 mg/ml (P<0.0001). Dose-
response assays were performed under sodium-independent condition in order to assess 
inhibitory effects by apple polyphenols on GLUT-mediated glucose uptake. There was 
an inhibition on GLUT-mediated glucose uptake following treatment with apple 
polyphenols (AE2) (P<0.0001) (Figure 4.12B). There was no inhibitory effect after 
0.07 mg/ml treatment but there was a highly significant decrease on GLUT-mediated 
glucose uptake following treatments 0.15, 0.3 and 0.5 mg/ml (P<0.0001). The estimated 
physiological concentrations corresponding to effective doses in the human study 
(GLU-FRU study) were 0.3 and 0.5 mg/ml and inhibited 51 and 67% and 46 and 62% 









Figure 4.12 Acute effects of increasing concentrations of apple polyphenols (AE2) on 
total and GLUT-mediated glucose uptake   
Caco-2/TC7 cells were treated with increasing concentrations of apple polyphenols contained in 
uptake media, except for Control (0 mg/ml). Values were corrected for simple diffusion by 
subtracting L-glucose uptake. Data are presented as mean ± SEM (n=3-5). One-way analysis of 
variance followed by multiple comparisons against Control with Dunnett’s adjustment: A) 
****P<0.0001 for the difference between Control and 0.15, 0.3, 0.5, 1.0 and 2.0 mg/ml 
treatments. B) GLUT-mediated glucose uptake: ***P<0.0005 for the difference between 
Control and 0.15, 0.3 and 0.5 mg/ml treatments. 
 















































































4.4.5 Oocytes injected to express rSGLT1 system  
All through the period of experimentation on the oocyte system phlorizin (dissolved in 
DMSO), a well-known SGLT1 inhibitor showed the in vitro system functioning as 
expected. Glucose uptake was decreased 85% and 59% by phlorizin and phloretin (0.5 
mM), respectively when compared to 0.1% DMSO treatment (P<0.0001), as expected 
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Figure 4.13 Inhibition of glucose uptake on oocytes expressing rSGLT1 by phlorizin 
and phloretin  
Oocytes injected to express rSGLT1 were treated with DMSO, Pz or Pt, contained in uptake 
media, except for control. DMSO, dimethyl sulfoxide; Pz, phlorizin; Pt, phloretin. Data are 
presented as mean ± SEM (n=3). Values were corrected by subtracting sham oocytes uptake. 
One-way analysis of variance followed by multiple comparisons against controls with Dunnett’s 





4.4.6 Effects of blackcurrant polyphenols (BE) on oocytes injected to 
express rSGLT1 
Dose-response assays on oocytes expressing rSGLT1 showed an inhibition on glucose 
uptake following treatment with blackcurrant polyphenols (P<0.0001). There was a 
highly significant decreased on glucose uptake after treatments 0.1, 0.2, 0.4, 0.8 and 1.6 
mg/ml (P<0.0001) (Figure 4.14).      
 
 
Figure 4.14 Effects of blackcurrant polyphenols on glucose uptake on oocytes 
expressing rSGLT1  
Oocytes injected to express rSGLT1 were treated with increasing concentrations of blackcurrant 
polyphenols.  Values were corrected by subtracting sham oocytes uptake. Data are presented as 
mean ± SEM (n=3). One-way analysis of variance followed by multiple comparisons against 
control with Dunnett’s adjustment ****P<0.0001 for the difference between 0 mg/ml and 0.1, 
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Concentration of blackcurrants polyphenols necessary to inhibit by half (IC50) glucose 
uptake was 0.12 ± 0.003 mg/ml (mean ± SE) (Figure 4.15).  
  
Figure 4.15 Blackcurrant polyphenols IC50 for glucose uptake on oocytes expressing 
rSGLT1 
Effects of blackcurrant polyphenols on glucose uptake after dose response assays were used to 


















































4.4.7 Effects of apple polyphenols (AE2) on oocytes injected to express 
SGLT1 
Dose-response assays on oocytes expressing rSGLT1 showed an inhibition on glucose 
uptake following treatment with apple polyphenols (P<0.0001). There was a highly 
significant decrease in glucose uptake after treatments 0.125, 0.25, 0.5, 1.0, 2.0 and 4.0 
mg/ml (P<0.0001) (Figure 4.16).      
 
Figure 4.16 Effects of apple polyphenols (AE2) on glucose uptake on oocytes 
expressing rSGLT1  
Oocytes injected to express rSGLT1 were treated with increasing concentrations of apple 
polyphenols.  Values were corrected by subtracting sham oocytes uptake. Data are presented as 
mean ± SEM (n=3). One-way analysis of variance followed by multiple comparisons against 
control with Dunnett’s adjustment ****P<0.0001 for the difference between 0 mg/ml and 
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4.5 Discussion  
As reported in our clinical trials (Chapter 3), the ingestion of blackcurrant and apple 
polyphenol-rich extracts decreased plasma glucose levels following starch and sucrose 
containing meals, and inhibited the secretion of insulin, GIP and to a lesser extent GLP-
1. Evidence from cell studies suggests that the inhibition of small intestinal glucose 
uptake by polyphenols is a potential mechanism mediating these effects (Johnston et al., 
2005, Alzaid et al., 2013). Therefore, the effects of anthocyanin-rich blackcurrant 
extract and polyphenol-rich apple extracts used in the clinical trials on glucose uptake 
were tested in Caco-2 cells, a well-established in vitro method of enterocytes in small 
intestine, and also in oocytes injected to express individual intestinal sugar transporters. 
Our in vitro results demonstrated that the anthocyanin-rich blackcurrant extract (BE) 
and polyphenol-rich apple extracts (AE1 and AE2) significantly reduced total and 
GLUT-mediated glucose uptake into human Caco-2/TC7 cells and glucose uptake in 
Xenopus laevis oocytes injected to express solely SGLT1.    
Our in vitro results showed that blackcurrant extract (BE) and apple extracts (AE1 and 
AE2) significantly reduced glucose uptake into human Caco-2/TC7 cells by inhibition 
of glucose transporters but pure blackcurrant anthocyanins and anthocyanidins did not 
show an inhibitory effect. AE2 exerted the greatest effect, with an inhibition of 50% on 
total glucose uptake (likely to be both SGLT1- and GLUT-mediated) after exposure to 
0.3 mg total polyphenols/ml, followed by BE with an inhibition of 50% by 0.5 mg/ml 
and AE1 with 30% inhibition after 0.3 mg/ml. GLUT-mediated glucose uptake 
(sodium-free conditions, effectively removing any transport by SGLT1) had a similar 
magnitude of inhibitory effect, with an inhibition of 46% by 0.3 mg/ml of AE2, 
followed by BE with an inhibition of 50% by 0.6 mg/ml and AE1 with 18 % inhibition 
after 0.3 mg/ml treatment. In vivo these concentrations of apple and blackcurrant 
polyphenols are achievable in the gut lumen after consumption of 2 medium apples (300 
g, whole raw dessert apple, Malus domestica) and a portion/handful of fresh 
blackcurrant fruit (130 g, Ribes nigrum L.), respectively (Rothwell et al., 2013). 
Comparison between results from total glucose uptake (SGLT1- and GLUT-mediated 
uptake) and GLUT-mediated glucose uptake suggest that inhibition of GLUT-mediated 
uptake by AE2 and BE was the main component in the attenuation of glucose uptake on 
the Caco-2 cells system. On the contrary, results from AE1 suggest that inhibition of 




on the Caco-2 cells system, despite the fact that the phlorizin contents of both apple 
extracts were similar.         
Inhibition of glucose uptake at concentrations BE 0.8 mg/ml and AE2 0.3 and 0.5 
mg/ml are consistent with outcomes showed in GLU-BERRY and GLU-FRU studies, 
where a reduced postprandial glycaemia was observed after ingestion of the top dose 
test drink in GLU-BERRY (corresponding to estimated gut lumen concentrations of 0.8 
mg blackcurrant polyphenols/ml) and the two tests drinks in GLU-FRU (corresponding 
to estimated gut lumen concentrations of 0.3 and 0.5 mg apple polyphenols/ml). Lower 
concentrations than those estimated in gut lumen after ingestion of effective doses on 
the human studies also inhibited glucose uptake in the Caco-2/TC7 system, although to 
a lesser extent. In the Caco-2 system concentrations equivalent to top doses of BE and 
AE2 test drinks inhibited total glucose uptake by more than 60%, while equivalent 
concentration of top dose test drink in GLU-APP (AE1 0.3 mg/ml) only inhibited total 
glucose uptake by 30%, this might explain the lack of effect on postprandial glycaemia 
by AE1 on the human study, and suggests that higher concentrations of AE1 may have 
been required to exert an inhibitory effect on postprandial glycaemia in vivo.   
HPLC analysis of BE revealed high concentrations of anthocyanins, accounting for 49 
% of the total polyphenols. A secondary hypothesis of this research was that 
anthocyanins were responsible for reduced glucose uptake into enterocytes, potentially 
by interaction with SGLT1 or GLUT2. Physiological concentrations of the 
anthocyanins; cyanidin-3-glucoside, cyanidin-3-rutinoside, delphinidin-3-glucoside and 
delphinidin-3-rutinoside and the anthocyanidins; cyanidin and delphinidin were tested. 
Anthocyanins and anthocyanidins did not decrease total glucose uptake in our Caco-2 
cell model, this was an unexpected result since opposing findings were previously 
reported. Caco-2 cells treated with cyanidin, cyanidin-3-glucoside or cyanidin-3-
rutinoside (each 0.1 mM) showed a decreased of ~20% on total and GLUT-mediated 
glucose uptake (Alzaid et al., 2013). We did not find a significant inhibitory effect when 
testing cyanidin (0.18 and 0.10 mM), cyanidin-3-glucoside (0.03 and 0.10 mM) and 
cyanidin-3-rutinoside (0.15 and 0.10 mM) on total glucose uptake. We did not test 
specifically GLUT-mediated glucose uptake, but since total uptake was unaffected then 
it GLUT-mediated effects would also be expected to be nil. Differences in cell culture 
conditions might explain opposing results in inhibition of glucose uptake by 




as in Alzaid et al. study, could stress the cells and modify the functionality of the cell 
monolayer (Sambuy et al., 2005). However, in vitro studies have suggested the 
involvement of glucose transporters SGLT1 and GLUT2 in the absorption of cyanidin-
3-glucoside (10 μM), since absorption into Caco-2 cells decreased when inhibitors 
phlorizin (10, 100 μM) and phloretin (1, 10, 100 μM) were added to uptake media (Zou 
et al., 2014) which might represent a route for competitive inhibition of glucose uptake 
by anthocyanins. Therefore further studies testing higher concentrations of BE 
anthocyanins and anthocyanidins under sodium-dependent and sodium-independent 
conditions might help to identify a possible inhibitory mechanism, although the 
physiological relevance of higher concentrations would be debatable. Since in our in 
vitro studies anthocyanins did not inhibit glucose uptake, it is therefore possible that 
other polyphenol compounds contained in the BE were responsible for the inhibition of 
glucose uptake. We do not know the polyphenol composition of the remaining 51 % of 
BE extract, however analyses of the raw fruit have showed significant quantities of 
proanthocyanidins, and to a lesser degree, flavanols and phenolic acids (Rothwell et al., 
2013); individual compounds of the flavanol and phenolic acid subclasses have showed 
inhibitory effects on glucose uptake in Caco-2 cells (Manzano and Williamson, 2010, 
Johnston et al., 2005, Dejiang et al., 2011). Previous in vitro studies suggest that the 
type and degree of inhibition varies according to the presence or absence of a sugar 
moiety in the structure. There is some evidence that glucosides (e.g. flavonol 
glucosides) inhibit primarily SGLT1 transporters and aglycones (e.g. flavanols) regulate 
GLUT transporters (Kwon et al., 2007), but further studies are required to confirm this. 
The combination of polyphenolics structures (aglycones and glucosides) that could 
potentially be in the blackcurrant extract may partially explain the marked inhibitory 
effect, since they may be acting through multiple mechanisms to inhibit glucose 
transport.   
 
HPLC analysis of the apple extracts were performed by different companies but they 
showed similar concentrations of phlorizin, a well-known SGLT1 inhibitor, and 
differences in the proportions of other polyphenols such as quercetin, epicatechin and 
proanthocyanidins. When tested alone, phlorizin at 0.5 mM inhibited total glucose 
uptake by 23%. AE2 decreased total glucose uptake by 50 and 70% at 0.3 and 0.5 
mg/ml concentrations, respectively, we estimated phlorizin concentrations in those 




concentrations of phlorizin show lower inhibitory effects. Phlorizin was among the 
major components in both extracts and it is unlikely that the greater effect of AE2 on 
glucose inhibition was attributable to it. Other compounds are present and potentially, 
contributing to inhibition. Other polyphenols, such as phloretin and chlorogenic acid, 
contained in the both apple extracts but not measured in both, have showed inhibitory 
effects on glucose uptake in Caco-2 cells (Manzano and Williamson, 2010). An in vitro 
study using Caco-2 cells indicated an inhibition of 50% on total glucose uptake by 
phloretin 0.5 mM and by chlorogenic acid 1.3 mM (Manzano and Williamson, 2010). In 
our in vitro studies total and GLUT-mediated glucose uptake was inhibited in 22 and 
14% by phloretin 0.5 mM, respectively. Concentration of phloretin in AE1 0.5 mg/ml 
was estimated to be 0.03 mM, although phloretin concentration was not specified for 
AE2, HPLC analysis suggested a concentration lower than 0.5 mM. Chlorogenic acid 
concentration in 0.5 mg/ml of AE2 was estimated to be 0.04 mM but the concentration 
was not available for AE1. Although concentrations of individual compounds in both 
apple extracts seem to be too low to exert a major percentage of inhibition separately, an 
additive effect might explain the inhibitory effect on glucose uptake since inhibition in 
Caco-2 cells has also been showed by several other polyphenols contained in the apple 
extracts, such as flavan-3-ols; (+)-catechin, (-)-epicatechin, epigallocatechin gallate, 
epigallocatechin and epicatechin gallate and flavonol quercetin (Johnston et al., 2005, 
Dejiang et al., 2011).  
 
Limitations to the present study include the need to further test other individual 
metabolites, besides anthocyanins, contained in blackcurrant and apple extracts e.g. 
proanthocyanidins, flavan-3-ols, flavonols and phenolic acids. Moreover the differences 
between in vivo and in vitro conditions should be considered. Although the Caco-2 cell 
system is a widely accepted model of the small intestine, in the in vitro system there is 
not interaction of the metabolites with other tissues, enzymes or proteins that might 
modify their structure and therefore their bioavailability and mechanism of action. 
Additionally, the approach precludes any simulation of the conditions of continuous 
absorption and excretion of metabolites by the enterohepatic circulation in the small 
intestine, and therefore any findings are just an indication of potential effects in vivo and 





The identification of which specific transporter was blocked by the blackcurrant and 
apple extracts was not possible since Caco-2 cells/TC7 express different glucose 
transporters namely SGLT1, GLUT1, GLUT2, GLUT3 and the fructose transporter 
GLUT5. To study inhibition of individual sugar transporters we employed the Xenopus 
oocytes expression system in which individual transporters can be isolated. Xenopus 
oocytes have proved to be a reliable system to study glucose transporters activity as 
they exhibit low levels of endogenous glucose transport activity in shams (non-injected 
or water-injected) oocytes (Gould and Lienhard, 1989). Since human enterocytes under 
normal conditions only express the glucose transporters SGLT1 and GLUT2 and results 
using Caco-2 cells suggest that GLUT-mediated glucose uptake was the major 
component in the total glucose uptake, clones of rSGLT1 and hGLUT2 were tested in 
the oocyte system. Only rSGLT1 system showed consistent results in the validation 
assays, hGLUT2 system was still inconsistent (data not shown) by the time this 
document was written.  
 
Our in vitro results demonstrate that blackcurrant extract (BE) and apple extract (AE2) 
significantly reduced glucose uptake into Xenopus laevis oocytes by inhibition of 
SGLT1. Inhibitory effects were similar to findings using Caco-2 cells; in oocytes 
injected to express SGLT1, AE2 demonstrated the most effective inhibition compared 
to BE. The lowest concentration of apple extract tested, 0.125 mg polyphenols/ml, 
proved to inhibit glucose uptake by 90% while comparable BE concentration 0.12 mg 
polyphenols/ml, showed inhibition of 50%. These results are in agreement with 
previous reports showing 50% glucose uptake inhibition by 0.24 μg of phlorizin-rich 
apple extract per mL and by 0.3 mg of quercetin-rich onion extract per mL, via 
inhibition of hSGLT1 (Schulze et al., 2014, Schulze et al., 2015). BE showed a dose-
response inhibition; to our knowledge we are the first showing decreased glucose 
uptake by a berry extract in oocytes expressing rSGLT1. Individual anthocyanins were 
not tested in the present study, however assays testing supra-physiological levels of 
anthocyanins pelargonidin and pelargonidin-3-glucoside (which were not detected in 
BE) showed 50% inhibition of hSGLT1 by 1.34 and 2.47 mM of pelargonidin and 
pelargonidin-3-glucoside, respectively (Kottra and Daniel, 2007). More studies testing 
physiological concentrations of individual anthocyanins contained in the blackcurrant 
extract are needed to elucidate the possible effect on SGLT1, although the magnitude of 




insignificant when taken in the context of the Caco-2 cell experimental results reported 
here.  
Apple extract (AE2) showed a greater inhibitory effect than BE on SGLT1-mediated 
glucose transport in oocytes, but the marked inhibition at the lowest dose tested meant 
that we were unable to demonstrate a dose-response inhibition. More assays testing 
lower concentrations of AE2 are needed in order to identify the IC50 value. SGLT1 
inhibition by several polyphenols contained in the apple extract has been demonstrated, 
e.g. competitive inhibition by the glycoside phlorizin (Kobayashi et al., 2000, Kottra 
and Daniel, 2007, Schulze et al., 2014) and non-competitive inhibition by the aglycone 
phloretin (Hirayama et al., 2001, Schulze, 2014). When tested individually phlorizin 
and phloretin 0.5 mM inhibited rSGLT1-mediated glucose uptake by 85 and 59%, 
respectively. AE2 0.125 mg/ml inhibited rSGLT1 glucose uptake by 90%, concentration 
of phlorizin contained was 0.02 mM, even though phloretin concentration in AE2 was 
not specified, HPLC analysis suggests a concentration much lower than 0.5 mM, 
therefore is it unlikely that the additive effects of phlorizin and phloretin alone 
accounted for the total inhibition showed by AE2. It might be possible that other 
components of the apple extract such as quercetin (0.02 mM in 0.5 mg/ml of AE2) and 
proanthocyanidins were also bioactive in this respect; flavonols quercetin (IC50= 0.62 
mM) and quercetin-4-O-glucoside (IC50= 0.17 mM) have previously been shown to 
inhibit hSGLT1 (Kottra and Daniel, 2007, Schulze et al., 2015). However other 
polyphenols contained in the AE2, such as chlorogenic acid (0.04 mM in 0.5 mg/ml of 
AE2) have shown no inhibitory effects on SGLT1 at a higher concentration (0.1 mM) 
(Schulze et al., 2014).      
 
SGLT1 is also expressed in enteroendocrine cells of the small intestine and has been 
shown to be closely related with the expression of GIP and GLP-1 using individual 
enteroendocrine cells of murine jejunal crypts. Studies in Sglt1-/- (knocked out) mice 
have shown the essential role of SGLT1 as a glucose sensor for secretion of gut 
incretins GIP and GLP-1 and upregulation of GLUT2 (Gorboulev et al., 2012). 
Moreover, a separate study in mice reported inhibited glucose induced SGLT1-mediated 
GIP secretion by apple polyphenol phlorizin (Moriya et al., 2009). Our clinical studies 
showed a decreased secretion of GIP after BE and AE2 treatments. The oocyte SGLT1 
inhibition studies presented here open up the possibility that inhibition of glucose-




of SGLT1 expressed by GIP-secreting K cells; this theory may be investigated in future 
research using cultured STC-1 cells, a model for GIP-secreting enteroendocrine cells.  
 
The blackcurrant and apple extracts in the current study contained a wide range of 
individual compounds with potential inhibition activity of both SGLT1 and GLUTs 
transporters, and a synergistic/additive effect might be responsible for the decreased on 
glucose uptake in Caco-2/TC7 cells and Xenopus oocytes systems. However the 
presence of high molecular weight polymers such as proanthocyanidins (PA), might 
also contributed to the highly significant inhibition on glucose uptake. The polymeric 
proanthocyanidins are components of both blackcurrant and apple polyphenol profiles. 
They are estimated to constitute 25 and 50% of the BE and AE2 polyphenols, 
respectively and consisting in blackcurrant, of dimers (2%), oligomers 3-10 mers (15%) 
and polymers >10 mers (82%) and in apple, of dimers (11%), oligomers 3-10 mers 
(52%) and polymers >10 mers (30%) (Rothwell et al., 2013). Proanthocyanidins (PA) 
are less able to permeate into intestinal cells, and show a high degree of interaction with 
the plasma membrane. Probable factors affecting absorption are size and polymerisation 
degree, hydrophilic characteristic and affinity for luminal proteins (Deprez et al., 2001). 
The absorption of PA tends to decrease when polymerisation increase, PA dimers and 
oligomers (2-5 mers) have demonstrated being absorbable but PA polymers (>5 mers) 
has showed nil permeation into intestinal cells in studies with animals and humans 
(Neilson et al., 2016). High molecular weight polyphenolic molecules such as PA, with 
a size up to 10 kDa (Yanagida et al., 2003), a high degree of polymerisation and 
hydrophilic characteristics, may interact by hydrogen bonding with the polar head 
groups of the phospholipids in the outer leaflet of the plasma membrane coating the 
surface and covering proteins inserted in the plasma membrane (Tarahovsky, 2008). 
Glucose transporters SGLT1 and GLUT2 are transmembrane protein with size range 
69-79 kDa for the former (Wright et al., 2011) and 69 kDa for the latter. Considering 
the possible quantity of polymers polyphenols present in the extracts, it might possible 
that a percentage of the glucose uptake inhibition correspond to a hindering of the 
glucose transporters by PA complexes rather than to a specific inhibition of the glucose 
transporters by monomeric polyphenols. Moreover structural studies have shown that 
the side chains of SGLT1 (C-13 terminal loop) interact with lipid bilayers (Raja and 
Kinne, 2005) therefore it is possible that polyphenol-phospholipid interactions interfere 




inhibition of glucose transport. A possible interaction between PA and integral 
membrane proteins by covalent and non-covalent bonds (Kroll et al., 2005) might also 
explain the blocking of glucose transporter structures by a specific or/and non-specific 
inhibition (Blade et al., 2016).  
 
Our results suggest that polyphenols contained in the blackcurrant and apple extracts 
used in our clinical trials inhibited glucose transporters; further investigation is 
necessary in order to identify the individual compounds of blackcurrant and apple 
extracts that played a significant role in the inhibition of glucose uptake. Testing 
physiological concentrations of different fractions of the extracts such as PA on Caco-2 
cells and oocytes, and individual compounds such as anthocyanins in oocytes, might 
help to identify the bioactive compounds and the glucose transporters involved. In vitro 
studies using oocytes expressing GLUT2 might help to identify if the polyphenols had 
an equal or greater effect on this transporter relative to SGLT1, in agreement with the 
Caco-2 cell experiments. In vitro enzymatic assays testing the extracts will be useful to 
identify the effect of blackcurrant and apple polyphenols on digestive enzymes, such as 






4.5.1 Conclusion    
Results from our clinical trials in humans have indicated that a moderate dose (1200 
mg) of blackcurrant polyphenols and/or apple polyphenols and a combination of 
blackcurrant and apple polyphenols (1200 mg + 600 mg) significantly lowered 
postprandial glycaemia, insulinaemia and gut hormone GIP levels in healthy volunteers. 
Although the mechanism of action still needs further exploration, our in vitro results 
suggest that the polyphenols contained in blackcurrant and apple extracts may reduce 
postprandial glycaemia by inhibiting glucose transporters since physiological 
concentrations of the extracts decreased effectively total (SGLT1- and GLUT-mediated) 
and GLUT-mediated glucose uptake in Caco-2/TC7 cells and inhibited glucose uptake 
via blocking of rSGLT1 expressed in oocytes. Regular dietary consumption of fresh 
blackcurrant and apple may improve glycaemia response by limiting or delaying 
glucose absorption in the intestine, and may also reduce postprandial insulinaemia by 
decreasing glucose-induced SGLT1-mediated GIP secretion. Future work could 
determine the relative impact of inhibition of both digestive enzyme action and glucose 
transporters, which would help inform developments in pharmaceutical science aimed at 







Chapter 5  






The overarching thesis of this research is that regular dietary intakes of blackcurrant and 
apple polyphenols may help reduce risk of cardio-metabolic diseases by lowering 
postprandial blood glucose concentrations. The results presented here show that: 1) 
urinary biomarkers of dietary intakes of polyphenols contained in apples (phloretin) and 
blackcurrants (e.g. gallic acid) are increased in a population who are following UK 
dietary guidelines and report higher fruits and vegetables intake in a food frequency 
questionnaire; 2) consuming blackcurrant and apple extracts immediately before a 
starch and sucrose containing meal suppresses the rise in blood glucose concentrations; 
3) using an in vitro model, blackcurrant and apple extracts inhibit glucose transport into 
intestinal cells. Linking these findings together, it might be suggested that adherence to 
fruits and vegetables dietary guidelines may help regulate blood glucose levels if 
consumed with a high-carbohydrate meal, and this is at least partly mediated by 
delaying the absorption of glucose. 
The implications of this research are that dietary recommendations could emphasise 
polyphenol-rich fruits such as berries and apples in order to increase the polyphenol 
consumption in the population. Chronic consumption of polyphenol-rich fruits may 
have a cumulative effect on metabolic disease risk through repeated episodes of 
lowering postprandial glycaemia, in addition to any beneficial cardio-metabolic effects 
of increased circulating polyphenol metabolites in the later phase and beyond of the 
postprandial period through interaction with endothelial cells, pancreatic beta cells, 
adipocytes, liver cells and any other tissues relevant to the pathogenesis of type 2 
diabetes and cardiovascular disease (Hanhineva et al., 2010). The marked effect on 
plasma glucose, insulin and GIP concentrations showed by the extracts used in the 
clinical trials administering a starch and sucrose challenge indicate that polyphenols are 
more effective inhibiting postprandial glycaemia when digestives enzymes are involved 
in the breakdown of carbohydrates than when intestinal glucose transporter are only 
responsible for glucose absorption (glucose load). Diverse phenolic compounds 
contained in the blackcurrant and apple extracts are potentially responsible for the 
beneficial effects, e.g. proanthocyanidins, anthocyanins, phenolic acids, flavonols, 
flavan-3-ols. Evidence from in vitro/animal models suggests that GIP secretion appears 
to act as sensitive marker of glucose absorption linked to the SGLT1 transporter 
(Gorboulev et al., 2012; Röder et al., 2014) and the marked suppression of postprandial 
GIP response may indicate a possible direct inhibition of the glucose transporter SGLT1 




glucose response; blackcurrant polyphenols (1600 mg, GLU-BERRY) had a less 
marked effect on glucose homeostasis than a smaller amount of apple polyphenols 
(1200 mg, GLU-FRU). It seems likely that differences in the extracts profile have had 
an influence on the results. Apple extract was particularly rich in proanthocyanidins, 
flavan-3-ols and phenolic acids besides phlorizin, which have proved to be effective 
inhibiting digestive enzyme activity and glucose transporters GLUT2 and SGLT1. 
Results from mechanistic studies testing blackcurrant and apple extracts are congruent 
with results from clinical trials. Apple extract inhibited glucose uptake in a stronger 
manner than blackcurrant extract, therefore the in vitro Caco-2 cells system could be 
used as prediction model when establishing doses for in vivo studies. Mechanisms of 
inhibition are complex to elucidate; further analysis, to test individual compounds 
besides anthocyanins, are needed. The mixture of polyphenols contained in blackcurrant 
and apple extracts include aglycones, glycosides and low and high molecular weight, all 
variables to take into account when testing inhibitory effects.    
In the dietary analysis of the CRESSIDA study participants (Chapter 2) it was found 
that adherence to UK dietary guidelines led to an increased self-reported intake of 
polyphenols associated with reduced risk of T2D such as anthocyanins (Wedick et al., 
2012). Increases in phenolic acids, isoflavones and lignans were also observed. Phenolic 
acids have been associated with improvement of endothelial function (Del Rio et al., 
2013). Intake of two classes of phytoestrogens, isoflavones and lignans, are closely 
related with intake of whole grain products, which are indicators of a healthier diet 
pattern, associated with reduced risk of T2D (Talaei and Pan, 2015). Although the main 
sources of polyphenols in the CRESSIDA population were non-alcoholic beverages 
such as tea and coffee, adherence to UK dietary guidelines showed an increased 
consumption of anthocyanin-rich fruits such as berries, phenolic acid-rich fruits such as 
apples, isoflavone-rich food such as soy-derived beverages and lignan-rich food such as 
nuts and linseed. The current UK dietary guidelines recommend an intake of > 5 
portions of fruit and vegetables per day (400 g/d), and higher consumption of fruits and 
vegetables by themselves have been associated with reduced risk of T2D (Wang et al., 
2016, Mursu et al., 2014), and greater consumption of specific fruits, such as 
blueberries, grapes and apples and green leafy vegetables has also been associated with 
reduced risk of T2D (Muraki et al., 2013, Cooper et al., 2012). It could be argued that 
an increase in the recommended intake of F&V in combination with more focused 




polyphenol-rich fruit/vegetable, instead of general recommendation of fruits and 
vegetables, would be helpful in some populations. A similar approach have been 
adopted by Finland where berries intake is recommended as separate item from general 
fruits and the recommended intake of vegetables, berries and fruit was raised to 500 g/d 
instead of 400 g/d (5 portions/d). The Mediterranean diet (Greece, Spain) has elevated 
recommend intakes of F&V, 9 servings per day (~720 g) (USDA, 2016). China has 
higher recommended intakes of F&V (500-900 g/d) and has also established a system of 
dietary reference intakes (DRIs) values for non-essential bioactive compounds including 
polyphenols, such as anthocyanin, resveratrol, quercetin, proanthocyanidins, 
chlorogenic acid and isoflavones (Lupton et al., 2014). Geographical and seasonal 
availability of fruits such as berries must be considered if specific recommendations are 
intended. Therefore it might be more convenient if recommendations take into account 
foods that are broadly available and with combined high concentrations of other diverse 
polyphenols associated with reduced risk of T2D, such as proanthocyanidins (Zamora-
Ros et al., 2013), e.g. foods with high concentration of proanthocyanidins 
dimers/trimers plus anthocyanins (plum, grape, strawberry, redcurrant, blackberry and 
sweet cherry), or foods high in proanthocyanidins dimers/trimers plus flavan-3-ols, 
(apple, peach). Although all dietary analysis per se has significant methodological 
limitations and biomarkers of dietary intake provide a more objective association 
analysis, nevertheless evidence suggests that regular intake of specific polyphenol-rich 
fruit and vegetables decrease the risk of T2D.   
Results presented in Chapter 3 showed that polyphenol-rich blackcurrant and apple 
extracts attenuated postprandial hyperglycaemia and inhibited the secretion of insulin 
and incretins. It is apparent from these studies that there is a role for blackcurrant and 
apple polyphenols in regulating digestion and absorption of carbohydrates. 
Gastrointestinal interactions, in combination with post-absorptive effects of 
blackcurrant and apple polyphenols, might be expected to result in a sum normalisation 
of the postprandial glucose curve if such fruits were habitually consumed with meals. 
However, considerations about the food matrix must be taken into account since 
blackcurrant and apple fresh fruit contained other components that might influence the 
postprandial response, such as fibre which might delay the rate of glucose absorption by 
slowing down gastric emptying thereby slowing down the digestion process and 
increasing satiety, and proteins that may bind to the proanthocyanins thus reducing their 




mechanical barrier to digestion of other components contained in fruits and interaction 
of non-starch polysaccharides and non-digestible oligosaccharides with microbiota in 
colon might exert a subsequent action on satiety as well (Blaak et al., 2012). On the 
other hand, fruits also contain fructose, high intakes of which have been related with 
increased liver fat, hepatic insulin resistance and increased serum uric acid level, 
although there is still disagreement about the clinical effects of fructose when consumed 
in normal levels (Rippe and Marcos, 2016, Johnston et al., 2013), and the total amount 
of fructose (as well as glucose) in the diet must be considered when targeting the control 
of postprandial glycaemia, particularly in developing food/drink products containing 
fruit syrups/nectars/concentrates high in polyphenols but not contained within cell 
walls.  
Besides the acute effect on postprandial glycaemia shown by blackcurrant and apple 
polyphenols in human studies, a number of animal studies have demonstrated acute and 
chronic inhibitory effects of berry anthocyanins and apple polyphenols on weight gain, 
fasting glucose and increases in insulin sensitivity. Mice consuming a very high-fat diet 
were changed to a low-fat diet supplemented with blueberry concentrate (providing an 
average of 4.4 mg blueberry anthocyanins/d), which resulted in a reduction in weight 
gain and increase in glucose tolerance compared to the blueberry-free low-fat and high-
fat controls (Roopchand et al., 2013). Purified blueberry anthocyanins (0.49 mg/d) 
reduced fasting glucose levels in mice receiving a high-fat diet to levels comparable 
with a low-fat diet, and also reduced percentage body fat and body weight (Prior et al., 
2010, Jayaprakasam et al., 2006), and pure cyanidin-3-glucoside (C3G) 
supplementation resulted in markedly lower fasting blood glucose concentrations after 3 
weeks of high-fat diet compared to high-fat diet with no supplementation, as well as in 
diabetic mice consuming regular chow (Guo et al., 2012). Diabetic KK-Ay mice 
subjected to 5-week daily administration of concentrated bilberry extract (27 g/kg diet) 
showed a marked reduction in fasting plasma glucose and improved insulin sensitivity 
(Takikawa et al., 2010). Similar results have been shown by apple extracts and apple 
polyphenols; acute administration of apple extract (150 mg/kg body weight) decreased 
glycaemic response (iAUC) following an oral load of maltodextrin in OZR mice, an 
insulin resistant model (Manzano et al., 2016). The effect of the apple extract was 
further tested with a second meal (maltodextrin) 5 h after the administration of the apple 
extract; the group supplemented with apple extract showed a 20% decrease in plasma 




administration of the apple extract improved glycaemic and insulinaemic responses in 
the OZR group supplemented with 3 g of apple extract/kg diet for four weeks. In a 
separate study a 10-day treatment with intraperitoneal injection of the apple polyphenol, 
quercetin (10/15 mg per kg of body weight) decreased plasma glucose levels in 
streptozocin-induced diabetic rats in a dose-response manner following a glucose 
tolerance test (Vessal et al., 2003). Animal studies have showed favourable effects of 
berry and apple polyphenols on glycaemic control during fasting and postprandial states 
in mice. The evidence as a whole suggests that berry anthocyanins and apple 
polyphenols may have potentially preventative effects on glycaemia and weight gain.  
In our in vitro assays (Chapter 4), physiological concentrations of blackcurrant and 
apple polyphenols significantly inhibited glucose uptake in in vitro models of small 
intestinal glucose absorption, via blocking glucose transporters SGLT1 and GLUTs. A 
number of in vitro studies have suggested that metabolism of blackcurrant and apple 
polyphenols might play an important role in the beneficial effect on postprandial 
glycaemia in human studies. Anthocyanin metabolites and berry and apple flavonoids 
have been shown to influence muscular glucose uptake, insulin signalling, and 
adipocytokine expression in in vitro studies in human and rat cells and in animal studies 
(Babu et al., 2013). Both berry and apple polyphenols and metabolites activate proteins 
involved in glucose uptake, such as AMP protein kinase (AMPK) and phosphoinositide 
3-kinase (PI3K) in skeletal muscle cells and mesenteric adipose and liver tissues. 
AMPK is involved in the secretion and membrane translocation of the glucose 
transporter GLUT4 in muscle cells and its activation in liver tissue might result in the 
down-regulation of glucose-synthesising genes. Berry anthocyanins and apple 
polyphenols have also been able to increase transcription of the peroxisome proliferator-
activated receptor (PPARs) involved in the expression of GLUT4 and adipocytokines, 
both effects related to increased insulin sensitivity in muscle cells and liver 
(Scazzocchio et al., 2015, Scazzocchio et al., 2011, Tsuda et al., 2004, Takikawa et al., 
2010, Manzano et al., 2016, Kim et al., 2016, Wang et al., 2014, Santangelo et al., 
2016). Altogether, these data suggest that in addition to influencing carbohydrate 
digestion and absorption, circulating blackcurrant and apple polyphenols metabolites 
may act to increase insulin sensitivity. Decreased glucose absorption and improved 
insulin sensitivity in hepatic and skeletal muscle tissue are targeting points in the 
pharmacological treatment of T2D. For example AMPK acts as sensor of cellular 




translocation of GLUT4 transporters in order to increase cellular influx of glucose 
(Hardie, 2008); this mechanism of action is actually exerted by some of the drugs most 
commonly used in diabetes management. Nowadays treatment for T2D includes a range 
of medications with different targets and mechanism of action, such as metformin to 
decrease glucose production by liver and increase insulin sensitivity (by indirect 
activation of AMPK), sulphonylureas and prandial glucose regulators to stimulate 
insulin secretion by pancreatic β-cells and sensitise β-cells to glucose, acarbose to 
inhibit α-glucosidase activity, thiazolidinedione to reduce insulin resistance and 
improve insulin sensitivity (by direct and indirect activation of PPARs and AMPK, 
respectively), incretin mimetics/GLP-1 analogues and DPP-4 inhibitors to increase 
insulin secretion and slow down digestion and gastric emptying (also AMPK activators) 
and SGLT2 inhibitors to reduce glucose absorption in kidneys, therefore reduce blood 
glucose (as review in Coughlan et al., 2014 and Diabetes UK, 2016). In summary 
evidence from in vitro and animal studies suggests that berry and apple polyphenols 








5.1 Future work 
Further randomised controlled clinical trials to identify the minimal effective dose on 
postprandial glycaemia by apple polyphenols are planned. Including quantification of 
polyphenol metabolites in biological samples, such as plasma and urine, would be 
helpful to identify the absorption and metabolism of polyphenols consumed in the test 
drink/meal. Investigating the durability of the effect of polyphenols on postprandial 
glycaemia with a second high-carbohydrate meal would help in formulating dietary 
advice on how to optimise normal glucose homeostasis by consumption of apples and 
berries. Quantification of other parameters such as glucose concentrations in urine 
might help to detect other effects like inhibition of SGLT2 in the kidney, reducing 
reabsorption of glucose back into the circulation and increasing urinary glucose output, 
which might be of relevance in the management of T2D. Collaboration with the food 
industry to produce and test functional foods supplemented with the blackcurrant and/or 
apple extracts will help to the development of commercially available and palatable 
beverages and foodstuffs. Further mechanistic insights might be made using additional 
in vitro studies focussing on structural relationships between individual blackcurrant 
and apple polyphenols and glucose transport GLUT2 and digestive enzymes which may 
highlight possible synergistic effects of different polyphenols, increasing the potential to 
exploit these mechanisms in the improvement of postprandial hyperglycaemia. The 
study of potential effects of blackcurrant and apple polyphenols and their metabolites in 
different in vitro models such as enteroendocrine and muscle cells, might be helpful to 
understanding the role played out by polyphenols in the reduction of postprandial 






Blackcurrant and apple polyphenols and metabolites decrease postprandial glycaemia, 
insulin secretion and GIP secretion in vivo and inhibit glucose absorption in vitro. The 
potential beneficial effects exerted by blackcurrant and apple polyphenols mimic several 
mechanisms targeted by T2D treatment drugs, such as inhibition of α-glucosidase 
activity, activation of AMPK and PPARs and inhibition of glucose transporters in small 
intestine (SGLT1 and GLUT2) and kidney (SGLT2). Therefore the habitual 
consumption of such fruits in a normal diet might be considered as hypoglycaemic 
treatment in pre-diabetic stages (IFG and IGT) and T2D, as a replacement or 
complement to pharmacological treatment, with the additional benefits of minimal side 
effects and representing a more sustainable economic strategy. The physiological 
concentrations proven to be effective in the human studies and in in vitro assays might 
represent challenging doses to be consumed immediately before a high-carbohydrate 
meal in their fruit form; however, the possibility remains that lower amounts, consumed 
on a more frequent basis, may exert similar results on the postprandial glucose response. 
In conclusion, consuming more apples and berries (or foods/beverages fortified with 
extracts from these fruits) presents an efficacious option for lowering postprandial 
glycaemia, but is somewhat limited in what this could achieve in terms of reducing risk 
of T2D. With obesity being the major risk factor for T2D, combined approaches with 
the potential for population-level impact could be considered to target healthy body 
weight maintenance and glucose homeostasis simultaneously. For example, food 
companies could add apple/berry extracts as functional ingredients to high-sugar/starch-
containing products, in combination with measures to reduce glycaemic loads/energy 
contents, and to increase the satiating capacity of the same products. The novel findings 
presented in this thesis show that advice to consume more fruits and vegetables can 
effectively increase intakes of specific polyphenols that have been associated with 
reduced risk of cardio-metabolic diseases, and provides robust mechanistic evidence for 
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